Document:

Exhibit
10.09

     

    
      Confidential
Treatment - All deleted information contained in this document is information
that Shire Limited. has requested receive confidential treatment pursuant to
Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as
amended.  Portions of this agreement which have been deleted have been
replaced by asterisks (“*****”).

       

      REVISED AND RESTATED MASTER
LICENCE AGREEMENT

       

      THIS
AGREEMENT is made the 20th day of November 1995 between

       

      GLAXO GROUP LIMITED,
a company organized and existing under the laws of England and having its
registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex
UB6 0NN England (“GROUP”), together with

       

      GLAXO WELLCOME INC.
(formerly Glaxo Canada Inc.) a corporation organized and existing under the laws
of the Province of Ontario and having its registered office at 7333 Mississauga
Road North, Mississauga, Ontario L5N 6L4, Canada (“GWC”) and

       

      GLAXO WELLCOME INC.
(formerly Glaxo Inc.) a corporation organized and existing under the laws of the
state of North Carolina and having its principal place of business at Five Moore
Drive, Research Triangle Park, North Carolina 27709, United States of America,
(“GWUS”) and

       

      BIOCHEM PHARMA INC.
(formerly IAF BioChem International Inc.) a corporation organized and existing
under the laws of the Province of Quebec and having an office at 275
Armand-Frappier Blvd., Laval, Quebec, H7V 4A7 Canada (“PHARMA”) and

       

      TANAUD HOLDINGS (BARBADOS)
LIMITED, a corporation incorporated under the laws of Barbados and a
wholly owned subsidiary of PHARMA (“THB”)

       

      TANAUD INTERNATIONAL
B.V. a corporation incorporated under the laws of the Netherlands and a
wholly owned subsidiary of PHARMA (“TIB”) and

       

      TANAUD LLC. a limited
liability company incorporated under the laws of the State of Delaware and a
wholly owned subsidiary of PHARMA (“TLLC”)

       

      WHEREAS:

       

      
        	
                A.

              	
                GROUP,
      GWC, GWUS and PHARMA entered into a Master Licence Agreement dated January
      31, 1990 as amended by the Addendum to Master License Agreement dated
      January 31, 1990, (collectively, the “Original Agreement”) and now
      mutually desire to replace and supersede the Original Agreement and to
      restate the terms of their agreement herein with effect from November 20,
      1995;

              

      

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      
        	
                B.

              	
                Since
      PHARMA has transferred to THB and TLLC the ownership and/or control over
      proprietary rights in certain patents and know-how relating to Modified
      Licensed Product (as hereinafter defined) and since THB has assigned and
      sold to TIB and TLLC the right to receive royalty payments due to PHARMA
      under the Original Agreement, GROUP, GWC, GWUS and PHARMA have added THB,
      TIB and TLLC as parties to this
Agreement;

              

      

       

      
        	
                C.

              	
                PHARMA
      desires that Modified Licensed Product be developed and commercialized and
      is willing to enter into a licence and other associated agreements for
      these purposes;

              

      

       

      
        	
                D.

              	
                GROUP,
      GWC and GWUS desire to collaborate with PHARMA in the development and
      commercialization of Modified Licensed Product and PHARMA, THB, TlB and
      TLLC are willing to grant rights to GROUP, GWC and GWUS on the terms and
      conditions set forth herein and to·enter into a separate agreement with
      GWC substantially on the basis of the outline of arrangements set forth in
      Schedule 3 hereto.

              

      

       

      NOW IT IS
HEREBY AGREED as follows:

       

      
        	
                1.  

              	
                DEFINITIONS

              

      

       

      For
purposes of this Agreement:

       

      
        	
                (A)  

              	
                “Affiliate”
      means any corporation or other legal entity owning, directly or
      indirectly, fifty percent (50%) or more of the voting capital shares or
      similar voting rights of BIOCHEM or GROUP; any corporation or other legal
      entity fifty percent (50%) or more of the voting capital shares or similar
      voting rights of which is owned, directly or indirectly, by BIOCHEM or
      GROUP; or any corporation or other legal entity fifty percent (50%) or
      more of the voting capital shares or similar voting rights of which is
      owned directly or indirectly by a corporation or other legal entity which
      owns, directly or indirectly, fifty percent (50%) or more of the voting
      capital shares or similar voting rights of BIOCHEM or GROUP; or any other
      relationship as, in fact, constitutes actual
  control

              

      

       

      
        	
                (B)  

              	
                “BIOCHEM”
      means PHARMA, THB, TIB and TLLC
collectively.

              

      

       

      
        	
                (C)  

              	
                “Calendar
      Quarter” means any period of three (3) months ending on the last day of
      March or June or September or
December

              

      

       

      
        	
                (D)  

              	
                “Calendar
      Year” means any period of twelve (12) months ending on the last day of
      December

              

      

       

      
        	
                (E)  

              	
                “Final
      Pharmaceutical Form” means any presentation of a Modified Licensed Product
      in any final packaged and labelled pharmaceutical dosage form suitable for
      sale to and use by the end-user

              

      

       

       

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

       

      
        	
                (F)  

              	
                “FTC”
      means
      (2R,cis)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(lH)-pyrimidinone.
      Also known as:-

              

      

       

      (2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine;
524W91; 5-fluoro-21-deoxy-31.
thiacytidine; FTC.

       

      
        	
                (G)  

              	
                “Independent
      Third Party” means any person or entity other than BIOCHEM or GROUP or any
      Affiliate or sublicensee of BIOCHEM or
GROUP

              

      

       

      
        	
                (H)  

              	
                “Know-How”
      means all information, data, discoveries and trade secrets, whether or not
      reduced to writing, pertinent to Modified Licensed Product or to the
      manufacture or use of Modified Licensed Product, now or hereafter owned or
      controlled by BIOCHEM

              

      

       

      
        	
                (I)  

              	
                “Licensed
      Patents” means the patents and patent applications set forth in Schedule 2
      hereto, and any patents filed or obtained in any country corresponding to
      the patents listed on Schedule 2, as well as any additional patents issued
      or granted on additional patent applications in any country relating to
      Modified Licensed Product or its method of manufacture or use, or
      intermediates therefor, or formulations thereof, and any continuations,
      continuations-in-part, divisions, registrations, confirmations, reissues,
      renewals or extensions of term thereof, and any registrations or
      confirmations of any United States patents listed on Schedule 2 or any
      application or any additional United States patents relating to Modified
      Licensed Product or its method of manufacture or use, or intermediates
      therefor, or formulations thereof, now or hereafter owned or controlled by
      BIOCHEM

              

      

       

      
        	
                (J)  

              	
                “Modified
      Licensed Product” means
      (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-y1)-(1H)-pyrimidin-2-one
      {also known as
      4-amino-l-(2R-hydroxymethyl-[1,3]oxathiolan-5S-y1)-(1H)-pyrimidin-2-one;
      (2R-cis)-4-amino-1[2-(hydroxymethyl)-1,3-oxathiolan-5-y1]-2-(1H)-pyrimidone;
      2’3’-dideoxy,3’-thiacytidine; lamivudine and 3TC}, the corresponding
      2S-enantiomer and mixtures of the R- and S-enantiomers in any ratio
      including racaemic mixtures.

              

      

       

      
        	
                (K)  

              	
                “Net
      Invoiced Sales Value” means the gross invoice price charged for Modified
      Licensed Product sold by GROUP or its Affiliates or its sublicensees to an
      Independent Third Party, less all allowances or credits granted on·such
      sales, including those in respect of rejected or returned goods, recalls,
      transportation charges or allowances, insurance charges, normal and
      customary trade, quantity and trade discounts, rebates and taxes, other
      than income taxes, and other governmental charges on, or measured by, the
      sale, transportation, or use of such Modified Licensed Product, which
      GROUP and/or its Affiliates and/or its sublicensees has or have to pay or
      absorb on such sales

              

      

       

       

      
        
          
          

        

        
          3

          
            

          

        

        
          
          

        

         

      

      
        	
                (L)  

              	
                “Net
      Sales” in any Calendar Quarter
means:

              

      

       

      
        
          	
                	
                  (i) 

                	
                  in
      the case of any Modified Licensed Product sold in a particular country
      hereunder by GROUP and/or its Affiliates and/or its sublicensees in Final
      Pharmaceutical Form to an Independent Third Party, uncompounded and not
      packaged with any other active therapeutic and/or prophylactic ingredient,
      the Net Invoiced. Sales Value of such Modified Licensed
      Product;

                

        

      

       

      
        
          	
                	
                  (ii) 

                	
                  in
      the case of any Modified Licensed Product sold in a particular country
      hereunder by GROUP and/or its Affiliates and/or its sublicensees in Final
      Pharmaceutical Form to an Independent Third Party, compounded, packaged or
      sold with any other active therapeutic and/or prophylactic ingredient,
      such that one price is charged for such combination the value of the total
      declared amount of the Modified Licensed Product contained therein as
      agreed by discussion between GROUP and PHARMA. If the value cannot be
      agreed then it shall be decided by an independent accountant mutually
      acceptable to GROUP and PHARMA whose decision shall be binding upon
      them;

                

        

      

       

      
        For
greater
clarity, the “total declared amount” shall mean the amount of active ingredient
in the Modified Licensed Product as specified on the label or package and as
approved for that dosage form by the governing health authority. For example,
“100 mg” means the total declared value will be 100 milligrams of active
ingredient, even though the actual formula for manufacture and formulation of
such dose of Modified Licensed product may require a different amount of active
ingredient to achieve an effective dose; and

      

       

      
        
          	
                	
                  (iii) 

                	
                  in
      the case of any Modified Licensed Product sold in a particular country
      hereunder by GROUP and/or its Affiliates and/or its sublicensees in bulk
      to an Independent Third Party, the Net Invoiced Sales Value of such
      Modified Licensed Product sold by said Independent Third Party in Final
      Pharmaceutical Form

                

        

      

       

      
        	
                (M)  

              	
                “Parties
      to the first part of this Agreement” means GROUP, GWC and
    GWUS

              

      

       

      
        	
                (N)  

              	
                “Patent
      Expenses” means all external fees and
costs

              

      

       

      
        
          	
                	
                  (i) 

                	
                  incurred
      by GROUP in accordance with the Original Agreement up to November 19,
      1995, in financing the patenting activities set forth in Paragraph 8 of
      the Original Agreement in relation to Modified Licensed Product and
      Residual Product, and

                

        

      

       

       

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

         

      

      
        
          	
                	
                  (ii) 

                	
                  incurred
      by GROUP from November 20, 1995 in financing the patenting activities set
      forth in paragraph 7 hereof, in relation to Modified Licensed Product
      only.

                

        

      

       

      Patent
Expenses shall include, but shall not be limited to, all official fees and
reasonable independent attorneys’ charges arising from preparation, filing,
prosecution, maintenance and defence [except as arising under the provisions of
subparagraph 7(I)] of the Licensed Patents, and translation charges

       

      
        	
                (O)  

              	
                “Residual
      Product” means any compound falling within the general formulae set out in
      Schedule 1, but excluding those products covered by the definition of
      Modified Licensed Product, and also excluding
  FTC.

              

      

       

      
        	
                (P)  

              	
                “Territory”
      means all countries of the world except Canada and the
  USA.

              

      

       

      
        	
                (Q)  

              	
                “USA”
      means the United States of America and its possessions and
      territories

              

      

       

      
        	
                2.  

              	
                GRANT OF
      RIGHTS

              

      

       

      
        	
                (A)  

              	
                BIOCHEM
      hereby grants to GROUP, for all purposes, in the
  Territory:

              

      

       

      
        
          	
                	
                  (i) 

                	
                  the
      exclusive right under Licensed Patents to develop, register, manufacture,
      have manufactured, use and sell Modified Licensed Product;
    and

                

        

      

       

      
        
          	
                	
                  (ii) 

                	
                  the
      exclusive right under Know-How to develop, register, manufacture, have
      manufactured, use and sell Modified Licensed Product, including the right
      to disclose such Know-How in the circumstances specified in paragraph 8
      hereof

                

        

      

       

      GROUP may
exercise the said rights through its Affiliates and Independent Third Party
consultants, contract manufacturers and distributors: PROVIDED THAT GROUP shall
remain responsible for the performance by such Affiliates, consultants, contract
manufacturers and distributors of any obligations imposed on GROUP by this
Agreement

       

      
        	
                (B)  

              	
                BIOCHEM
      hereby grants to GWC in Canada (which term shall include its territories
      and possessions):

              

      

       

      
        
          	
                	
                  (i) 

                	
                  the
      sole right in conjunction with PHARMA under Licensed Patents to develop,
      register, manufacture, have manufactured, use and sell Modified Licensed
      Product; and

                

        

      

       

      
        
          	
                	
                  (ii) 

                	
                  the
      sole right in conjunction with PHARMA under Know-How to develop, register,
      manufacture, have manufactured, use and
sell

                

        

      

       

       

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

         

        
          Modified
Licensed Product, including the right to disclose such Know-How in the
circumstances specified in paragraph 8 hereof

        

         

      

      GWC shall
exercise the said rights in the manner described in this Agreement and the
Partnership Agreement set forth in Schedule 3 hereto. Without derogation from
the general applicability of the previous sentence GWC may exercise the said
rights through its Affiliates and Independent Third Party consultants, contract
manufacturers and distributors: PROVIDED GWC shall remain responsible for the
performance by such Affiliates, consultants, contract manufacturers and
distributors of any obligations imposed on GWC by this Agreement

       

      
        	
                (C)  

              	
                BIOCHEM
      hereby grants to GWUS in the USA:

              

      

       

      
        
          	
                	
                  (i) 

                	
                  the
      exclusive right under Licensed Patents to develop, register, manufacture,
      have manufactured, use and sell Modified Licensed Product;
    and

                

        

      

       

      
        
          	
                	
                  (ii) 

                	
                  the
      exclusive right under Know-How to develop, register, manufacture, have
      manufactured, use and sell Modified Licensed Product, including the right
      to disclose such Know-How in the circumstances specified in paragraph 8
      hereof

                

        

      

       

      GWUS may
exercise the said rights through its Affiliates and Independent Third Party
consultants, contract manufacturers and distributors: PROVIDED THAT GWUS shall
remain responsible for the performance by such Affiliates, consultants, contract
manufacturers and distributors of any obligations imposed on GWUS by this
Agreement.

       

      
        	
                (D)  

              	
                GROUP
      in the Territory and GWUS in the USA shall have the right to grant
      sublicences of GROUP’s and GWUS’ respective rights under the Licensed
      Patents and Know-How: PROVIDED THAT GROUP and GWUS shall each remain
      “responsible for the performance by it and by its sublicensees of any
      obligations imposed on GROUP or GWUS hereunder. GROUP and GWUS shall
      provide BIOCHEM with prior written notice of the identity of any such
      proposed sublicensee(s) and shall not formally appoint the organization
      identified as a sublicensee unless and until BIOCHEM shall have given its
      approval to such appointment, it being understood that such approval shall
      not be unreasonably withheld or
delayed

              

      

       

      
        	
                (E)  

              	
                GROUP,
      GWUS and GWC grant back to BIOCHEM the rights to the Residual Products
      which GROUP, GWUS and GWC held under the Original Agreement: PROVIDED
      THAT

              

      

       

       

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

         

      

      
        
          	
                	
                  (i) 

                	
                  BIOCHEM
      shall not exploit commercially any Residual Product outside the Field
      (hereinafter in subclause (E)(v) defined) between
  *****

                

        

      

       

      After
November 19, 1999, if BIOCHEM seeks through an Independent Third Party to
exploit commercially any Residual Product outside the Field, it shall offer to
GROUP a first right to negotiate an exclusive licence for such Residual
Product.

       

      Further,
if GROUP wishes to exploit commercially a Residual Product, GROUP may seek a
licence from BIOCHEM. The terms of such licence, if any, shall be as agreed
between BIOCHEM and GROUP; PROVIDED THAT BIOCHEM shall not be obligated to
entertain discussions or negotiations pertaining to, or conclude, such a license
with GROUP.

       

      
        
          	
                	
                  (ii) 

                	
                  BIOCHEM
      shall not exploit commercially any Residual Product within the Field until
      the patent for such Residual Product
expires.

                

        

      

       

      
        
          	
                	
                  (iii) 

                	
                  BIOCHEM
      shall not exploit commercially any compound tested under the Sponsored
      Research Agreement dated January 1, 1990 between BIOCHEM and GWC as
      amended (the “SRA”) between ***** if BIOCHEM seeks through an Independent
      Third Party to exploit commercially any such compound it shall offer to
      GROUP a first right to negotiate an exclusive licence for such
      compound.

                

        

      

       

      
        
          	
                	
                  (iv) 

                	
                  GROUP
      and GWUS shall not exploit commercially any compound within the Field with
      the principal purpose of reducing the royalty payable to BIOCHEM under
      this Agreement.

                

        

      

       

      
        
          	
                	
                  (v) 

                	
                  In
      this paragraph 2(E), a Residual Product or compound shall be regarded as
      exploited within the Field if that Residual Product or
      compound:

                

        

      

       

      a)     is
a cytidine L nucleoside analogue with no distinct biological difference to
Modified Licensed Product,

       

      b)     has
such similar therapeutic properties and such an absence of distinguishing
therapeutic advantages compared to Modified Licensed Product as to be perceived
as clinically interchangeable, and

       

      c)     has
its sole clinical use as a direct therapeutic substitute or replacement for
Modified Licensed Product, without any improved ability to compete with other
compounds in the field other than Modified Licensed Product.

       

      Furthermore,
the term “exploited outside the Field”, shall be construed in accordance with
this subclause.

       

       

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

         

      

      
        	
                (F)  

              	
                BIOCHEM
      acknowledges that the obligations imposed on BIOCHEM as set out in
      paragraph 2(E) mean that BIOCHEM shall not directly or indirectly
      manufacture, have manufactured, use or sell, a Residual Product or
      compound (for the purposes of this Section 2(F) collectively a “Compound”
      other than in accordance with that paragraph. The restriction on use shall
      not preclude BIOCHEM from conducting research and development activities
      related to Compounds.

              

      

       

      BIOCHEM
acknowledges that where the provisions of paragraph 2(E) require BIOCHEM to
offer to GROUP a first right to negotiate, BIOCHEM shall provide to GROUP a
written notice of BIOCHEM’s intention to exploit a Compound and allow GROUP
thirty (30) days from the date of such notice to provide to BIOCHEM return
written notice indicating whether or not GROUP wishes to enter into negotiations
with BIOCHEM for an exclusive worldwide licence for a Compound, with the right
to sublicense.

       

      Where
GROUP indicates to BIOCHEM in its return notice GROUP’s wish to commence
negotiations, BIOCHEM shall provide to GROUP all relevant information concerning
the Compound to allow GROUP and BIOCHEM to conduct negotiations toward an
exclusive licence agreement for the Compound.

       

      Where
these license negotiations are not completed within ninety (90) days from the
date of GROUP’s receipt of the written notice, or GROUP indicates that it does
not wish to further consider such Compound, BIOCHEM shall be allowed to exploit
such Compound or to grant to an Independent Third party the right to exploit
such Compound; PROVIDED THAT BIOCHEM will not offer more favourable terms to any
Individual Third Party without first offering such more favourable terms
exclusively to GROUP. If BIOCHEM desires to sign with an Independent Third Party
dealing at arm’s length with BIOCHEM a licence containing more favourable terms
than those offered to GROUP hereunder (the “Third Party Offer”), BIOCHEM shall,
once the details of the licence agreement shall have been negotiated between
BIOCHEM and such Independent Third Party, offer (the “GROUP Offer”) to GROUP the
right to execute an exclusive licence agreement upon the same terms and
conditions as those contained in the Third Party Offer. The GROUP Offer and a
copy of the Third Party Offer shall be sent to GROUP and shall be open for
acceptance by GROUP for thirty (30) days from the receipt of the Group Offer by
GROUP. GROUP shall be obliged by notice to BIOCHEM within the said thirty (30)
days, either to accept or refuse the GROUP Offer. If GROUP accepts the GROUP
Offer, GROUP and BIOCHEM shall execute the GROUP Offer immediately following
receipt by BIOCHEM of the notice of acceptance of GROUP. If GROUP refuses the
GROUP Offer or fails to notify BIOCHEM of its decision within the said thirty
(30) days, BIOCHEM shall be free to execute the Third Party Offer.

       

       

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

      

       

      In
determining whether any terms are more favourable than terms offered to GROUP,
regard shall be had to the totality of the terms rather to any single component
or parts thereof.

       

      GROUP,
GWUS and GWC grant back to BIOCHEM the right to FTC which GROUP, GWUS and GWC
held under the Original Agreement

       

      
        	
                3.  

              	
                CONSIDERATION

              

      

       

      
        	
                (A)  

              	
                In
      consideration of the rights granted to GROUP herein, GROUP has paid to
      PHARMA and TIB collectively in accordance with the Original Agreement the
      sum of *****

              

      

       

      
        	
                (B)  

              	
                In
      consideration of the rights granted to GROUP herein, GROUP shall pay to
      TIB a royalty on GROUP’s Net Sales of any Modified Licensed Product as
      follows:

              

      

       

      
        	
              	
                (i)  

              	
                in
      each country of the Territory, for so long as there is in that country a
      Licensed Patent covering the particular Modified Licensed Product sold in
      such country by GROUP or its Affiliates or its sublicensees, the said
      royalty shall be ***** Net Sales of that Modified Licensed
      Product;

              

      

       

      
        	
              	
                (ii)  

              	
                if
      there is no Licensed Patent covering a particular Modified Licensed
      Product sold in any country in the Territory by GROUP, or its Affiliates
      or its sublicensees, the said royalty shall be ***** of Net Sales of that
      Modified Licensed Product, and such royalty shall be paid for a
      period  of ***** from the date of first commercial sale of that
      Modified Licensed Product in that
country;

              

      

       

      
        	
              	
                (iii)  

              	
                if a
      Licensed Patent exists in any such country but is declared invalid by a
      court of competent jurisdiction from which no appeal has been or can be
      made such that it no longer validly covers a particular Modified Licensed
      Product sold the said royalty shall be ***** of Net Sales of that Modified
      Licensed Product, commencing on the date of declaration of invalidity and
      continuing for the balance of the period of ***** from the date of first
      commercial sale of that Modified Licensed Product in that country;
      and

              

      

       

      
        	
              	
                (iv)  

              	
                upon
      the expiration of the last-to-expire Licensed Patent in any country in the
      Territory covering a particular Modified Licensed Product sold in such
      country by GROUP or its Affiliates or its sublicensees, GROUP shall have
      no further royalty obligation for sales in such country of that Modified
      Licensed Product

              

      

       

      
        	
                (C)  

              	
                GROUP
      shall not be obliged to pay royalties at the full rate set forth in
      subparagraph 3(B)(i) on Net Sales of a Modified Licensed Product sold
      in

              

      

       

       

      
        
          
          

        

        
          9

          
            

          

        

        
          
          

        

      

       

      
        a given
country in the Territory by GROUP, or its Affiliates or its sublicensees, if no
patent covering the manufacture, use, or sale of Modified Licensed Product has
yet proceeded to grant or issue; it being understood and agreed that in such
countries such royalties shall be paid at the reduced rate in accordance with
the provisions of subparagraph 3(B)(ii) until such time as a patent is granted
or issued, covering the manufacture, use, or sale of that Modified Licensed
Product by GROUP or its Affiliates or its sublicensees, whereupon GROUP shall
pay when royalties next fall due under the provisions of paragraph 4 an
additional lump sum royalty of ***** on Net Sales of Modified Licensed Product
sold from the date of commercial sale of Modified Licensed Product in that
country until the date of grant or issue of such patent in that country and
shall pay royalties on Net Sales at the full rate set forth in subparagraph
3(B)(i) for the Modified Licensed Product concerned in the relevant country with
effect from the date of grant or issue of such patent in that
country

      

       

      
        	
                (D)  

              	
                In
      the event that any patent included among the Licensed Patents is declared
      invalid by a court of competent jurisdiction from which no appeal has been
      or can be made such that it no longer validly covers the Modified Licensed
      Product sold, royalties pertaining to that patent shall, from the date of
      such declaration, cease to be made at the full rate set forth in
      subparagraph 3(B)(i) but shall instead be made at the reduced rate set
      forth in subparagraph 3(B)(iii)

              

      

       

      
        	
                (E)  

              	
                The
      Patent Expenses incurred by GROUP and ***** of the payments made by GROUP
      pursuant to subparagraph 3(A) shall be deducted from royalty payments
      arising under subparagraph 3(B) using the following procedure: at the end
      of the Calendar Year in which the first commercial sale of a Modified
      Licensed Product takes place, the Patent Expenses and ***** being ***** of
      the total payments made pursuant to subparagraph 3(A) incurred to date,
      shall be calculated and added together to determine the “Royalty Credit.”·
      Said Royalty Credit shall be deducted in whole or in part to a maximum of
      ***** the royalties due in each Calendar Quarter, from the royalties due
      for the first Calendar Quarter in which royalties are due, and each
      Calendar Quarter thereafter until the total deductions made equal the
      Royalty Credit. In the event that the said total deductions made in a
      Calendar Quarter do not equal the outstanding balance of the Royalty
      Credit, deductions from royalties will continue to be made in each
      successive Calendar Quarter in accordance will the aforesaid procedure
      until GROUP has recovered the full Royalty Credit. At the end of each
      Calendar Quarter, after the Calendar Quarter during which the first
      commercial sale of a Modified Licensed Product took place, the Royalty
      Credit shall be recalculated by adding to it any further Patent Expenses
      incurred during the Calendar Quarter just ended, and subtracting from the
      resulting sum the deductions made from royalties during the previous
      Calendar Quarter.

              

      

       

       

      
        
          
          

        

        
          10

          
            

          

        

        
          
          

        

         

      

      Such
Patent Expenses deductions from royalty payments shall be calculated separately
for Modified Licensed Products which are sold for significantly different
indications, such that the Patent Expenses attributable to one indication are
deducted from the royalties payable on Net Sales of Modified Licensed Product
for that indication.

       

      
        	
                (F)  

              	
                If,
      in order to manufacture, have manufactured, use or sell Modified Licensed
      Product GROUP shall decide following reasonable consultation with BIOCHEM
      that it or its Affiliates or sublicensees shall require any
      indemnifications relating to, or licenses under, any patents owned in
      whole or in part in the Territory by an Independent Third Party which
      cover Modified Licensed Product or formulations or uses thereof or
      processes for or intermediates used in the manufacture thereof the amount
      of the royalty payable to TIB by GROUP on Net Sales of Modified Licensed
      Product in the Territory in any Calendar Quarter shall be reduced by the
      amount of royalty and/or lump sum payments that GROUP or its sublicensees
      shall be required to pay to such Independent Third Party in consideration
      of its activities in respect of Modified Licensed Product in that Calendar
      Quarter: PROVIDED THAT, irrespective of the number of such arrangements
      made with Independent Third Parties, the total permitted royalty reduction
      shall not exceed ***** of the amount that would otherwise be payable by
      way of royalty by GROUP to TIB on Net Sales of such Modified Licensed
      Product in the Territory in the said Calendar Quarter.  GROUP
      shall provide TIB with documentation of such royalties or such lump sum
      payments so paid to any Independent Third
Party

              

      

       

      
        	
                (G)  

              	
                In
      consideration of the rights granted to GWUS herein, GWUS has paid to
      PHARMA, TIB and TLLC collectively in accordance with the Original
      Agreement the sum of *****

              

      

       

      
        	
                (H)  

              	
                In
      consideration of the rights granted to GWUS herein, GWUS shall pay to TLLC
      a royalty on GWUS’ Net Sales of any Modified Licensed Product as
      follows:

              

      

       

      
        	
              	
                (i)  

              	
                *****
      commencing on ***** or sales made until
*****

              

      

       

      
        	
              	
                (ii)  

              	
                *****
      commencing on ***** or sales made until December 30, 1998;
    and

              

      

       

      
        	
              	
                (iii)  

              	
                *****
      commencing December 31, 1998.

              

      

       

      PROVIDED
THAT

       

      
        	
                 
      

              	
                (a)

              	
                such
      royalty rates shall be payable for so long as there is in the USA a
      Licensed Patent covering the particular Modified Licensed Product sold in
      the USA by GWUS;

              

      

       

       

      
        
          
          

        

        
          11

          
            

          

        

        
          
          

        

      

       

      
        	
                 
      

              	
                (b)

              	
                if
      there is no Licensed Patent covering a particular Modified Licensed
      Product sold in the USA by GWUS, the royalty rates applicable to such
      Modified Licensed Product shall be reduced to ***** Net Sales of that
      Modified Licensed Product respectively, for the relevant time periods set
      out above and such royalty rates shall be paid for a period ***** from the
      date of first commercial sale of that Modified Licensed Product in the
      USA;

              

      

       

      
        	
                 
      

              	
                (c)

              	
                if a
      Licensed Patent exists in the USA but is declared invalid by a court of
      competent jurisdiction from which no appeal has been or can be made such
      that it no longer validly covers a particular Modified Licensed Product
      sold the said royalty rates shall be reduced to ***** of Net Sales of that
      Modified Licensed Product respectively, for the relevant time periods set
      out above, commencing on the date of declaration of invalidity and
      continuing for the balance of the period of ***** from the date of first
      commercial sale of that Modified Licensed Product in the USA;
      and

              

      

       

      
        	
                 
      

              	
                (d)

              	
                upon
      the expiration of the last-to-expire Licensed Patent in the USA covering
      the particular Modified Licensed Product sold in the USA by GWUS, GWUS
      shall have no further royalty obligation for sales in the USA of that
      Modified Licensed Product

              

      

       

      
        	
                (I)  

              	
                *****
      of the total payments made pursuant to subparagraphs 3(G) hereof shall
      constitute a “Royalty Credit” to GWUS. Said Royalty Credit shall be
      deducted in whole or in part from the royalties due from GWUS to TLLC in
      accordance with the procedure, mutatis mutandis, set forth in subparagraph
      3(E). Furthermore the provisions of subparagraph 3(F) shall apply mutatis
      mutandis to any arrangements made by or for the benefit of GWUS with
      Independent Third Parties. PROVIDED THAT, irrespective of the number of
      such arrangements made with Independent Third Parties, the total permitted
      royalty reduction shall not exceed a maximum of ***** from GWUS to TLLC on
      Net Sales of such Modified Licensed Product in the USA in the said
      Calendar Quarter.

              

      

       

      
        	
                (J)  

              	
                Nothing
      contained herein shall obligate GROUP or GWUS to pay royalties on sales of
      Modified Licensed Product to its Affiliates or its sublicensees or to pay
      more than one royalty on sales of any specific units of Modified Licensed
      Product

              

      

       

      
        	
                4.  

              	
                ACCOUNTING

              

      

       

      
        	
                (A)  

              	
                GROUP
      shall deliver to TIB for Net Sales in the Territory, and GWUS shall
      deliver to TLLC for Net Sales in the USA, written statements of and the
      royalties due thereon in each Calendar Quarter, on or before the thirtieth
      (30th) day following the end of that Calendar Quarter.
  In

              

      

       

       

      
        
          
          

        

        
          12

          
            

          

        

        
          
          

        

         

        
          GROUP’s
statements, Net Sales shall be expressed separately for major countries and
convenient groupings of other countries, and separately where Modified Licensed
Product is sold for significantly different indications.

        

         

      

      
        	
                (B)  

              	
                GROUP
      shall, on or before the sixtieth (60th) day following the end of each
      Calendar Quarter, pay to TIB or to whomsoever BIOCHEM shall direct in
      writing in pounds sterling to a bank designated in writing by BIOCHEM (or
      in such other currency or manner as may be agreed between the parties from
      time to time), the amount of such royalties shown in each written
      statement to be due, less any permitted deduction pursuant to subparagraph
      3(E) and/or 3(F) hereof. All foreign currencies shall be converted into
      pounds sterling or other agreed currency at the rate of exchange published
      in the Financial
      Times of London or in any other financial source mutually agreed
      upon between the parties on the last business day of the Calendar Quarter
      in question

              

      

       

      
        	
                (C)  

              	
                GWUS
      shall, on or before the sixtieth (60th) day following the end of each
      Calendar Quarter, pay to TLLC or to whomsoever BIOCHEM shall direct in
      writing in United States dollars to a bank designated in writing by
      BIOCHEM (or in such other currency or manner as may be agreed between the
      parties from time to time), the amount of such royalties shown in each
      written statement to be due, less any permitted deduction pursuant to
      subparagraph 3(I) hereof.

              

      

       

      
        	
                (D)  

              	
                Any
      tax which GROUP or its Affiliates or GWUS is required to pay or withhold
      with respect to payments to be made to TIB, TLLC or BIOCHEM hereunder
      shall be deducted from the amount otherwise due: PROVIDED THAT, in regard
      to any such deduction, GROUP shall give BIOCHEM such assistance as may
      reasonably be necessary to enable or assist BIOCHEM to claim exemption
      therefrom or a reduction thereof and shall upon request provide
      documentation from time to time as to confirm the payment of the
      tax

              

      

       

      
        	
                (E)  

              	
                GROUP
      and GWUS shall each keep books and records in sufficient detail to
      determine the calculation of royalties payable by GROUP and GWUS
      hereunder. Such books and records shall, at·the request and expense of
      BIOCHEM, be made available for reasonable review by an independent,
      certified public accountant acceptable to both parties for the sole
      purpose of verifying the accuracy of the royalty payments made by GROUP
      and GWUS under this Agreement: PROVIDED THAT if an inaccuracy in the
      royalty payments of greater than five percent (5%) is determined by such a
      review the cost of the review shall be borne by GROUP or GWUS. Such review
      shall be conducted no more frequently than once per Calendar Year and
      shall be scheduled during ordinary business hours. Such books and records
      shall be retained by GROUP and GWUS for three (3) years from the date of
      their origin: PROVIDED THAT, if a review is
  requested

              

      

       

       

      
        
          
          

        

        
          13

          
            

          

        

        
          
          

        

      

       

      
        during the
third year, each such book and record subjected to review shall be retained for
one (1) year beyond the completion of the review

      

       

      
        	
                5.  

              	
                EXCHANGE OF
      INFORMATION AND REPORTS

              

      

       

      
        	
                (A)  

              	
                Promptly
      upon execution of this Agreement, BIOCHEM shall, insofar as it has not
      already done so, and, insofar as it is not precluded by statute or
      regulation, communicate to GROUP all Know-How in its possession at that
      time. Thereafter, BIOCHEM shall, insofar as it is not precluded by statute
      or regulation, promptly communicate to GROUP all Know-How that it
      generates or acquires

              

      

       

      
        	
                (B)  

              	
                GROUP
      shall promptly provide to BIOCHEM all relevant information related to the
      Modified Licensed Product on a timely basis. BIOCHEM shall have prompt
      access to marketing plans for Modified Licensed Product through GROUP.
      GROUP shall provide to BIOCHEM quarterly written reports on the progress
      of the technical development of Modified Licensed Product. GROUP shall
      provide BIOCHEM with periodic summary reports on its progress in seeking
      regulatory approval for Modified Licensed Product and of plans for launch
      of Modified Licensed Product in the USA and in countries of the Territory
      and of the anticipated commercial potential therefor in such
      countries

              

      

       

      
        	
                (C)  

              	
                The
      parties will each identify individual employees within their respective
      organizations who will be responsible as contacts for the information
      exchange activities required herein. Each party will advise the other
      parties of the identity of its selected individuals within thirty (30)
      days following the signing of this Agreement, and within thirty (30) days
      of any change to that selection. The selected individuals will meet at
      least three (3) times per year.

              

      

       

      
        	
                (D)  

              	
                BIOCHEM
      shall promptly provide to GROUP all information in its possession or
      control concerning side-effects, injury, toxicity or sensitivity reaction
      and incidents or severity thereof associated with all uses, studies,
      investigations or tests with Modified Licensed Product (animal or human)
      throughout the world, whether or not determined to be attributable to
      Modified Licensed Product

              

      

       

      
        	
                (E)  

              	
                The
      parties will cooperate in arranging scientific meetings, announcing the
      results of clinical trials and distributing appropriate information to the
      public in a timely manner

              

      

       

      
        	
                (F)  

              	
                GROUP
      and its Affiliates shall, at their own expense, pursue with reasonable
      diligence and use every reasonable effort to develop Modified Licensed
      Product for use in treatment of Hepatitis B. Although GROUP shall have the
      principal responsibility for the development of
  Modified

              

      

       

       

      
        
          
          

        

        
          14

          
            

          

        

        
          
          

        

      

       

      
        Licensed
Product it shall generally cooperate with BIOCHEM in the developmental
activities

      

       

      
        	
                6.  

              	
                EXPLOITATION OF
      MODIFIED LICENSED PRODUCT

              

      

       

      
        	
                (A)  

              	
                GROUP
      shall use commercially reasonable efforts to launch Modified Licensed
      Product in such countries of the Territory where it believes there to be
      significant commercial potential for Modified Licensed Product and it
      shall also use commercially reasonable efforts, consistent with GROUP’s
      sound and reasonable business practice and judgement, to maximize sales of
      Modified Licensed Product in such countries of the
    Territory.

              

      

       

      
        	
                (B)  

              	
                PHARMA
      and GWC shall enter into a Partnership Agreement as set out in Schedule 3
      hereto and establish a partnership (hereinafter called “the Partnership”)
      to exploit Modified Licensed Product in
Canada.

              

      

       

      
        	
                (C)  

              	
                GWUS
      shall use commercially reasonable efforts, consistent with GWUS’ sound and
      reasonable business practice and judgment, to maximize sales of Modified
      Licensed Product in the USA. GWUS will hold the NDA for Modified Licensed
      Product but shall make suitable reference to PHARMA in compliance with FDA
      requirements, on all packaging and promotional
  materials.

              

      

       

      
        	
                (D)  

              	
                GROUP
      shall supply to GWC at GROUP’s expense any and all supplies of Modified
      Licensed Product for

              

      

       

      
        	
              	
                (i)  

              	
                clinical
      evaluation packages to health care
personnel,

              

      

       

      
        	
              	
                (ii)  

              	
                compassionate
      use, and

              

      

       

      
        	
              	
                (iii)  

              	
                samples
      requested by government.

              

      

       

      
        	
                (E)  

              	
                GROUP
      and GWUS shall be free to set prices for Modified Licensed Product as they
      choose taking into account cost of manufacture, market conditions and all
      other relevant factors but GROUP and GWUS shall not set such a price with
      the principal purpose of reducing the royalties payable to BIOCHEM under
      this Agreement.

              

      

       

      
        	
                7.  

              	
                PATENTS

              

      

       

      
        	
                (A)  

              	
                BIOCHEM
      shall undertake and/or continue at the expense of, and in full
      consultation with, GROUP or its designated
  Affiliate:

              

      

       

      
        	
              	
                (i)  

              	
                the
      filing of any additional patent applications in the Territory and USA and
      Canada based upon patent applications set out in Schedule 2 hereto or
      relating to Modified Licensed Products: PROVIDED THAT BIOCHEM shall
      consult with GROUP

              

      

       

       

      
        
          
          

        

        
          15

          
            

          

        

        
          
          

        

         

        
          regarding
countries in which such additional patent applications should be filed and shall
also file patent applications in those countries where GROUP requests that
BIOCHEM files;

        

         

      

      
        	
              	
                (ii)  

              	
                prosecuting
      all pending and new patent applications included within Licensed Patents
      and responding to oppositions or any other form of action for invalidity
      or revocation of patent rights filed by third parties against the grant of
      patents for such applications [except as arising under subparagraphs 7(H)
      and 7(I)]; and

              

      

       

      
        	
              	
                (iii)  

              	
                maintaining
      in force any patents and patent applications included within Licensed
      Patents by duly filing all necessary papers and paying any fees required
      by the patent laws of the particular country in which such patents were
      granted or such patent applications were
filed

              

      

       

      
        	
                (B)  

              	
                BIOCHEM
      may use independent patent counsel and/or advisors satisfactory to BIOCHEM
      and GROUP for the purposes of the activities to be conducted pursuant to
      subparagraph 7(A). BIOCHEM shall provide to GROUP copies of all documents
      relating to the prosecution of all patent applications. BIOCHEM shall
      provide to GROUP every six (6) months a report on its progress in seeking
      patent protection pursuant to subparagraph
7(A)

              

      

       

      
        	
                (C)  

              	
                BIOCHEM
      shall notify GROUP in a timely manner of any decision to abandon a patent
      application or an issued patent included within Licensed Patents.
      Thereafter GROUP shall have the option of continuing to prosecute any such
      patent application or of keeping the issued patent in
  force

              

      

       

      
        	
                (D)  

              	
                BIOCHEM
      shall execute, and BIOCHEM agrees to procure from any inventor(s) or the
      beneficiaries or executors of such inventor(s), his or her agreement to
      execute all documents and perform all acts, at GROUP’s expense, reasonably
      necessary to file, prosecute, maintain and enforce the Licensed
      Patents.

              

      

       

      
        	
                (E)  

              	
                GROUP
      and GWUS shall each be entitled to offset all Patent Expenses incurred by
      it under this Paragraph 7 against royalties due under subparagraph 3(B)
      and 3(H) respectively, in accordance with the Royalty Credit provisions
      set forth in subparagraphs 3(E) and
3(I)

              

      

       

      
        	
                (F)  

              	
                GROUP,
      GWUS and BIOCHEM shall cooperate fully on all matters relating to the
      filing, prosecution and maintenance of Licensed
  Patents

              

      

       

      
        	
                (G)  

              	
                Recognizing
      the interests of the parties in avoiding disclosures that might prejudice
      the Licensed Patents, it is hereby agreed that GROUP, GWUS and BIOCHEM
      shall have the right to make publications or presentations relating to
      Modified Licensed Product PROVIDED THAT the
  party

              

      

       

       

      
        
          
          

        

        
          16

          
            

          

        

        
          
          

        

         

        
          intending
to publish shall furnish the other with a copy of the manuscript for any
proposed publication or presentation no later than ninety (90) days prior to the
submission of such proposed publication or presentation to a journal, editor, or
other third party for the purpose of review and comment. The other party shall
have the right to request modifications of any manuscript to be published or
presented, if such manuscript will jeopardize a patent application, patent,
trade secret, or other proprietary right relating to this Agreement. If the
party intending to publish does not agree with such modification, the parties
shall consult independent patent counsel satisfactory to both parties, whose
determination shall be binding. Either party shall also have the right to
request a reasonable additional period of time in which to obtain, as necessary
in its sole discretion, additional patent protection, before information
contained in a manuscript is published or presented by the
other

        

         

      

      
        	
                (H)  

              	
                In
      the event that BIOCHEM, GROUP or GWUS determines that an Independent Third
      Party is making, using, or selling a product that may infringe a Licensed
      Patent, it will promptly notify the other party in writing. GROUP or GWUS
      may, at its sole option, bring suit against such alleged infringer. In the
      event that GROUP or GWUS decides to bring suit, it shall give prompt
      written notice to BIOCHEM of that fact, and BIOCHEM shall take all
      reasonable steps to assist GROUP or GWUS in such suit. GROUP or GWUS shall
      be entitled to all amounts recovered in such suit, except that BIOCHEM
      shall have the right to elect to pay up to ***** of the litigation costs
      and receive a percentage of any recovery equal to the percentage of
      litigation costs paid. BIOCHEM must make such election within sixty (60)
      days of its receipt of GROUP’s or GWUS’ notice that GROUP or GWUS
      respectively has decided to bring suit. BIOCHEM shall also have the right
      to be represented by separate counsel at its own expense in any such suit.
      GROUP or GWUS shall have control over any such suit, and decisions as to
      settlement, methods and/or terms and conditions for resolving the suit
      shall be made by GROUP or GWUS after consultation with BIOCHEM. If GROUP
      or GWUS elects not to bring a suit against the alleged infringer, it shall
      promptly notify BIOCHEM of that fact, and BIOCHEM shall have the right to
      commence such action at its own cost and expense, in which case BIOCHEM
      shall be entitled to all amounts recovered in such action. GROUP or GWUS
      shall take all reasonable steps to assist BIOCHEM in such
    suit

              

      

       

      
        	
                (I)  

              	
                In
      the event that GROUP or its Affiliates or its sublicensee(s) is or are
      sued by an Independent Third Party charging patent infringement for the
      manufacture, use or sale of a Modified Licensed Product, GROUP shall
      promptly notify BIOCHEM and both parties shall meet to consider a common
      strategy for responding to the suit. Failure to agree upon a strategy will
      result in the matter being referred to independent patent counsel
      satisfactory to both parties whose determination shall be binding. BIOCHEM
      shall take all reasonable steps to assist GROUP in
  the

              

      

       

       

      
        
          
          

        

        
          17

          
            

          

        

        
          
          

        

      

       

      
        response
to such suit which response shall be progressed by GROUP in full consultation
with BIOCHEM. GROUP shall be entitled to withhold up to ***** of the royalties
otherwise payable to BIOCHEM until such time as the suit is resolved or settled,
and use that withheld royalty to cover external legal defence costs incurred in
such infringement suit. If GROUP avails itself of the provisions of this
paragraph, GROUP agrees to supply BIOCHEM with documentation to confirm the
legal costs incurred

      

       

      
        	
                (J)  

              	
                BIOCHEM
      shall inform GROUP of any change in the status of any patent related to
      Residual Products where such change will entitle GROUP to rights to those
      Residual Products in this
Agreement.

              

      

       

      
        	
                8.  

              	
                CONFIDENTIALITY

              

      

       

      Unless
otherwise provided for in this Agreement, the parties shall treat any and all
information and data (including Know-How) received or derived under this
Agreement as strictly confidential, and shall not disclose the same to any
Independent Third Party for the period of thirty (30) years from the date first
above written, except for information which:

       

      
        	
                (A)  

              	
                is
      or shall have been known to the receiving party prior to the disclosure by
      the other party as evidenced by written record or other proof;
      or

              

      

       

      
        	
                (B)  

              	
                is
      or shall have been public knowledge through no fault of the receiving
      party; or

              

      

       

      
        	
                (C)  

              	
                is
      acquired lawfully by the receiving party from a third party that has no
      confidentiality obligation to the disclosing party;
  or

              

      

       

      
        	
                (D)  

              	
                the
      receiving party needs to disclose to a third party for the purposes of
      this Agreement: PROVIDED, HOWEVER, THAT such third party shall be bound by
      a similar confidentiality obligation, and the disclosing party shall take
      such action as is necessary to procure that any such information revealed
      is treated as strictly confidential, including obtaining a signed
      confidential disclosure agreement

              

      

       

      Notwithstanding
the above, the parties may disclose such information:

       

      
        	
              	
                (i)  

              	
                to
      their employees;

              

      

       

      
        	
              	
                (ii)  

              	
                in
      the case of GROUP and GWUS, to their Affiliates and employees, their
      sublicensees and employees and to Independent Third Party consultants and
      contractors subject to such consultants and contractors entering into
      suitable secrecy agreements with GROUP, GWUS or their Affiliates. GROUP,
      GWUS or their Affiliates shall promptly notify BIOCHEM of any such
      agreements and provide copies of such agreements to
    BIOCHEM;

              

      

       

       

      
        
          
          

        

        
          18

          
            

          

        

        
          
          

        

         

      

      
        	
              	
                (iii)  

              	
                in
      the case of GWC, to its Affiliates and employees, and to Independent Third
      Party consultants and contractors subject to such consultants and
      contractors entering into suitable secrecy agreements with GWC or its
      Affiliates. GWC or its Affiliates shall promptly notify BIOCHEM of any
      such agreements and provide copies of such agreements to
      BIOCHEM;

              

      

       

      
        	
              	
                (iv)  

              	
                to
      competent government agencies; and

              

      

       

      
        	
              	
                (v)  

              	
                as
      required by law;

              

      

       

      to the
extent such disclosure is necessary to achieve the purposes of this
Agreement

       

      
        	
                9.  

              	
                INDEMNIFICATION

              

      

       

      
        	
                (A)  

              	
                GROUP
      shall indemnify, protect and hold BIOCHEM and BIOCHEM’s directors,
      officers, employees and agents harmless against any and all losses,
      damages, fines, costs, expenses (including attorneys’ fees) and
      liabilities (including but not limited to claims, actions, legal
      proceedings or lawsuits, based on any civil or criminal claims of
      liability, including without limitation, negligence, gross negligence,
      recklessness, willful misconduct, product liability, strict liability,
      breach of express or implied warranty, fraud, misrepresentation, or
      violation of any statute, regulation or rule) (referred to collectively as
      “Liabilities”), asserted at any time arising out of or involving GROUP’s
      or its Affiliates’ or sublicensees’ development, manufacture, use or sale
      of Modified Licensed Products. Such indemnification shall not extend to
      Liabilities to the extent that they result from the negligence,
      recklessness, willful misconduct or fraud of BIOCHEM, its directors,
      officers, employees or agents. To the extent such Liabilities result from
      the negligence, recklessness or willful misconduct or fraud of or by
      BIOCHEM, its directors, officers, employees and agents, BIOCHEM shall
      indemnify, protect and hold harmless GROUP and GROUP’s directors,
      officers, employees, agents, Affiliates and sublicensees against any and
      all such Liabilities

              

      

       

      
        	
                (B)  

              	
                A
      party seeking indemnification under section 9(A) (hereinafter called the
      “Indemnified Party”) shall give prompt written notification to the party
      from whom indemnification is sought (hereinafter called the “Indemnifying
      Party”) or any claims, actions, legal proceedings or lawsuits for which
      the Indemnified Party may assert indemnification from the Indemnifying
      Party under this Agreement. The Indemnifying Party shall have the right,
      at its own cost to defend any such claim, action, legal proceeding or
      lawsuit. The Indemnified Party shall have the right to be represented by
      separate counsel at its own expense, in any such claim, action, legal
      proceeding or lawsuit. The Indemnifying Party shall have control over any
      such suit and any decisions as to settlement,
  method

              

      

       

       

      
        
          
          

        

        
          19

          
            

          

        

        
          
          

        

      

       

      
        and/or
terms and conditions for resolving the suit shall be made by the Indemnifying
Party after consultation with the Indemnified Party.

      

       

      
        	
                (C)  

              	
                The
      Indemnified Party agrees to provide reasonable assistance to the
      Indemnifying Party which may be necessary or desirable for the defence
      and/or settlement of any such claim, action, legal proceeding or lawsuit.
      The Indemnifying Party shall reimburse the Indemnified Party for its
      reasonable out-of-pocket expenses related
  thereto.

              

      

       

      
        	
                10.  

              	
                TERM

              

      

       

      This
Licence Agreement shall commence with effect from 20 November 1995 and from that
date shall replace the Original Agreement. Unless sooner terminated as provided
herein, this Licence Agreement shall expire

       

      
        	
                 
      

              	
                (i)

              	
                upon
      the expiration date of the last to expire Licensed Patent,
    or

              
	 	 	 
	 	      
                (ii)

              	      
                in
      the absence of any such Licensed Patent, upon the ***** anniversary of the
      date of first commercial sale of Modified Licensed Product by GROUP, or
      its Affiliates or its sublicensees, in the particular country in the
      Territory wherein GROUP or its Affiliates or its sublicensees last
      introduced Modified Licensed
Product.

              

      

       

      Upon
expiration of this Agreement under this paragraph, *****

       

      
        	
                11.  

              	
                TERMINATION

              

      

       

      
        	
                (A)  

              	
                If
      GROUP shall fail to pay to TIB, or GWUS shall fail to pay to TLLC,
      royalties as provided under this Licence Agreement for ***** TIB or TLLC
      as the case may be, may in its sole discretion, terminate this Licence
      Agreement and the licenses granted hereunder after giving GROUP or GWUS as
      the case may be, ***** written notice thereof and ***** additional days
      for GROUP or GWUS to cure such breach. Such cure shall be effected by
      GROUP remitting to TIB, or GWUS remitting to TLLC as the case may be, the
      full amount of the unpaid royalties together with interest on said amount
      calculated at a rate that is ***** above the base lending rate of the Bank
      of Montreal from the date when payment of the outstanding royalties
      originally fell due

              

      

       

      
        	
                (B)  

              	
                Other
      than as provided for in subparagraph
11(A):

              

      

       

      
        	
              	
                (i)  

              	
                BIOCHEM
      may terminate this Licence Agreement in the event of a material breach by
      a party to the first part of this Agreement, PROVIDED ONLY that BIOCHEM
      gives to the breaching party written notice of the breach and a reasonable
      time, not to exceed ninety (90) days, in which to cure or to take
      reasonable steps to cure such breach;
and

              

      

       

       

      
        
          
          

        

        
          20

          
            

          

        

        
          
          

        

      

       

      
        	
              	
                (ii)  

              	
                GROUP
      may terminate this Agreement on behalf of the parties to the first part of
      this Agreement in the event of material breach by PHARMA, THB, TIB or
      TLLC, PROVIDED ONLY that GROUP gives to the breaching Party written notice
      of the breach and a reasonable time, not to exceed ***** in which to cure
      or to take reasonable steps to cure such
breach

              

      

       

      
        	
                (C)  

              	
                This
      Agreement shall terminate forthwith on written notice from GROUP to
      BIOCHEM or from BIOCHEM to GROUP if BIOCHEM (in the case of a notice from
      GROUP) or GROUP (in the case of a notice from BIOCHEM shall make an
      assignment for the benefit of creditors, file a petition in bankruptcy,
      petition or apply to any tribunal for the appointment of a custodian,
      receiver or any trustee for it or a substantial part of its assets, or
      shall commence any proceeding under any bankruptcy, reorganization,
      arrangement, readjustment of debt, dissolution or liquidation law or
      statute of any jurisdiction, whether now or hereafter in effect; or if
      there shall have been filed any such petition or application against
      BIOCHEM or GROUP, or any such proceeding shall have been commenced against
      it, in which an order for relief is entered or which remains undismissed
      for a period of thirty (30) days or more; or BIOCHEM or GROUP by any act
      or omission shall indicate its consent to, approval of or acquiescence in,
      any such petition, application or proceeding or order for relief or the
      appointment of a custodian, receiver or any trustee for it or any
      substantial part of any or its properties, or shall suffer any such
      custodianship, receivership or trusteeship to continue undischarged for a
      period of thirty (30) days or more

              

      

       

      
        	
                12.  

              	
                RIGHTS ON TERMINATION
      OR EXPIRATION

              

      

       

      
        	
                (A)  

              	
                If
      this Agreement is terminated by BIOCHEM pursuant to subparagraphs 11(A) or
      11(B) or is terminated under subparagraph 11(C) as a result of GROUP being
      affected by any of the circumstances listed
  therein:

              

      

       

      
        	
              	
                (i)  

              	
                GROUP
      shall promptly return to BIOCHEM all written Know-How provided by BIOCHEM
      during the term of this Agreement. GROUP, its Affiliates and sublicensees
      shall immediately cease to use and thereafter refrain from using such
      Know-How; and

              

      

       

      
        	
              	
                (ii)  

              	
                GROUP,
      its Affiliates and sublicensees shall promptly transfer all rights and
      copies to BIOCHEM of all product registrations, product licence
      applications and other drug designations relating to Modified Licensed
      Product

              

      

       

      
        	
                (B)  

              	
                If
      this Agreement is terminated by GROUP pursuant to subparagraph 11(B) or is
      terminated under subparagraph 11(C) as a ·result of BIOCHEM or any of its
      Affiliates being affected by any of the circumstances listed therein,
      GROUP and its Affiliates shall have a non-exclusive,
      worldwide,

              

      

       

       

      
        
          
          

        

        
          21

          
            

          

        

        
          
          

        

      

       

      
        paid-up
licence with a right to sublicense under Licensed Patents and Know-How to
manufacture, have manufactured, use and sell Modified Licensed Product and to
disclose Know-How in the circumstances set out in paragraph 8 herein and shall
be without further financial obligation to BIOCHEM

      

       

      
        	
                (C)  

              	
                Termination
      of this Agreement for any reason shall be without prejudice to the right
      of BIOCHEM to receive all royalties accrued and unpaid on the effective
      date of termination and shall not relieve either party of any liability or
      from any obligations which accrued hereunder prior to such
      termination.

              

      

       

      
        	
                (D)  

              	
                The
      confidentiality obligation set forth in paragraph 8 shall survive the
      termination or expiration of this
Agreement

              

      

       

      
        	
                13.  

              	
                WARRANTIES

              

      

       

      
        	
                (A)  

              	
                BIOCHEM
      warrants and represents that the rights granted herein are free of any
      encumbrance, and that it has not executed and agrees it will not execute
      any agreements inconsistent with or impair the exclusive licenses granted
      hereunder

              

      

       

      
        	
                (B)  

              	
                BIOCHEM
      warrants and represents that all patent applications, patents and Know-How
      relevant to Modified Licensed Product hereunder have been disclosed to
      GROUP and are included within the definition of Licensed Patents, and/or
      Know-How

              

      

       

      
        	
                (C)  

              	
                Each
      party warrants and represents to the other party that it has the full
      right and authority to enter into this Agreement without the consent or
      approval of any Independent Third Party and that its obligations and
      duties hereunder are not contrary to, or in conflict with, any of its
      obligations and duties to any Independent Third
  Party

              

      

       

      
        	
                14.  

              	
                PUBLICITY

              

      

       

      No party
shall issue any press release or other publicity materials or make any
representation with respect to the existence of this Agreement or the subject
matter thereof without the prior written consent of the other party. However,
this restriction shall not apply to announcements required by law or regulation
except that in such event the parties shall coordinate to the extent possible
with respect to the wording of any such announcement

       

      
        	
                15.  

              	
                FORCE
      MAJEURE

              

      

       

      No party
shall be liable to the other for failure or delay in the performance of any of
its obligations under this Agreement for the time and to the extent such failure
or delay is caused by riots, civil commotions, wars, hostilities between
nations, governmental laws, orders or regulations, embargoes, actions by the
government

       

       

      
        
          
          

        

        
          22

          
            

          

        

        
          
          

        

      

       

      or any
agency thereof, acts of God, storms, fires, accidents, labour disputes or
strikes, sabotage, explosions or other similar or different contingencies, in
each case, beyond the reasonable control of the respective parties (“Force
Majeure”). If the performance of any obligation under this Agreement is delayed
owing to Force Majeure for any continuous period of more than six (6) months,
the parties hereto shall consult with respect to an equitable solution,
including the possible termination of this Agreement

       

      
        	
                16.  

              	
                SEVERABILITY

              

      

       

      In the
event that any provision of this Agreement is held by a court of competent
jurisdiction to be unenforceable because it is invalid or in conflict with any
law of any relevant jurisdiction, the validity of the remaining provisions shall
be construed and enforced as if the Agreement did not contain the particular
provisions held to be unenforceable

       

      
        	
                17.  

              	
                ASSIGNMENT

              

      

       

      This
Agreement shall not be assignable in whole or in part by either party hereto
except to a successor thereto (or, in the case of GROUP, to an Affiliate)
without the prior written consent of the other party hereto. When duly assigned
in accordance herewith this Agreement shall be binding upon and inure to the
benefit of the successor or assignee

       

      
        	
                18.  

              	
                AMENDMENT

              

      

       

      This
Agreement replaces the Original Agreement and all other documents executed or
delivered pursuant thereto, including the documents related to the Original
Agreement listed in Schedule 4 hereto, with effect from November 20, 1995. The
Original Agreement shall be used solely to determine the rights and obligations
as between the parties in existence up to and including 19 November 1995 in
relation to Modified Licensed Product and Residual Product. Schedule 4 hereto
sets out a table of concordance indicating the documents agreements and
schedules related to the Original Agreement, and the documents, agreements and
schedules related to this Agreement.

       

      No
modification or amendment of this Agreement shall be valid or binding upon the
parties hereto unless made in writing and duly executed on behalf of the parties
hereto

       

      
        	
                19.  

              	
                RELATIONSHIP OF
      PARTIES

              

      

       

      All
parties are independent contractors under this Agreement. Nothing contained in
this Agreement is intended nor is to be construed so as to constitute BIOCHEM or
GROUP as partners or joint venturers with respect to this Agreement except to
the extent contemplated in the Partnership Agreement set out in Schedule 3 to
this Agreement. Neither party hereto shall have any express or implied right or
authority to assume or create any obligations on behalf of or in the name of
the

       

       

      
        
          
          

        

        
          23

          
            

          

        

        
          
          

        

         

      

      other
party or to bind the other party to any other contract, agreement, or
undertaking with any third party

       

      
        	
                20.  

              	
                NOTICES

              

      

       

      All
notices or communications sent or delivered hereunder by one party to the other
party shall be in writing and shall be deemed duly given when delivered to the
other party at the address set out in Schedule 5 hereto or by telecopier to the
number set out on Schedule 5, or at such other address (or to such other person)
as the other party may designate by notice to the said one party
hereunder.

       

      
        	
                21.  

              	
                WAIVER

              

      

       

      The
failure on the part of either party hereto to exercise or enforce any right
conferred upon it hereunder shall not be deemed to be a waiver of any such right
or operate to bar the exercise or enforcement thereof at any time or times
thereafter.

       

      
        	
                22.  

              	
                TITLES

              

      

       

      The
marginal headings have been inserted for convenience only and do not form part
of this Agreement.

       

      
        	
                23.  

              	
                DISPUTE SETTLEMENT AND
      GOVERNING LAW

              

      

       

      The
parties agree to attempt to settle any dispute, controversy or difference
arising out of or relating to this Agreement, or breach thereof, by friendly
discussions. If and when any such dispute, controversy or difference is not
settled by such measures, then it shall be decided in accordance with the rules
of the International Chamber of Commerce by a single arbitrator appointed
pursuant to such rules. The parties shall cause such arbitrator to be bound by
confidentiality undertakings substantially equivalent in their effect to those
contained in paragraph 8 hereof. The parties agree to be bound by the award of
such arbitration and that such award may be enforced by any court of competent
jurisdiction. The place of arbitration shall be the city of the respondent party
in any dispute. In the event of multiple respondents involving GROUP and/or GWUS
and/or GWC, the parties to the arbitration agree that the place of arbitration
will be Toronto, Canada unless otherwise agreed to by the parties to the
arbitration. This Agreement shall be construed in all respects and take effect
in accordance with the laws of the Province of Ontario unless otherwise agreed
to by the parties to the arbitration.

       

      
        	
                24.  

              	
                SRA

              

      

       

      The
parties hereby confirm that the SRA was extended by the parties to December 31,
1995, in consideration of an aggregate payment by GWC of *****. A final
installment of ***** of the said amount shall be payable on the signing of this
Agreement.

       

       

      
        
          
          

        

        
          24

          
            

          

        

        
          
          

        

      

       

      
        	
                25.  

              	
                JOINT and
      SEVERAL

              

      

       

      The
parties acknowledge and agree that all of the covenants, agreements,
representations, warranties and other obligations of BIOCHEM hereunder are joint
and several covenants, obligations, representations, warranties and obligations
of PHARMA, THB, TIB and TLLC.

       

      
        	
                26.  

              	
                LANGUAGE

              

      

       

      The
Parties hereto have expressly requested that this Agreement and all related
documents and notices be drafted in the English language. Les parties aux
présentes ont exigé, de façon expresse, que le présent contrat de meme que tous
les documents et avis qui s’y rattachent soient rédigés en langue
anglaise.

       

      IN WITNESS
WHEREOF, the parties hereto have caused this Agreement to be executed on the day
and year first above written.

       

      
        	
                SIGNED
      BY:

                GLAXO
      GROUP LIMITED

                in
      the presence of:

              	
                )

                )

                )

              	 
      
	 
      	 
      	 
      
	
                SIGNED
      BY:

                for
      and on behalf of

                GLAXO
      WELLCOME INC. (GWUS)

                in
      the presence of:

              	
                )

                )

                )

                )

                )

              	 
      
	 
      	 
      	 
      
	
                SIGNED
      BY:

                for
      and on behalf of

                GLAXO
      WELLCOME INC. (GWC)

                in
      the presence of:

              	
                )

                )

                )

                )

              	 
      
	 
      	 
      	 
      
	
                SIGNED
      BY:

                for
      and on behalf of

                BIOCHEM
      PHARMA INC.

                in
      the presence of:

              	
                )

                )

                )

                )

              	 
      
	 
      	 
      	 
      
	
                SIGNED
      BY:

                for
      and on behalf of

                TANAUD
      HOLDINGS (BARBADOS) LIMITED

                in
      the presence of:

              	
                )

                )

                )

                )

                )

              	 
      
	 
      	 
      	 
      
	
                SIGNED
      BY:

                for
      and on behalf of

                TANAUD
      INTERNATIONAL B.V.

                in
      the presence of:

              	
                )

                )

                )

                )

              	 
      

      

       

       

      
        
          
          

        

        
          25

          
            

          

        

        
          
          

        

      

       

      
        	
                SIGNED
      BY:

                for
      and on behalf of

                TANAUD
      LLC.

                in
      the presence of:

              	
                )

                )

                )

                )

              	 
      

      

       

       

      
        
          
          

        

        
          26

          
            

          

        

        
          
          

        

      

      
 

      SCHEDULE
1

       

      “Residual
Product” means any compound falling within the general formula (1) the geometric
and optical isomers thereof, and mixtures of those isomers:

       

      

       

      wherein:

       

      R1 is
selected from a group consisting of hydrogen, an acyl group having 1 to 16
carbon atoms, benzoyl and a benzoyl substitued in any position by at least one
halogen, lower alkyl, lower alkoxy, nitro and trifluoromethyl
groups;

       

      R2 is a
heterocyclic radical selected from a group consisting of:

       

       

      

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      

       

      Cont’d/p.2

       

      R3 and R4 are
independently selected from the group consisting of hydrogen and lower alkyl
groups;

       

      RS is
selected from the group consisting of lower alkyl and halogens;

       

      or any
compound falling within the general formula (II), the geometric and optical
isomers thereof, and mixtures of those isomers:

       

      

       

      wherein:

       

      R6 is
hydrogen;

       

      R7 is a
purine or pyrimidine base or an analogue or derivative thereof;

       

      Z is
selected from the group consisting of S1 S =O or
SO2;

       

      and
pharmaceutically acceptable derivatives thereof.

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      

       

      SCHEDULE
2

       

      *****

       

      
        	
                COUNTRY

              	
                SERIAL
      NO.

              	
                FILING
      DATE

              	
                STATUS

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                ARIPO

              	
                AP/P/90/00163

              	
                8
      February 1990

              	
                Patent
      AP 136

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Australia

              	
                49201/90

              	
                8
      February 1990

              	
                Patent
      630913

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                European
      Patent Designated

                Countries:

                Austria

                Belgium

                Switzerland

                Germany

                Denmark

                France

                United
      Kingdom

                Italy

                Liechtenstein

                Luxembourg

                Netherlands

                Spain

                Sweden

                Greece

              	
                90301335.7

                EP
      0382526

              	
                8
      February 1990

              	
                Allowed

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Hungary

              	
                708/90

              	
                7
      February 1990

              	
                Patent
      208,134

              
	
                Hungary
      / Pipeline

              	
                P /
      P 00058

              	
                15
      December 1994

              	
                Patent
      210537

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              

      

       

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      Page
2

       

      *****

       

      
        	
                COUNTRY

              	
                SERIAL
      NO.

              	
                FILING
      DATE

              	
                STATUS

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Malaysia

              	
                9000206

              	
                8
      February 1990

              	
                Patent
      MY105523A

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                New
      Zealand

              	
                232421

              	
                8
      February 1990

              	
                Patent
      232421

              
	
                Nigeria

              	
                31/90

              	
                8
      February 1990

              	
                Patent
      RP 10849

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                OAPI

              	
                59/35

              	
                8
      February 1990

              	
                Patent
      9193

              
	
                Pakistan

              	
                57/90

              	
                8
      February 1990

              	
                Patent
      132128

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                South
      Africa

              	
                90/0943

              	
                8
      February 1990

              	
                Patent
      90/0943

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Taiwan

              	
                79101049

              	
                10
      February 1990

              	
                Patent
      050260

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                United
      States

              	
                07/308,101

              	
                8
      February 1889

              	
                Patent
      5,047,407

              
	
                United
      States DIV

              	
                07/716,627

              	
                17
      June 1991

              	
                Patent
      5,151,426

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              

      

       

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      *****

       

      
        	
                COUNTRY

              	
                SERIAL
      NO.

              	
                FILING
      DATE

              	
                STATUS

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Australia

              	
                11534/92

              	
                3
      January 1992

              	
                Patent
      660650

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                European
      Patent Designated

                Countries:

                Austria

                Belgium

                Switzerland

                Germany

                Denmark

                France

                United
      Kingdom

                Italy

                Liechtenstein

                Luxembourg

                Netherlands

                Spain

                Sweden

                Greece

                Monaco

                Portugal

              	
                92901354.8

                EP
      0565549

              	
                3
      January 1992

              	
                Patent

                0565549131

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Germany

              	
                P69201

                94810-08

              	 
      	
                Patent

                565549131

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              

      

       

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      Page
2

       

      *****

       

      
        	
                COUNTRY

              	
                SERIAL
      NO.

              	
                FILING
      DATE

              	
                STATUS

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                South
      Africa

              	
                92/0058

              	
                3
      January 1992

              	
                Patent
      92/0058

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              

      

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      *****

       

      
        	
                COUNTRY

              	
                SERIAL
      NO.

              	
                FILING
      DATE

              	
                STATUS

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Australia

              	
                16394/92

              	
                20
      May 1992

              	
                Patent
      655973

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                European
      Patent Designated

                Countries:

                Austria

                Belgium

                Switzerland

                Germany

                Denmark

                France

                United
      Kingdom

                Italy

                Liechtenstein

                Luxembourg

                Netherlands

                Spain

                Sweden

                Greece

                Monaco

                Portugal

              	
                92304552.0

                EP
      0515157

              	
                20
      May 1992

              	
                Accepted

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              

      

       

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      Page
2

       

      *****

       

      
        	
                COUNTRY

              	
                SERIAL
      NO.

              	
                FILING
      DATE

              	
                STATUS

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                New
      Zealand

              	
                242817

              	
                20
      May 1992

              	
                Patent
      242817

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Pakistan

              	
                240/92

              	
                21
      May 1992

              	
                Patent
      133215

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                South
      Africa

              	
                92/3640

              	
                19
      May 1992

              	
                Patent
      92/3640

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Sri
      Lanka

              	
                10587

              	
                21
      May 1992

              	
                Patent
      10587

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              

      

       

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      *****

       

      
        	
                COUNTRY

              	
                SERIAL
      NO.

              	
                FILING
      DATE

              	
                STATUS

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                ARIPO

              	
                AP/P/91/00255

              	
                2
      May 1991

              	
                Patent
      AP 182

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              

      

       

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      Page
2

       

      *****

       

      
        	
                COUNTRY

              	
                SERIAL
      NO.

              	
                FILING
      DATE

              	
                STATUS

              
	
                *****

              	
                *****

              	
                Not
      confirmed

              	
                Pending

              
	
                *****

              	
                *****

              	
                2
      May 1991

              	
                Pending

              
	
                *****

              	
                *****

              	
                20
      April 1995

              	
                Patent
      (Number Not Confirmed)

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Morocco

              	
                PV
      22144

              	
                29
      April 1991

              	
                Patent
      PV22144

              
	
                New
      Zealand

              	
                238017

              	
                1
      May 1991

              	
                Patent
      238017

              
	
                Nigeria

              	
                71/91

              	
                30
      April 1991

              	
                Patent
      RP 11.263

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                OAPI

              	
                PV
      60122

              	
                2
      May 1991

              	
                Patent
      9559

              
	
                Pakistan

              	
                160/91

              	
                30
      April 1991

              	
                Patent
      132680

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Poland

              	
                P293181

              	
                2
      May 1991

              	
                Accepted

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                South
      Africa

              	
                91/3293

              	
                30
      April 1991

              	
                Patent
      91/3293

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Sri
      Lanka

              	
                10346

              	
                2
      May 1991

              	
                Patent
      10346

              
	
                Taiwan

              	
                80105621

              	
                19
      July 1991

              	
                Patent
      59316

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                Tunisia

              	
                SN91029

              	
                2
      May 1991

              	
                Patent
      16428

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              

      

      

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      Page
3

       

      *****

       

      
        	
                COUNTRY

              	
                SERIAL
      NO.

              	
                FILING
      DATE

              	
                STATUS

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              
	
                *****

              	
                *****

              	
                *****

              	
                *****

              

      

      

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

         

      

       

      GLAXO
WELLCOME INC.

      

      

      

      -and-

      

      

      

      BIOCHEM
PHARMA INC.

      

      

      

      

      

      

      

      _______________________________

      

      PARTNERSHIP
AGREEMENT

      

      January
1, 1996

      _______________________________

       

       

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      

      INDEX

       

      
        
          	
                  ARTICLE
      1

                
	 
      	 
      	 
      
	
                  INTERPRETATION

                
	
                  1.1

                	
                  Defined
      Terms

                	
                  2

                
	
                  1.2

                	
                  General
      Definitions

                	
                  4

                
	 	 	 
	
                  ARTICLE
      2

                
	 
      	 
      	 
      
	
                  FORMATION
      OF PARTNERSHIP

                
	 
	
                  2.1

                	
                  Formation
      of the Partnership

                	
                  5

                
	
                  2.2

                	
                  Purpose
      of the Partnership

                	
                  5

                
	
                  2.3

                	
                  Interests
      of the Partners

                	
                  6

                
	
                  2.4

                	
                  Scope
      of Authority

                	
                  6

                
	
                  2.5

                	
                  Partition

                	
                  6

                
	
                  2.6

                	
                  Partnership
      Interest of the Partners

                	
                  6

                
	 	 	 
	
                  ARTICLE
      3

                
	 
      	 
      	 
      
	
                  EXPLOITATION
      RIGHTS

                
	 
	
                  3.1

                	
                  Master
      Licence Agreement

                	
                  7

                
	
                  3.2

                	
                  Additional
      Conveyance Documents

                	
                  7

                
	 	 	 
	
                  ARTICLE
      4

                
	 
      	 
      	 
      
	
                  MANAGEMENT
      COMMITTEE

                
	 
	
                  4.1

                	
                  Function
      of the Management Committee

                	
                  7

                
	
                  4.2

                	
                  Major
      Decisions

                	
                  7

                
	
                  4.3

                	
                  Composition
      of the Management Committee

                	
                  9

                
	
                  4.4

                	
                  Meetings
      of the Management Committee

                	
                  10

                
	
                  4.5

                	
                  Quorum
      of the Management Committee

                	
                  10

                
	
                  4.6

                	
                  Decisions
      of the Management Committee

                	
                  10

                
	
                  4.7

                	
                  Rules
      and Regulations

                	
                  11

                
	
                  4.8

                	
                  Chairman

                	
                  11

                
	
                  4.9

                	
                  Appointment
      of a Secretary

                	
                  11

                
	
                  4.10

                	
                  Minutes
      of Meetings

                	
                  11

                
	
                  4.11

                	
                  Technical
      and Professional Assistance

                	
                  11

                

        

         

         

        
          
            
            

          

          
            (i)

            
              

            

          

          
            
            

          

           

        

        
          	
                  ARTICLE
      5

                
	 
      	 
      	 
      
	
                  CAPITAL
      ACCOUNTS AND DISTRIBUTIONS

                
	 
	
                  5.1

                	
                  Capital
      Accounts

                	
                  11

                
	
                  5.2

                	
                  Increases
      to Capital Accounts

                	
                  11

                
	
                  5.3

                	
                  Decreases
      in Capital Accounts

                	
                  12

                
	
                  5.4

                	
                  Allocations
      of Profit and Loss

                	
                  12

                
	
                  5.5

                	
                  Liquidation

                	
                  12

                
	
                  5.6

                	
                  Distribution
      Rules

                	
                  12

                
	
                  5.7

                	
                  Fiscal
      Year

                	
                  13

                
	 	 	 
	
                  ARTICLE
      6

                
	 
      	 
      	 
      
	
                  FINANCING
      AND BUDGETING

                
	 
	
                  6.1

                	
                  Required
      Initial Contributions

                	
                  13

                
	
                  6.2

                	
                  Additional
      Contributions

                	
                  13

                
	
                  6.3

                	
                  Books
      and Accounts

                	
                  13

                
	
                  6.4

                	
                  Audits

                	
                  13

                
	 	 	 
	
                  ARTICLE
      7

                
	 
      	 
      	 
      
	
                  DISPUTE
      RESOLUTION

                
	 
	
                  7.1

                	
                  Final
      and Binding Arbitration

                	
                  14

                
	
                  7.2

                	
                  Notice

                	
                  14

                
	
                  7.3

                	
                  Selection
      of Arbitrator

                	
                  14

                
	
                  7.4

                	
                  Arbitration
      Hearing

                	
                  14

                
	 	 	 
	
                  ARTICLE
      8

                
	 
      	 
      	 
      
	
                  TRANSFERS
      AND DISPOSITIONS

                
	 
	
                  8.1

                	
                  Prohibition
      on Transfer

                	
                  15

                
	
                  8.2

                	
                  Transfer
      to Affiliates

                	
                  15

                
	 	 	 
	
                  ARTICLE
      9

                
	 
      	 
      	 
      
	
                  TERM

                
	 
	
                  9.1

                	
                  Commencement
      of Term

                	
                  15

                
	 	 	 
	
                  ARTICLE
      10

                
	 
      	 
      	 
      
	
                  NOTICES

                
	 
	
                  10.1

                	
                  Addresses
      of Service

                	
                  15

                

        

         

         

        
          
            
            

          

          
            (ii)

            
              

            

          

          
            
            

          

        

         

        
          	
                  10.2

                	
                  Change
      of Address for Service

                	
                  16

                
	
                  10.3

                	
                  Deemed
      Receipt

                	
                  16

                
	
                  10.4

                	
                  Postal
      Interruption

                	
                  16

                
	 	 	 
	
                  ARTICLE
      11

                
	 
      	 
      	 
      
	
                  INDEMNIFICATION
      AND SURVIVAL

                
	 
	
                  11.1

                	
                  BioChcm
      Indemnity

                	
                  16

                
	
                  11.2

                	
                  Glaxo
      Indemnity

                	
                  17

                
	
                  11.3

                	
                  Extent
      of Indemnification

                	
                  17

                
	
                  11.4

                	
                  Claim

                	
                  17

                
	
                  11.5

                	
                  Failure
      to Defend

                	
                  18

                
	
                  11.6

                	
                  Defence

                	
                  18

                
	
                  11.7

                	
                  Set-off

                	
                  18

                
	
                  11.8

                	
                  Interest

                	
                  18

                
	
                  11.9

                	
                  Decisions

                	
                  18

                
	 	 	 
	
                  ARTICLE
      12

                
	 
      	 
      	 
      
	
                  GENERAL
      PROVISIONS

                
	 
	
                  12.1

                	
                  Extension
      of Meaning

                	
                  19

                
	
                  12.2

                	
                  “Herein”,
      etc

                	
                  19

                
	
                  12.3

                	
                  Headings
      of Articles and Sections

                	
                  19

                
	
                  12.4

                	
                  Partial
      Invalidity

                	
                  19

                
	
                  12.5

                	
                  Entire
      Agreement

                	
                  19

                
	
                  12.6

                	
                  Governing
      Law

                	
                  19

                
	
                  12.7

                	
                  Waiver

                	
                  20

                
	
                  12.8

                	
                  Amendments

                	
                  20

                
	
                  12.9

                	
                  Enurement

                	
                  20

                
	
                  12.10

                	
                  English
      Language

                	
                  20

                

        

        
          
             

          

          
            (iii)

            
              

            

          

          
             

          

        

      THIS PARTNERSHIP AGREEMENT
made as of the 1st day of January, 1996.

       

      B E T W E
E N:

       

      GLAXO WELLCOME
INC.,

      a
corporation amalgamated under the laws of Ontario and having an office at 7333
Mississauga Road North, Mississauga, Ontario

       

      (hereinafter
called “Glaxo”)

       

      OF
THE FIRST PART

       

      -and-

       

      BIOCHEM
PHARMA INC.,

      a
corporation incorporated under the laws of Quebec and having an office at 275
Armand-Frappier Boulevard, Lava1, Quebec

       

      (hereinafter
called “BioChem”)

       

      OF
THE SECOND PART

       

      RECITALS

       

      
        	
                A.

              	
                Pursuant
      to the Master Licence Agreement (hereinafter defined) Glaxo was granted
      the rights, in conjunction with BioChem, (i) under Licensed Patents
      (hereinafter defined) to develop, register, manufacture, have
      manufactured, use and sell Modified Licensed Product (hereinafter defined)
      in Canada, and (ii) under Know-how (hereinafter defined) to develop,
      register, manufacture, have manufactured, use and sell Modified Licensed
      Product.

              

      

       

      
        	
                B.

              	
                Glaxo
      and BioChem have agreed to form a partnership for the purpose of
      exploiting the rights referred to in the preceding
  recital.

              

      

       

      
        	
                C.

              	
                Glaxo
      and BioChem have entered into this Agreement for the purpose of
      establishing their respective rights and obligations in relation to the
      partnership hereby constituted.

              

      

       

      NOW.
THEREFORE, THE PARTIES AGREE AS FOLLOWS:

       

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      Page
2

       

       

       

      ARTICLE
1

       

      INTERPRETATION

       

      1.1 Defined
Terms.  In
this Agreement, unless the context or subject matter is inconsistent therewith,
the following terms and phrases shall have the following meanings:

       

      
        	
                (a)  

              	
                “Additional
      Contribution” shall have the meaning ascribed to it in section
      6.2.

              

      

       

      
        	
                (b)  

              	
                “Agreement”
      means this Partnership Agreement and all of the Schedules attached hereto
      and all amendments to this Partnership Agreement as permitted by the terms
      of this Partnership Agreement.

              

      

       

      
        	
                (c)  

              	
                “Auditors”
      means the chartered accounting firm ***** or such other firm of certified
      chartered accountants as may be appointed from time to time by the
      Management Committee to be the auditors for the
    Partnership.

              

      

       

      
        	
                (d)  

              	
                “Business”
      means the business of exploiting the Modified Licensed Products in Canada
      under the Licensed Patents as contemplated by and in accordance with the
      provisions of the Master License Agreement and this
    Agreement.

              

      

       

      
        	
                (e)  

              	
                “Business
      Day” means every day except Saturdays, Sundays and days on which banks
      located in Ontario or Quebec are not required to be
  open.

              

      

       

      
        	
                (f)  

              	
                “Dollars”
      and the sign “$” mean lawful money of
Canada.

              

      

       

      
        	
                (g)  

              	
                “Effective
      Dale” means the 1st day of January,
1996.

              

      

       

      
        	
                (h)  

              	
                “GAAP”
      means those accounting principles which are recognized as being generally
      accepted in Canada from time to
time.

              

      

       

      
        	
                (i)  

              	
                “Know-how”
      means all information, data. discoveries and trade secrets, whether or not
      reduced to writing, pertinent to Modified Licensed Product or to the
      manufacture or use of Modified Licensed Product. now or hereafter owned or
      controlled by BioChem or any of its
affiliates;

              

      

       

       

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

      
        Page
3

         

         

         

      

      
        	
                (j)  

              	
                “Licensed
      Patents” means the patents and patent applications set forth in Schedule
      “A” hereto, as well as any additional patents issued or granted or
      additional patent applications in the Territory relating to Modified
      Licensed Product or its method of manufacture or use, or intermediates
      therefor, or formulations thereof; and any divisions, reissues, renewals
      or extensions of the term thereof; and any registrations or confirmations
      of any patents issued relating to Modified Licensed Product in the
      Territory or its method of manufacture or use, or intermediates therefor
      or formulations thereof, now or hereafter owned or controlled by BioChem
      or its affiliates.

              

      

       

      
        	
                (k)  

              	
                “Major
      Decisions” means the decisions with respect to the matters enumerated in
      section 4.2 hereof, and when used in the singular, means anyone of such
      decisions.

              

      

       

      
        	
                (l)  

              	
                “Management
      Committee” means the committee established in accordance with and pursuant
      to the provisions of Article 4 of this
  Agreement.

              

      

       

      
        	
                (m)  

              	
                “Master
      Licence Agreement” means • revised and restated master licence agreement
      made as of the 20th day of November, 1995 among Glaxo Group Limited,
      Glaxo; Glaxo Wellcome Inc. (formerly Glaxo Inc.), BioChem. Tanaud
      International B.V., Tanaud LLC and Tanaud Holdings (Barbados)
      Limited.

              

      

       

      
        	
                (n)  

              	
                “Modified
      Licensed Product” has the meaning ascribed thereto in the Master Licence
      Agreement

              

      

       

      
        	
                (o)  

              	
                “Partners”
      means the persons who are party to this Agreement from time to time and
      “Partner” shall mean anyone of
them.

              

      

       

      
        	
                (p)  

              	
                “Partnership”
      means the partnership established by the Partners pursuant to Article 2 of
      this Agreement.

              

      

       

      
        	
                (q)  

              	
                “Partnership
      Interest” for each Partner means the undivided percentage interest of such
      Partner in the Partnership as set forth in section 2.6 of this
      Agreement.

              

      

       

      
        	
                (r)  

              	
                “Partner’s
      Representatives” means the persons appointed from time to time by each
      Partner to be that Partner’s representatives on the Management Committee
      pursuant to section 4.3 of this
Agreement.

              

      

       

       

      
        
          
          

        

        
          3

          
            

          

        

        
          
          

        

        
          Page
4

           

           

           

        

      

      
        	
                (s)  

              	
                “Prime
      Rate” means the prime commercial lending rate publicly announced by the
      Canadian Imperial Bank of Commerce as its Canadian prime rate as in effect
      from time to time.

              

      

       

      
        	
                (t)  

              	
                “Term”
      means the term of this Agreement as provided in Article 9
      hereof.

              

      

       

      1.2 General
Definitions. In this
Agreement, unless the context or subject matter is inconsistent therewith, the
following terms and phrases shall have the following meanings:

       

      
        	
                (a)  

              	
                “affiliate”
      means, with respect to any person, any other person who directly or
      indirectly controls, is controlled by, or is under common control with
      such first person;

              

      

       

      
        	
                (b)  

              	
                “contract”
      means all contracts, agreements, indentures, guarantees, notes, bonds,
      leases, mortgages, deeds of trust, licenses, franchises, commitments,
      arrangements, sales orders, purchase orders, warranties to third persons,
      arrangements, plans or understandings, whether oral or written, express or
      implied;

              

      

       

      
        	
                (c)  

              	
                “control”
      of any person means:

              

      

       

      
        	
                 
      

              	
                (i)

              	
                in
      respect of a person, none of whose securities are publicly traded, direct
      or indirect beneficial ownership of more than fifty percent (50%) of
      voting stock, or more than fifty percent (50%) interest in the income, of
      such person; and

              

      

       

      
        	
                 
      

              	
                (ii)

              	
                in
      respect of a person, any of whose securities are publicly traded, direct
      or indirect beneficial ownership of at least thirty-five percent (35%) of
      the voting stock;

              

      

       

      and the
words “controlled” and “controlling” and similar expressions have corresponding
meanings. In no event shall one of the Partners be deemed to control the
Partnership;

       

      
        	
                (d)  

              	
                “judgments”
      means all judgments, orders, writs, injunctions, rulings and decrees of
      any court, governmental authority or arbitration
  panel;

              

      

       

      
        	
                (e)  

              	
                “laws”
      means all laws, statutes, codes, rules, regulations and ordinances of any
      jurisdiction;

              

      

       

       

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

      

      
        Page
5

         

         

         

      

      
        	
                (f)  

              	
                “liabilities”
      means all liabilities, debts and obligations, whether direct or indirect,
      whether absolute, accrued, contingent or otherwise and whether due or to
      become due;

              

      

       

      
        	
                (g)  

              	
                “lien”
      means any lien, pledge, license, mortgage, security interest, claim,
      lease, charge, condition, restriction, assessment, conditional sales
      agreement, title retention agreement, hypothec, option, right of first
      refusal, pre-emptive right, easement or any other encumbrance whatsoever,
      whether direct or indirect, contingent, accrued, absolute or
      otherwise;

              

      

       

      
        	
                (h)  

              	
                “person”
      means any individual, corporation, partnership, firm, joint venture,
      association, joint-stock company, syndicate, trust, unincorporated
      organization, business enterprise or other entity;
  and

              

      

       

      
        	
                (i)  

              	
                “property”
      means all assets, properties and business, real, personal or mixed,
      tangible or intangible, moveable or immoveable, including the goodwill of
      a person.

              

      

       

      ARTICLE
2

       

      FORMATION OF
PARTNERSHIP

       

      2.1 Formation of the
Partnership. The
Partners hereby agree to form a partnership under the laws of the Province of
Ontario as of the Effective Date. The Partnership shall operate under the name
of Glaxo Wellcome BioChem or such other name as the Partners may agree upon from
time to time. The Partnership shall conduct the Business in accordance with the
terms and conditions of this Agreement. The Partners hereby agree that this
Agreement shall govern and define the respective rights and obligations of the
Partners as partners in the Partnership. The principal office of the Partnership
shall be located at 7333 Mississauga Road North, Mississauga, Ontario L5N 6IA or
at such other location as the Management Committee may determine from time to
time.

       

      2.2 Purpose of the
Partnership. The
purpose and scope of the Partnership shall be limited to:

       

      
        	
                (a)  

              	
                the
      operation of the Business;

              

      

       

      
        	
                (b)  

              	
                such
      other purposes as may be mutually agreed upon from time to time by the
      Partners; and

              

      

       

      
        	
                (c)  

              	
                all
      other things necessary or appropriate for the accomplishment of the
      foregoing purposes.

              

      

       

       

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

        
          Page
6

           

           

           

        

      

      2.3 Interests of the
Partners. All
Partnership properties shall be owned by the Partnership and no Partner shall
have any ownership interests therein. Except as otherwise provided in this
Agreement, each Partner shall, in proportion to its respective Partnership
Interest:

       

      
        	
                (a)  

              	
                contribute
      and be liable for its share of the liabilities of the Partnership;
      and

              

      

       

      
        	
                (b)  

              	
                be
      entitled to the rights and benefits of the
  Partnership.

              

      

       

      2.4 Scope of
Authority. A
Partner shall not be responsible or liable for any liability incurred by the
other Partner before or after the execution hereof; except with regard to those
liabilities relating to the Partnership incurred or assumed pursuant to the
terms of this Agreement. Except as provided ‘pursuant to the terms of this
Agreement. a Partner shall not have any authority to act for, to bind or to
assume any obligation or responsibility on behalf of the other Partner or on
behalf of the Partnership. Each Partner covenants and agrees with the other
Partner to indemnify and save harmless such other Partner in accordance with
Article 11 from any and all liabilities whatsoever resulting from any
unauthorized acts of such indemnifying Partner with respect to the
Partnership.

       

      2.5 Partition. A
Partner shall not have the right to partition Partnership property or any part
thereof; nor shall any Partner make any application to a court having
jurisdiction over the matter, or commence or prosecute any action for partition,
and each Partner shall, in addition to all other rights and remedies in law and
in equity, be entitled to a decree or order restraining and enjoining such
application, petition, action or proceeding, and the Partner in breach of this
section 2.5 shall not plead in defense thereto that there would not be another
remedy at law adequate to meet such breach, it being recognized and agreed that
the injury and damage resulting from such breach would be difficult, if not
impossible, to measure monetarily and each Partner hereby expressly waives any
right to partition that is provided to it pursuant to any law.

       

      2.6 Partnership Interest of the
Partners.
Initially, the respective Partnership Interests of the Partners are as
follows:

       

      
        	
                (a)  

              	
                as
      to Glaxo, an undivided fifty percent (50%) interest;
  and

              

      

       

      
        	
                (b)  

              	
                as
      to BioChem, an undivided fifty percent (50%)
  interest.

              

      

       

      The
aforesaid undivided interests may be varied from time to time only with the
consent of the Partners.

       

       

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

        
          Page
7

           

           

           

        

      

      ARTICLE
3

       

      EXPLOITATION
RIGHTS

       

      3.1 Master Licence
Agreement. The
Partners hereby acknowledge and agree that the Partnership is the partnership
referred to in the Master Licence Agreement, formed for the purpose of
exploiting the Modified Licensed Product in Canada as contemplated under
Sections 2B and 6B of the Master Licence Agreement

       

      3.2 Additional Conveyance
Documents. The
Partners shall execute and deliver to the Partnership such other good and
sufficient instruments of conveyance, assignment and transfer, in form and
substance satisfactory to the Partners, and shall take such actions as the
Partners may deem necessary or desirable in order to more effectively transfer,
convey and assign to the Partnership, and to confirm the Partnership’s title to
exploitation rights granted to the Partners pursuant to the Master Licence
Agreement.

       

      ARTICLE
4

       

      MANAGEMENT
COMMITTEE

       

      4.1 Function of the Management
Committee. There
shall be a Management Committee of the Partnership which shall exercise overall
supervision and control of the Partnership and shall determine all Major
Decisions.

       

      4.2 Major
Decisions. Major
Decisions shall be as follows:

       

      
        	
                (a)  

              	
                the
      approval of all operating and capital budgets, forecasts, capital plans
      and long-range plans in respect of the operation of the Business and all
      amendments thereto and variations
therefrom;

              

      

       

      
        	
                (b)  

              	
                the
      making of any capital expenditure in any amount, if not included in an
      approved budget, exceeding $10,000 for anyone capital expenditure in any
      calendar year of the Term, exceeding $30,000 in the aggregate for all such
      capital expenditures made in that calendar year or any capital expenditure
      (even if included in an approved budget) in excess of $50,000; provided
      that for purposes of this section 4.2(b) expenditures for related items
      shall be aggregated and deemed to be one (1)
  expenditure;

              

      

       

      
        	
                (c)  

              	
                the
      appointment of the Auditors and the settlement of any questions or the
      approval or disapproval of any recommendations based upon or arising out
      of any audit of the Partnership’s books and records, the approval of the
      audited annual financial statements of the Partnership and the approval of
      the Auditors’ fees;

              

      

       

       

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

        
          Page
8

           

           

           

        

      

      
        	
                (d)  

              	
                the
      appointment or designation of committees or sub-committees to study any
      issue in connection with the
Business;

              

      

       

      
        	
                (e)  

              	
                the
      transfer of any asset of the Partnership out of the ordinary course of
      business of the Partnership having a cost or a fair market value in excess
      of $50,000, unless provision therefore is contained in an approved budget;
      provided that for purposes of this section 4.2(e), transfers of related
      items shall be aggregated and deemed to be one (1)
    transfer;

              

      

       

      
        	
                (f)  

              	
                the
      surrender or termination of any contract unless provision therefore is
      contained in an approved budget;

              

      

       

      
        	
                (g)  

              	
                the
      approval of all matters concerning pay scales and employee and consultants
      arrangements;

              

      

       

      
        	
                (h)  

              	
                the
      approval of the terms and conditions of any contracts made between the
      Partnership and a Partner or any affiliate of a Partner and any amendments
      to such contracts, including, without limiting the generality of the
      foregoing, approval of any proposed change in the purchase price payable
      from time to time by the Partnership to Glaxo for Modified Licensed
      Product purchased under the supply agreement for Modified Licensed
      Product, to meet the Partners’ objective for each year commencing January
      1, 1998 that the profit earned by Glaxo in supplying Modified Licensed
      Product to the Partnership will equal the profit earned by BioChem under
      its marketing agreement with the
Partnership;

              

      

       

      
        	
                (i)  

              	
                the
      granting of a lien on any Partnership
property;

              

      

       

      
        	
                (j)  

              	
                the
      approval of the incurrence on behalf of the Partnership of any debt or any
      refinancing of debt on behalf of the Partnership other than trade accounts
      payable incurred in the normal course of business consistent with prior
      practice;

              

      

       

      
        	
                (k)  

              	
                the
      commencement, prosecution or defense of any actions or proceedings
      relating to a third party dispute and the approval of the settlement or
      other resolution of any such dispute; provided, however if any such action
      or proceeding involves a Partner or any of its affiliates in a position
      adverse in interest to the Partnership, any action or decision relating
      thereto shall be taken or made by the other Partner on behalf of the
      Partnership;

              

      

       

      
        	
                (l)  

              	
                the
      approval of the accounting principles and any changes to such accounting
      principles to be applied by the
Partnership;

              

      

       

       

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

        
          Page
9

           

           

           

        

      

      
        	
                (m)  

              	
                the
      entering into of any business by the Partnership other than the Business
      and all matters relating to such new
business;

              

      

       

      
        	
                (n)  

              	
                the
      making of loans to any person or the entering into of contents of
      guarantee or indemnity with respect to the liabilities of any
      person;

              

      

       

      
        	
                (o)  

              	
                the
      approval of Additional Contributions to be made by the
      Partners;

              

      

       

      
        	
                (p)  

              	
                the
      hiring of persons as employees of the Partnership and the designation of
      any person as Chief Medical Officer or any other officer of the
      Partnership together with the terms of authority and responsibility of
      such persons;

              

      

       

      
        	
                (q)  

              	
                distributions
      to the Partners;

              

      

       

      
        	
                (r)  

              	
                the
      approval of the Partnership’s annual operating plan (including the sales,
      marketing, personnel and operating plan and budget) and amendments
      thereto; and

              

      

       

      
        	
                (s)  

              	
                any
      other decision or action which by the provisions of this Agreement, or any
      other contract, is required to be approved by the Management Committee or
      which the Management Committee determines should be subject to its
      approval.

              

      

       

      4.3 Composition of the
Management Committee. The
Management Committee shall be composed of four (4) persons, two (2) being
Partnership Representatives appointed by Glaxo and two (2) being Partnership
Representatives appointed by BioChem. The initial Partnership Representatives
are as follows:

       

      
        	
                Partner

              	
                Partnership
  Representatives

              
	
                Glaxo

              	
                Paul
      Lucas

                Paul
      L’Archeveque

              
	
                BioChem

              	
                Francesco
      Bellini

                Michael
      Grey

              

      

      

      The
Partners may appoint alternate persons to act as their Partnership
Representatives. The notice of appointment of Partnership Representatives or
alternates to the Management Committee or the notice of any change in the
Partnership Representatives or alternates so appointed shall be given by one
Partner to the other Partner by a notice in writing. The Partnership
Representatives and alternates shall be authorized to represent and bind
the

       

       

      
        
          
          

        

        
          9

          
            

          

        

        
          
          

        

        
          Page
10

           

           

           

        

      

      Partners
at meetings of the Management Committee. Each Partner may remove or replace any
of its Partnership Representatives or alternates by notice to the other
Partner.

       

      4.4 Meetings of the Management
Committee. There
shall, unless otherwise agreed by the Partners, be quarterly meetings of the
Management Committee. Meetings shall be held alternately at the offices of each
of the Partners at the times determined by the Management Committee. Either
Partner may call a special meeting of the Management Committee upon five (5)
Business Days’ notice, with agenda attached, to the other Partner. Such special
meetings shall be held at such location as the Partners may agree upon or,
failing agreement, at the offices of the Partner on whom the notice is served.
Other meetings of the Management Committee may be held at such times and at such
places as may be agreed upon by the Partners. The Partners may jointly waive the
requirement for notice of a meeting of the Management Committee. Management
Committee meetings may be held by conference telephone whereby each person
participating is able to hear and be heard by the other persons participating.
No compensation or reimbursement of expenses shall be paid by the Partnership to
the Partnership Representatives or alternates.

       

      4.5 Quorum of the Management
Committee. A quorum
of the Management Committee shall consist of one (1) Partnership Representative
or alternate of Glaxo and one (1) Partnership Representative or alternate of
BioChem. There shall be a total of two (2) votes on the Management Committee and
the Partnership Representatives or alternates of Glaxo shall collectively have
one (1) vote and the Partnership Representatives or alternates of BioChem shall
collectively have one (I) vote. The Management Committee shall not conduct any
business at meetings of the Management Committee when there is not a quorum
present at such meeting except as otherwise provided in this Agreement
Notwithstanding the foregoing, if none of the Partnership Representatives or
alternates of a Partner attend at a properly convened Management Committee
meeting, then the quorum required for such a Management Committee meeting shall
be one (I) Partnership Representative or one (1) alternate of Glaxo or BioChem,
as the case may be.

       

      4.6 Decisions of the Management
Committee.
Decisions of the Management Committee must be approved by unanimous vote at
meetings of the Management Committee or by a resolution in writing signed by at
least one (1) Partnership Representative or alternate of Glaxo and one (1)
Partnership Representative or alternate of BioChem. The Management Committee
shall make its decisions solely in the best interests of the Partnership and
within a period of time such !bat the Partnership may proceed without undue
delay, having regard to the objectives and contractual commitments of the
Partnership.

      
 

      
        
          
          

        

        
          10

          
            

          

        

        
          
          

        

        
          Page
11

           

           

           

        

      

      4.7 Rules and
Regulations. The
Management Committee may fix such rules and procedures as are necessary to carry
out its duties hereunder in addition to those rules set forth
herein.

       

      4.8 Chairman. During
the Term, the Partners shall appoint a person to act as chairman (the
“Chairman”) of the Management Committee, with the Chairman alternately being a
Partnership Representative of Glaxo and BioChem. Each Chairman shall serve for a
one (1) year term, provided that the first Chairman shall serve from the
Effective Date through December 31, 1996. The first Chairman shall be a
partnership Representative of Glaxo. The Chairman shall be responsible for
conducting meetings of the Management Committee. The Chairman shall not, in any
event, have a casting vote.

       

      4.9 Appointment of a
Secretary. The
Management Committee shall appoint a secretary for the Management Committee or.
failing agreement upon a secretary. the Chairman shall have the power to
designate a secretary, who need not be a member of the Management Committee.
Minutes in summary form shall be kept of the proceedings at meetings of the
Management Committee and of the matters decided thereat.

       

      4.10 Minutes of
Meetings. Minutes
of each meeting of the Management Committee shall be distributed to each
Partner, addressed to the attention of the Partnership Representatives. The
minutes shall be deemed to be an accurate record of the meeting and the
disposition of the matters raised thereat, unless any Partner objects thereto
within twenty (20) Business Days after the minutes are received by the Partner
or, if the next meeting of the Management Committee is earlier, at such meeting.
If an objection is raised by a Partner following receipt of the minutes, but is
not raised at the next ensuing meeting of the Management Committee, the
objection will be deemed to have been withdrawn.

       

      4.11 Technical and Professional
Assistance. At
meetings of the Management Committee, Partnership Representatives and alternates
may be accompanied by technical and professional personnel whose advice may be
required for the business an the agenda, but such personnel shall not be
entitled to vote.

       

      ARTICLE
5

       

      CAPITAL ACCOUNTS AND
DISTRIBUTIONS

       

      5.1 Capital
Accounts.
Throughout the Term, the Partnership shall maintain a separate Capital Account
for each Partner (the “Capital Accounts”).

       

      5.2 Increases to Capital
Accounts. Each
Partner’s Capital Account shall be increased by:

       

       

      
        
          
          

        

        
          11

          
            

          

        

        
          
          

        

        
          Page
12

           

           

           

        

      

      
        	
                (a)  

              	
                the
      amount of money contributed by such Partner to the
      Partnership;

              

      

       

      
        	
                (b)  

              	
                the
      fair market value of property contributed by such Partner to the
      Partnership (net of liabilities secured by the contributed property that
      the Partnership assumes or takes subject to);
  and

              

      

       

      
        	
                (c)  

              	
                allocations
      to such Partner of Partnership income, including realized capital
      gains.

              

      

       

      5.3 Decreases in Capital
Accounts. Each
Partner’s Capital Account shall be decreased by:

       

      
        	
                (a)  

              	
                the
      amount of money distributed to such Partner by the
      Partnership;

              

      

       

      
        	
                (b)  

              	
                the
      fair market value of property distributed to such Partner by the
      Partnership (net of liabilities secured by such distributed property that
      such Partner assumes or takes subject to);
and

              

      

       

      
        	
                (c)  

              	
                allocations
      to such Partner of Partnership
losses.

              

      

       

      5.4 Allocations of Profit and
Loss. Profits
and losses of Partnership and any other allocations not otherwise provided for
shall be allocated among the Partners in proportion to their respective
Partnership Interest.

       

      5.5 Liquidation.

       

      
        	
                (a)  

              	
                Upon
      dissolution, the Partners shall sell or otherwise convert all property of
      the Partnership into cash or receivables (or transfer the same in
      satisfaction of Partnership obligations) and, after payment or making
      provisions for payment, when due, of any debts of the Partnership,
      including, without limitation, debts to Partners who are creditors of the
      Partnership, shall distribute all proceeds thereof to the Partners,
      subject to any liabilities of the Partnership, in proportion to their
      respective Capital Accounts.

              

      

       

      
        	
                (b)  

              	
                Upon
      the dissolution of the Partnership, each Partner will contribute to the
      Partnership an aggregate cash amount equal to the deficit balance in such
      Partner’s respective Capital Account not later than ninety (90) days after
      the date of liquidation of the Partnership or the end of the taxable year
      in which the liquidation occurs, whichever is
  later.

              

      

       

      5.6 Distribution
Rules. The
amount of cash flow, if any, that is surplus to the operational requirements of
the Partnership from time to time shall be determined

       

       

      
        
          
          

        

        
          12

          
            

          

        

        
          
          

        

        
          Page
13

           

           

           

        

      

      by the
Management Committee and shall be distributed to the Partners in proportion to
their allocation of profit and loss set forth in section 5.4 hereof at such
times as the Management Committee determines.

       

      5.7 Fiscal
Year. The
fiscal year of the Partnership shall be the calendar year.

       

      ARTICLE
6

       

      FINANCING AND
BUDGETING

       

      6.1 Required Initial
Contributions. Each
Partner shall make the following cash contributions to the
Partnership:

       

      Glaxo               -           $1,000

       

      BioChem         
-          $1,000

       

      6.2 Additional
Contributions. The
Partners shall contribute all funds required from time to time for the purposes
of the Partnership in excess of the funds provided for pursuant to section 6.1
hereof and the Cash flow generated from the operations of the Partnership (the
“Additional Contributions”). Additional Contributions may take the form of debt
or capital contributions, as the Management Committee may determine. Each
Partner shall contribute its share, in accordance with its Partnership Interest,
of any Additional Contributions, without deduction or set-off, within ten (10)
Business Days after receipt of a notice from the Management Committee requesting
the payment of such Additional Contributions.

       

      6.3 Books and
Accounts. The
Partnership shall keep proper accounts of all transactions of the Business,
including financial records and statements prepared in accordance with GAAP
consistently applied. The accounts so maintained shall at all times be in
sufficient detail to enable the Partners to keep accounts in accordance with the
requirements of the applicable regulatory bodies and GAAP and to file financial
reports and tax returns in accordance with such requirements.

       

      6.4 Audits. Regular
audits of the books and records of the Partnership shall be conducted once each
calendar year. The costs of such audits shall be for the account of the
Partnership. Each such audit shall be conducted by the Auditors or such other
independent firm of chartered accountants appointed from time to time by the
Management Committee. Upon conclusion of an audit, a copy of the audit report
shall be furnished, within two (2) months, to each Partner and proposed
adjustments will be referred to the Management Committee for appropriate
adjustments and adjustments approved by the Management Committee shall be made.
In the event that the Management Committee does not make an adjustment
recommended in the audit report and in the further event that one of the
Partners

       

       

      
        
          
          

        

        
          13

          
            

          

        

        
          
          

        

      

      
        Page
14

         

         

         

      

      gives
notice in writing to the other Partner that it believes such adjustment should
be approved by the Management Committee, then the Management Committee shall
retain a firm of chartered accountants and that firm of chartered accountants
shall review the matter and shall advise the Management Committee and the
Partnership shall be bound by the decision of such firm. Each Partner shall also
be entitled to audit the books and records of the Partnership at such Partner’s
own expense.

       

      ARTICLE
7

       

      DISPUTE
RESOLUTION

       

      7.1 Final and Binding
Arbitration. In the
event of any claim, dispute or controversy between the Partners relating to this
Agreement, the matter shall be resolved by final and binding arbitration in
Toronto, Canada in accordance with the provisions of this Article 7 and there
shall be no appeal therefrom.

       

      7.2 Notice. It shall
be a condition precedent that the right of any Partner to submit a matter to
arbitration pursuant to the provisions hereof to give not less than ten (10)
days prior notice to the other Partner of its intention to do so. Upon the
expiration of such ten (10) day period, the Partner who has given such notice
may proceed to refer the dispute to arbitration as provided herein.

       

      7.3 Selection of
Arbitrator. The
Partner entitled to refer a matter to arbitration shall proceed to refer the
matter to arbitration by appointing one (I) arbitrator and notifying the other
Partner of such appointment. The other Partner shall, upon receiving such
notice, appoint a second arbitrator, and the two (2) arbitrators shall within
fifteen (15) days of the appointment of the second arbitrator agree upon the
appointment of a third arbitrator who will act with them and be chairman of the
panel In the event that a Partner shall fail to appoint an arbitrator within
thirty (30) days of commencement of the arbitration proceeding, the arbitrator
shall be appointed by a judge of the Ontario Court (General Division). In the
event of a failure of the said two (2) arbitrators to agree within sixty (60)
days after commencement of the arbitration proceedings upon the appointment of a
chairman, the chairman shall also be appointed by a judge of the Ontario Court
(General Division) on application by either Partner.

       

      7.4 Arbitration
Hearing. In any
arbitration pursuant to this Agreement, the award or decision shall be rendered
by a majority of the members of the panel provided for herein. The chairman
shall fix a time and place in Toronto within twenty (20) days of his appointment
for the purpose of hearing evidence and representations of the parties and shall
preside over the arbitration and shall determine all questions of procedure not
provided for herein in accordance with the Arbitration Act (Ontario). After
hearing any evidence and representations that

       

       

      
        
          
          

        

        
          14

          
            

          

        

        
          
          

        

      

      
        Page
15

         

         

         

      

      each
Partner may submit, the arbitrator shall make an award and reduce the same to
writing and deliver one (1) copy to each Partner within ten (10) days after the
hearing. Judgment upon the award rendered by the arbitrators may be entered in
any Court having jurisdiction thereof; provided, however, that the law
applicable to any controversy shall be the law set forth in section 12.6. The
cost of arbitration shall be paid as specified in the award unless otherwise
agreed to by the Partners.

       

      ARTICLE
8

       

      TRANSFERS AND
DISPOSITIONS

       

      8.1 Prohibition on
Transfer. Except
as otherwise provided in this Article 8, a Partner shall not transfer its
Partnership Interest, in whole or in part. Any transfer of a Partnership
Interest shall be void and without effect unless made in accordance with the
provisions of this Article 8 or with the prior approval in writing of the
Partners.

       

      8.2 Transfer to
Affiliates.
Notwithstanding section 8.1 hereof; either Partner may transfer all or part of
its Partnership Interest to an affiliate of that Partner (other than a company
that is an affiliate by virtue of the definition of “control” in section
l.2(c)(ii) hereof) provided that such affiliate becomes a party to this
Agreement and in the event of such transfer, the Partner effecting the transfer
of all or part of its Partnership Interest to its Affiliate shall remain fully
obligated to observe and perform all of its obligations under this Agreement.
For purposes of this Agreement, such Partner and affiliate shall collectively be
deemed to be one (1) partner.

       

      ARTICLE
9

       

      TERM

       

      9.1 Commencement of
Term.
Notwithstanding the date of execution of this Agreement, this Agreement shall
commence on the Effective Date and unless sooner terminated with the consent of
the Partners shall continue until the first anniversary date of the expiry of
the Licensed Patents which provide for market exclusivity of the Modified
Licensed Products in Canada.

       

      ARTICLE
10

       

      NOTICES

       

      10.1 Addresses of
Service. Any
notice, request, demand, consent or other communication provided or permitted
hereunder shall be in writing and given by personal delivery, delivered by
courier, transmitted by facsimile, or sent by first 

       

       

      
        
          
          

        

        
          15

          
            

          

        

        
          
          

        

      

      
        Page
16

         

         

         

      

      class
mail, postage prepaid, return receipt requested, addressed to the Partner for
which it is intended at the forwarding addresses:

       

      
        	
                (a)  

              	
                Glaxo:

              

      

       

      7333
Mississanga Road

      North
Mississauga,

      Ontario
L5N 6IA

       

      Attention:     The
President

      Fax:               905-819-3087

       

      
        	
                (b)  

              	
                BioChem:

              

      

       

      275
Armand-Frappier Boulevard

      Lava1,
Quebec

      H7V
4A7

       

      Attention:     The
President

      Fax:               514-978-7755

       

      10.2 Change of Address for
Service. Any
Partner may change its address for purposes of transmittal or receipt of any
communication by giving written notice of such change to the other Partner in
the manner prescribed in section 10.1 hereof.

       

      10.3 Deemed
Receipt. Any
notice so given shall be deemed to have been received on the date on which it
was delivered if given by personal delivery or courier or transmitted by
facsimile, or, if mailed, on the fifth (5th) Business Day following the mailing
thereof.

       

      10.4 Postal
Interruption. In the
event of any postal interruption occurring during the Term, any notice, request,
demand, consent or other communication provided or permitted hereunder shall be
given by personal delivery, courier or facsimile.

       

      ARTICLE
11

       

      INDEMNIFICATION AND
SURVIVAL

       

      11.1 BioChem
Indemnity. BioChem
hereby agrees to indemnify and to hold the Partnership and Glaxo harmless from,
against and in respect of, and shall on demand reimburse the Partnership and/or
Glaxo for and shall have no recourse against the Partnership or Glaxo with
respect to, any and all loss, expense, liability or damages suffered or incurred
by the Partnership or Glaxo by reason of

       

       

      
        
          
          

        

        
          16

          
            

          

        

        
          
          

        

        
          Page
17

           

           

           

        

      

      any
nonfulfillment of any covenant or agreement by BioChem contained herein or
contained in any agreement between the Partnership and BioChem (or any affiliate
of BioChem).

       

      11.2 Glaxo
Indemnity. Glaxo
hereby agrees to indemnify and to hold the Partnership and BioChem harmless
from, against and in respect of, and shall on demand reimburse the Partnership
and/or BioChem for and shall have no recourse against the Partnership or BioChem
with respect to, any and all loss, expense, liability or damages suffered or
incurred by the Partnership or BioChem by reason of any nonfulfillment of any
covenant or agreement by Glaxo contained herein or contained in any agreement
between the Partnership and Glaxo (or any affiliate of Glaxo).

       

      11.3 Extent of
Indemnification. All
indemnifications under this Article 11 shall include the costs of any and all
actions, suits, proceedings, claims, demands, assessments, judgments, costs and
expenses, including, without limitation, legal fees and expenses, incident to
any of the foregoing or incurred in investigating or attempting to avoid the
same or to oppose the imposition thereof, or in enforcing this
indemnity.

       

      11.4 Claim. Each of
Glaxo and BioChem agree that within ten (10) Business Days after it becomes
aware of a right to claim indemnification pursuant to Article 11, the party
asserting such a claim (the “Indemnitee”) shall notify the other party (the
“Indemnitor”) of any claim or demand which the Indemnitee has determined has
given or could give rise to a right of indemnity under this Agreement. If such
claim or demand relates to a claim or demand asserted by a third party against
the Indemnitee (a “Third Party Claim”), the Indemnitor shall have the right to
defend the same at its own cost and expense with counsel of its own selection,
provided that (i) the Indemnitee shall at all times have the right to fully
participate in the defense at its own expense; (ii) the Third Party Claim seeks
only monetary damages and does not seek any injunctive or other relief against
the Indemnitee; (iii) the Indemnitor unconditionally acknowledges in writing its
obligation to indemnify and bold the Indemnitee harmless with respect to the
Third Party Claim; (iv) counsel chosen by the Indemnitor is satisfactory to the
Indemnitee, acting reasonably; and (v) the Indemnitor shall have deposited in
trust with the Indemnitee’s legal counsel either an amount sufficient to secure
the Indemnitor’s potential indemnity liability in the full amount of the
indemnification due with respect to the Third Party Claim, inclusive of
reasonably estimated interest and costs or a letter of credit, surety bond or
similar security in form and substance reasonably satisfactory to the Indemnitee
in an amount sufficient to satisfy the said potential indemnity liability and
shall have executed a letter of instruction in form and substance acceptable to
the Indemnitee acting reasonably, instructing such legal counsel to apply the
amounts held by it or to realize on the letter of credit, surety bond or similar
security held by it in

       

       

      
        
          
          

        

        
          17

          
            

          

        

        
          
          

        

        
          Page
18

           

           

           

        

      

      satisfaction
of any judgment rendered against the Indemnitee in connection with such Third
Party Claim.

       

      11.5 Failure to
Defend. If the
Indemnitor shall, within a reasonable time after notice of a Third Party Claim,
fail to defend a Third Party Claim or shall fail to comply at all times with
this Article 11, the Indemnitee shall have the right, but not the obligation, to
undertake the defense of and to compromise or settle the Third Party Claim on
behalf; for the account and at the risk and expense of the
Indemnitor.

       

      11.6 Defence. In the
event the Indemnitor defends a Third Party Claim, it will not be permitted to
control the settlement of the claim, unless (i) the terms of the settlement
require only the payment of money and do not require the Indemnitee to admit any
wrongdoing or take or refrain from taking any action; (ii) the full amount of
the settlement is paid by the Indemnitor; (iii) the Indemnitee receives, as part
of the settlement, a legally binding and enforceable and unconditional release,
which is in form and substance satisfactory to the Indemnitee, acting
reasonably; and (iv) the Third Party Claim and any claim or liability of the
Indemnitee with respect to the claim is being fully satisfied because of the
settlement and the Indemnitee is being released from any and all obligations or
liabilities it may have with respect to the Third Party Claim.

       

      11.7 Set-off. Without
prejudice to the other rights, recourses and remedies of the Indemnitee in order
to recover any amounts payable to it by the Indemnitor hereunder, the Indemnitee
may, at its option, set-off and compensate any amounts payable by it to the
Indemnitor under any provision of this Agreement or any other contract between
the Indemnitor and the Indemnitee against any amounts payable to it by the
Indemnitor, and any amount thus set-off or compensated shall be deemed to have
been paid by the Indemnitee to the Indemnitor.

       

      11.8 Interest. Any
amount payable by the Indemnitor pursuant to this Article 11 shall bear interest
at an annual percentage rate of interest equal to the sum of the Prime Rate plus
one percent (1%) per annum, calculated daily in arrears from the date the
Indemnitee incurs such liability, loss, expense or damage, provided that in no
case shall such interest rate exceed the applicable maximum legal interest
rate.

       

      11.9 Decisions. When the
Partnership is an Indemnitee pursuant to this Article 11, Glaxo shall make all
decisions on behalf of the Partnership if the indemnification is pursuant to
section 11.1 and BioChem shall make all decisions on behalf of the Partnership
if indemnification is pursuant to section 11.2.

       

       

      
        
          
          

        

        
          18

          
            

          

        

        
          
          

        

        
          Page
19

           

           

           

        

      

      ARTICLE
12

       

      GENERAL
PROVISIONS

       

      12.1 Extension of
Meaning. Unless
the context or subject matter otherwise requires, words importing the singular
number include plural and vice versa; references herein to any contract shall be
deemed to include references to such contract as varied or replaced from time to
time; and references herein to any law shall be deemed to include references to
such law as re-enacted, amended or extended from time to time.

       

      12.2 “Herein”,
etc. In this
Agreement the expressions “herein”, “hereof”, “hereunder”, “hereto”,
“hereinafter” and similar expressions refer to this Agreement and not to any
particular Article, section, paragraph or other portion of this
Agreement.

       

      12.3 Headings of Articles and
Sections. The
titles to the Articles and the sections of this Agreement are inserted herein
solely for convenience; are not part of this Agreement; do not in any way limit
or amplify the terms of the Agreement; and shall not be used as a means of
interpreting the provisions of this Agreement.

       

      12.4 Partial
Invalidity. If any
of the provisions contained in this Agreement shall be declared invalid, illegal
or unenforceable by a court or other authority of competent jurisdiction, then
this Agreement shall continue in force with respect to the enforceable
provisions and all rights and remedies accrued under the enforceable provisions
shall survive any such declaration, and any non-enforceable provision shall, to
the extent permitted by law, be replaced by a provision which being valid, comes
closest to the intention underlying the invalid, illegal or unenforceable
provision.

       

      12.5 Entire
Agreement. This
Agreement together with the Master Licence Agreement, the marketing and licence
agreement between the Partnership and BioChem dated as of January 1, 1996, and
the marketing and services agreement between the Partnership and Glaxo dated as
of January 1, 1996 contain the entire agreement with respect to the subject
matter herein as of the date of this Agreement and supersede all prior
agreements, understandings and negotiations, whether oral or written, of the
Partners with respect to the subject matter of this Agreement.  There
are no representations, warranties or conditions of either of the Partners with
respect to the subject matter of this Agreement except as are specifically set
forth herein.

       

      12.6 Governing
Law. This
Agreement shall be governed by the laws of the Province of Ontario and the law
of Canada applicable therein. Each party

       

       

      
        
          
          

        

        
          19

          
            

          

        

        
          
          

        

        
          Page
20

           

           

           

        

      

      irrevocably
attorns to the non-exclusive jurisdiction of the Courts of Ontario in connection
with the interpretation and enforcement of this Agreement.

       

      12.7 Waiver. No
provision of this Agreement shall be deemed waived and no breach excused unless
such waiver or consent excusing the breach shall be in writing and signed by the
Partner to be charged with such waiver or consent.  A waiver by a
Partner of any provision of this Agreement shall not be construed as a wavier of
any further breach of the same or any other provision of this
Agreement

       

      12.8 Amendments. No
amendment, modification or rescission of this Agreement shall be effective
unless set forth in writing signed by a duly authorized representative of each
Partner.

       

      12.9 Enurement. The
terms and conditions contained in this Agreement shall bind the Partners and
their respective successors and permitted assigns from and after the Effective
Date of this Agreement

       

      12.10 English
Language. The
parties hereto have expressly requested that this Agreement and all related
documents and notices be drafted in the English language. Les parties aux
présentes ont exigé, de façon expresse, que le présent contrat de même que tous
les documents et avis qui s’y rattachent soient rédigés en langue
anglaise.

       

      IN WITNESS
WHEREOF the parties hereto have duly executed this Agreement.

       

      
        	
                GLAXO
      WELLCOME INC.

              	 
	 	 
	
                Per:

              	 
      	 
	 	
                Authorized
      Officer

              	 
	 
      	 	 

      

      

      

      
        
          
          

        

        
          20

          
            

          

        

        
          
          

        

        
          Page
21

           

           

           

        

        
           

          
            	
                    BIOCHEM
      PHARMA INC.

                  	 
	 	 
	
                    Per:

                  	 
      	 
	 	
                    Authorized
      Officer

                  	 
	 
      	 	 

          

           

        

        
          
            
              	
                      Per:

                    	 
      	 
	 	
                      Authorized
      Officer

                    	 
	 
      	 	 

            

             

             

            
              
                
                

              

              
                21

                
                  

                

              

              
                
                

              

            

          

        

      

      

      SCHEDULE “A” - LICENSED
PATENTS

       

      
        	
                DOCKET
      NUMBER

              	
                COUNTRY

              	
                STATUS

              	
                APP.
      NUMBER

              	
                APP.
      DATE

              	
                CURRENT
      OWNER

              	
                FILE
      NUMBER

                (GLAXO)

              
	
                *****

              	
                *****

              	
                Filed

              	
                *****

              	
                *****

              	
                BIOCHEM
      PHARMA INC.

              	
                *****

              
	
                *****

              	
                *****

              	
                Filed

              	
                *****

              	
                *****

              	
                BIOCHEM
      PHARMA INC.

              	
                *****

              
	
                *****

              	
                *****

              	
                Filed

              	
                *****

              	
                *****

              	
                BIOCHEM
      PHARMA INC.

              	
                *****

              

      

      

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      SCHEDULE
4

       

      TABLE OF
CONCORDANCE

       

      
        	
                Original
      Agreement

              	
                This
      Agreement

              
	
                31
      January 1990

                Master
      Licence Agreement

              	
                20
      November 1995

                Revised
      and Restated Master Licence Agreement

              
	
                $
      Schedule 1 “Proposed Development Plan”

              	
                deleted

              
	
                $
      Schedule 2 “Licensed Product”

              	
                Schedule
      1 “Residual Product”

              
	
                $
      Schedule 3 “Licensed Patents”

              	
                Schedule
      2 “Licensed Patents”

              
	
                $
      Schedule 4 “Joint Venture Formation Agreement”

              	
                Schedule
      3 “Partnership Agreement”

              
	
                $
      Schedule 5 “Outline of Arrangements for Manufacture, Supply and
      Distribution” (Canada)

              	
                deleted

              
	
                $
      Schedule 6 “Outline of Arrangements for Distribution and Supply
      Agreement” (USA)

              	
                deleted

              
	
                Sponsored
      Research Agreement, as amended

              	
                concluded

              
	
                Addendum
      to Master Licence Agreement

              	
                deleted

              
	
                24
      January 1991

                Revised
      Joint Venture Formation Agreement

              	
                 

                deleted

              
	
                $
      Schedule 1 “Articles of Incorporation”

              	
                joint
      venture corporation to be dissolved

              
	
                $
      Schedule 2 “‘Unanimous Shareholders Agreement”

              	
                deleted

              
	
                $
      Schedule 3 “Joint Venture Operation Agreement”

              	
                Partnership
      Agreement

              

      

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      
        	
                $
      Schedule 4 “Rights Agreement”

              	
                deleted

              
	
                $
      Schedule 5 “Addendum to Master

              	
                deleted

              
	
                $
      Schedule 5 “Addendum to Master Licence Agreement”

              	
                deleted

              
	
                Subscription
      Agreement

              	
                concluded

              
	
                Shareholders
      Agreement

              	
                terminated

              
	
                1
      August 1991

                Collaborative
      Research Agreement, as amended

              	
                concluded

              
	 
      	
                Schedule
      4 Table of Concordance

              

      

       

      
 

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

         

      

      SCHEDULE
5

       

      TO
BIOCHEM:

      BioChem
Pharma Inc.

      275
Armand-Frappier Blvd.

      Laval,
Quebec H7V 4A7

      Canada

      Attn:
President

      Fax: (514)
978-7787

       

      TO
GROUP:

      Glaxo
Group Limited

      Lansdowne
House

      Berkeley
Square

      W1X 6BQ
England

      Attn:
Company Secretary

      Fax:
011-44-1-81-966-8330

       

      TO GLAXO
WELLCOME INC. (GWUS)

      Glaxo
Wellcome Inc.

      Five Moore
Drive

      Research
Triangle Park

      North
Carolina 27709 USA

      Attn:
General Counsel

      Fax: (919)
549-8687

       

      TO GLAXO
WELLCOME INC. (GWC)

      Glaxo
Wellcome Inc.

      7333
Mississauga Road North

      Mississauga,
Ontario

      L5N 6L4
Canada

      Attn:
President

      Fax: (905)
819-3087

       

      TANAUD
HOLDINGS (BARBADOS) LIMITED

      Chancery
Chambers

      Chancery
House, High Street

      Bridgetown,
Barbados

      Attn: Dr.
Trevor Carmichael

      Fax: (809)
431-0076

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

       

      TO TANAUD
INTERNATIONAL B.V. (TIB)

      Nieuwezijds
Voorburgwal 328 G

      1012 RW
Amsterdam

      The
Netherlands

      Attn:
Managing Director

      Fax:
31-20-627-0125

       

      TO TANAUD
LLC. (TLLC)

      Ernst
& Young Building

      Bush Hill,
Bay Street

      Bridgetown,
Barbados

      Attn:
Managing Director

      Fax: (809)
429-6446EX-4.1

 

 

Allianz SE

TO

The Bank of New York,

as Trustee

Senior Indenture

Dated as of ____________, 200_

 

 

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	 	 	Page
	 	 	 	 	 
	Parties	 	1
	Recitals of the Company	 	1
	 
	 	 	 	 
	ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF
GENERAL APPLICATION	 	1
	 
	 	 	 	 
	Section 101.
	 	Definitions	 	1
	Section 102.
	 	Compliance Certificates and Opinions	 	7
	Section 103.
	 	Form of Documents Delivered to Trustee	 	8
	Section 104.
	 	Acts of Holders; Record Dates	 	8
	Section 105.
	 	Notices, Etc., to Trustee and Company	 	10
	Section 106.
	 	Notice to Holders; Waiver	 	11
	Section 107.
	 	Conflict with Trust Indenture Act	 	11
	Section 108.
	 	Effect of Headings and Table of Contents	 	11
	Section 109.
	 	Successors and Assigns	 	11
	Section 110.
	 	Separability Clause	 	12
	Section 111.
	 	Benefits of Indenture	 	12
	Section 112.
	 	Governing Law	 	12
	Section 113.
	 	Submission to Jurisdiction; Appointment of Agent for
Service of Process	 	12
	Section 114.
	 	Legal Holidays	 	13
	Section 115.
	 	Waiver of Jury Trial	 	13
	 
	 	 	 	 
	ARTICLE TWO SECURITY FORMS	 	13
	 
	 	 	 	 
	Section 201.
	 	Forms Generally	 	13
	Section 202.
	 	Form of Face of Security	 	13
	Section 203.
	 	Form of Reverse of Security	 	15
	Section 204.
	 	Form of Legend for Global Securities	 	19
	Section 205.
	 	Form of Trustee's Certificate of Authentication	 	19
	 
	 	 	 	 
	ARTICLE THREE THE SECURITIES	 	19
	 
	 	 	 	 
	Section 301.
	 	Amount Unlimited; Issuable in Series	 	19
	Section 302.
	 	Denominations	 	22
	Section 303.
	 	Execution, Authentication, Delivery and Dating	 	22
	Section 304.
	 	Temporary Securities	 	24
	Section 305.
	 	Registration, Registration of Transfer and Exchange	 	24
	Section 306.
	 	Mutilated, Destroyed, Lost and Stolen Securities	 	26
	Section 307.
	 	Payment of Interest; Interest Rights Preserved	 	27
	Section 308.
	 	Persons Deemed Owners	 	28
	Section 309.
	 	Cancellation	 	29
	Section 310.
	 	Computation of Interest	 	29
	Section 311.
	 	CUSIP Numbers	 	29

 

			
	Note:	 	This table of contents shall not, for any purpose, be deemed to be a part of the Indenture.

-i-

 

	 	 	 	 	 
	 	 	 	 	Page
	 
	 	 	 	 
	ARTICLE FOUR SATISFACTION AND DISCHARGE	 	29
	 
	 	 	 	 
	Section 401.
	 	Satisfaction and Discharge of Indenture	 	29
	Section 402.
	 	Application of Trust Money	 	31
	 
	 	 	 	 
	ARTICLE FIVE REMEDIES	 	31
	 
	 	 	 	 
	Section 501.
	 	Events of Default	 	31
	Section 502.
	 	Acceleration of Maturity; Rescission and Annulment	 	32
	Section 503.
	 	Collection of Indebtedness and Suits for Enforcement by Trustee	 	33
	Section 504.
	 	Trustee May File Proofs of Claim	 	34
	Section 505.
	 	Trustee May Enforce Claims Without Possession of Securities	 	34
	Section 506.
	 	Application of Money Collected	 	34
	Section 507.
	 	Limitation on Suits	 	35
	Section 508.
	 	Unconditional Right of Holders to Receive Principal, Premium and Interest and to Convert	 	35
	Section 509.
	 	Restoration of Rights and Remedies	 	36
	Section 510.
	 	Rights and Remedies Cumulative	 	36
	Section 511.
	 	Delay or Omission Not Waiver	 	36
	Section 512.
	 	Control by Holders	 	36
	Section 513.
	 	Waiver of Past Defaults	 	36
	Section 514.
	 	Undertaking for Costs	 	37
	Section 515.
	 	Waiver of Usury, Stay or Extension Laws	 	37
	 
	 	 	 	 
	ARTICLE SIX THE TRUSTEE	 	37
	 
	 	 	 	 
	Section 601.
	 	Certain Duties and Responsibilities	 	37
	Section 602.
	 	Notice of Defaults	 	38
	Section 603.
	 	Certain Rights of Trustee	 	38
	Section 604.
	 	Not Responsible for Recitals or Issuance of Securities	 	39
	Section 605.
	 	May Hold Securities	 	40
	Section 606.
	 	Money Held in Trust	 	40
	Section 607.
	 	Compensation and Reimbursement	 	40
	Section 608.
	 	Conflicting Interests	 	41
	Section 609.
	 	Corporate Trustee Required; Eligibility	 	41
	Section 610.
	 	Resignation and Removal; Appointment of Successor	 	41
	Section 611.
	 	Acceptance of Appointment by Successor	 	43
	Section 612.
	 	Merger, Conversion, Consolidation or Succession to Business	 	44
	Section 613.
	 	Preferential Collection of Claims Against Company	 	44
	Section 614.
	 	Appointment of Authenticating Agent	 	44
	Section 615.
	 	Appointment of Co-Trustee	 	46
	 
	 	 	 	 
	ARTICLE SEVEN HOLDERS’ LISTS AND REPORTS BY TRUSTEE AND COMPANY	 	47
	 
	 	 	 	 
	Section 701.
	 	Company to Furnish Trustee Names and Addresses of Holders	 	47
	Section 702.
	 	Preservation of Information; Communications to Holders	 	48
	Section 703.
	 	Reports by Trustee	 	48
	Section 704.
	 	Reports by Company	 	48

-ii-

 

	 	 	 	 	 
	 	 	 	 	Page
	 
	 	 	 	 
	ARTICLE EIGHT CONSOLIDATION, MERGER, CONVEYANCE, TRANSFER OR LEASE	 	49
	 
	 	 	 	 
	Section 801.
	 	Company May Consolidate, Etc., Only on Certain Terms	 	49
	Section 802.
	 	Successor Substituted	 	50
	Section 803.
	 	Substitution of the Company on Certain Terms	 	50
	 
	 	 	 	 
	ARTICLE NINE SUPPLEMENTAL INDENTURES	 	51
	 
	 	 	 	 
	Section 901.
	 	Supplemental Indentures Without Consent of Holders	 	51
	Section 902.
	 	Supplemental Indentures With Consent of Holders	 	52
	Section 903.
	 	Execution of Supplemental Indentures	 	53
	Section 904.
	 	Effect of Supplemental Indentures	 	54
	Section 905.
	 	Conformity with Trust Indenture Act	 	54
	Section 906.
	 	Reference in Securities to Supplemental Indentures	 	54
	 
	 	 	 	 
	ARTICLE TEN COVENANTS	 	54
	 
	 	 	 	 
	Section 1001.
	 	Payment of Principal, Premium and Interest	 	54
	Section 1002.
	 	Maintenance of Office or Agency	 	54
	Section 1003.
	 	Money for Securities Payments to Be Held in Trust	 	55
	Section 1004.
	 	Statement by Officers as to Default	 	56
	Section 1005.
	 	Waiver of Certain Covenants	 	56
	Section 1006.
	 	Payment of Additional Amounts	 	57
	 
	 	 	 	 
	ARTICLE ELEVEN REDEMPTION OF SECURITIES	 	58
	 
	 	 	 	 
	Section 1101.
	 	Applicability of Article	 	58
	Section 1102.
	 	Election to Redeem; Notice to Trustee	 	58
	Section 1103.
	 	Selection by Trustee of Securities to Be Redeemed	 	58
	Section 1104.
	 	Notice of Redemption	 	59
	Section 1105.
	 	Deposit of Redemption Price	 	60
	Section 1106.
	 	Securities Payable on Redemption Date	 	60
	Section 1107.
	 	Securities Redeemed in Part	 	60
	Section 1108.
	 	Optional Redemption for Tax Reasons	 	61
	 
	 	 	 	 
	ARTICLE TWELVE SINKING FUNDS	 	61
	 
	 	 	 	 
	Section 1201.
	 	Applicability of Article	 	61
	Section 1202.
	 	Satisfaction of Sinking Fund Payments with Securities	 	62
	Section 1203.
	 	Redemption of Securities for Sinking Fund	 	62
	 
	 	 	 	 
	ARTICLE THIRTEEN DEFEASANCE AND COVENANT DEFEASANCE	 	62
	 
	 	 	 	 
	Section 1301.
	 	Company’s Option to Effect Defeasance or Covenant Defeasance	 	62
	Section 1302.
	 	Defeasance and Discharge	 	63
	Section 1303.
	 	Covenant Defeasance	 	63
	Section 1304.
	 	Conditions to Defeasance or Covenant Defeasance	 	63

-iii-

 

	 	 	 	 	 
	 	 	 	 	Page
	 
	 	 	 	 
	Section 1305.
	 	Deposited Money and U.S. Government Obligations
to Be Held in Trust;	 	 
	 
	 	Miscellaneous Provisions	 	65
	Section 1306.
	 	Reinstatement	 	66

-iv-

 

Allianz SE

Certain Sections of this Indenture relating to Sections 310 through 318,

inclusive, of the Trust Indenture Act of 1939:

	 	 	 
	Trust Indenture	 	 
	Act Section	 	Indenture Section
	 	 	 
	§ 310 (a)(1)
	 	609
	(a)(2)
	 	609
	(a)(3)
	 	615
	(a)(4)
	 	Not Applicable
	(b)
	 	608, 610
	§ 311 (a)
	 	613
	(b)
	 	613
	§ 312 (a)
	 	701
	 
	 	702
	(b)
	 	702
	(c)
	 	702
	§ 313 (a)
	 	703
	(b)
	 	703
	(c)
	 	703
	(d)
	 	703
	§ 314 (a)
	 	704
	(a)(4)
	 	1004
	(b)
	 	Not Applicable
	(c)(1)
	 	102
	(c)(2)
	 	102
	(c)(3)
	 	Not Applicable
	(d)
	 	Not Applicable
	(e)
	 	102
	§ 315 (a)
	 	601
	(b)
	 	602
	(c)
	 	601
	(d)
	 	601
	(e)
	 	514
	§ 316 (a)
	 	 
	(a)(1)(A)
	 	502, 512
	(a)(1)(B)
	 	513
	(a)(2)
	 	Not Applicable
	(b)
	 	508
	(c)
	 	104
	§ 317 (a)(1)
	 	503
	(a)(2)
	 	504
	(b)
	 	1003
	§ 318 (a)
	 	107

 

			
	Note:	 	This reconciliation and tie shall not, for any purpose, be deemed to be a part of
the Indenture.

-v-

 

     SENIOR INDENTURE, dated as of                     , 200_, between Allianz SE, a European Company
incorporated in the Federal Republic of Germany and organized under the laws of the Federal
Republic of Germany and the European Union (herein called the “Company”), having its
principal office at Königinstrasse 28, 80802 Munich, Germany, and The Bank of New York, a New York
banking corporation, as Trustee (herein called the “Trustee”), having its Corporate Trust
Office at 101 Barclay Street, New York, New York 10286.

Recitals of the Company

     The Company has duly authorized the execution and delivery of this Indenture to provide for
the issuance from time to time of its unsecured debentures, notes or other evidences of
indebtedness (herein called the “Securities”), to be issued in one or more series as in
this Indenture provided.

     All things necessary to make this Indenture a valid agreement of the Company, in accordance
with its terms, have been done.

     Now, Therefore, This Indenture Witnesseth:

     For and in consideration of the premises and the purchase of the Securities by the Holders
thereof, it is mutually covenanted and agreed, for the equal and proportionate benefit of all
Holders of the Securities or of any series thereof, as follows:

ARTICLE ONE

Definitions and Other Provisions

of General Application

Section 101. Definitions.

     For all purposes of this Indenture, except as otherwise expressly provided or unless the
context otherwise requires:

     (1) the terms defined in this Article have the meanings assigned to them in this
Article and include the plural as well as the singular;

     (2) all other terms used herein which are defined in the Trust Indenture Act, either
directly or by reference therein, have the meanings assigned to them therein;

     (3) all accounting terms not otherwise defined herein have the meanings assigned to
them in accordance with International Financial Reporting Standards as adopted by the
European Union;

     (4) unless the context otherwise requires, any reference to an “Article” or a
“Section” refers to an Article or a Section, as the case may be, of this Indenture;

 

 

     (5) the words “herein”, “hereof” and “hereunder” and other words of similar import
refer to this Indenture as a whole and not to any particular Article, Section or other
subdivision; and

     (6) when used with respect to any Security, the words “convert”, “converted” and
“conversion” are intended to refer to the right of the Holder or the Company to convert or
exchange such Security into or for securities or other property in accordance with such
terms, if any, as may hereafter be specified for such Security as contemplated by Section
301, and these words are not intended to refer to any right of the Holder or the Company
to exchange such Security for other Securities of the same series and like tenor pursuant
to Section 304, 305, 306, 906 or 1107 or another similar provision of this Indenture,
unless the context otherwise requires; and references herein to the terms of any Security
that may be converted mean such terms as may be specified for such Security as
contemplated in Section 301.

     “Act”, when used with respect to any Holder, has the meaning specified in Section 104.

     “Additional Amounts” has the meaning specified in Section 1006.

     “Affiliate” of any specified Person means any other Person directly or indirectly
controlling or controlled by or under direct or indirect common control with such specified Person.
For the purposes of this definition, “control” when used with respect to any specified Person means
the power to direct the management and policies of such Person, directly or indirectly, whether
through the ownership of voting securities, by contract or otherwise; and the terms “controlling”
and “controlled” have meanings correlative to the foregoing.

     “Applicable Procedures” of a Depositary means, with respect to any matter at any time,
the policies and procedures of such Depositary, if any, that are applicable to such matter at such
time.

     “Authenticating Agent” or “Agent” has the meaning specified in Section 614.

     “Authorized Agent” has the meaning specified in Section 113.

     “Board Resolution” means a copy of a resolution or relevant extract of minutes of a
meeting of the Management Board, evidencing actions or decisions taken within its authority,
certified by any member of the Management Board, any person duly appointed by the Management Board
or any authorized signatory of the Company and to be in full force and effect on the date of such
certification, and delivered to the Trustee.

     “Business Day”, when used with respect to any Place of Payment, means each Monday,
Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in that
Place of Payment and New York City are authorized or obligated by law, regulation or executive
order to close; provided that, when used with respect to any Security, “Business Day” may have such
other meaning, if any, as may be specified for such Security as contemplated by Section 301.

-2-

 

     “Commission” means the Securities and Exchange Commission, as from time to time
constituted, created under the Exchange Act, or, if at any time after the execution of this
Indenture such Commission is not existing and performing the duties now assigned to it under the
Trust Indenture Act, then the body performing such duties at such time.

     “Company” means the Person named as the “Company” in the first paragraph of this
Indenture until a successor Person shall have become such pursuant to the applicable provisions of
this Indenture, and thereafter “Company” shall mean such successor Person.

     “Company Request” or “Company Order” means a written request or order signed
in the name of the Company by any member of the Management Board or any other officer or officers
(Prokuristen) of the Company designated in writing by or pursuant to authority of the Management
Board and delivered to the Trustee from time to time.

     “Corporate Trust Office” means the principal corporate trust office of the Trustee, at
which office at any particular time its corporate trust business shall be administered, which at
the date hereof is located at 101 Barclay Street, Floor 4E, New York, New York 10286.

     “Corporation” means a corporation, association, company (including a limited liability
company), joint-stock company, business trust or other similar entity.

     “Covenant Defeasance” has the meaning specified in Section 1303.

     “Defaulted Interest” has the meaning specified in Section 307.

     “Defeasance” has the meaning specified in Section 1302.

     “Depositary” means, with respect to the Securities of any series issuable or issued in
whole or in part in the form of one or more Global Securities, a clearing agency that is designated
to act as Depositary for such Securities as contemplated by Section 301.

     “Event of Default” has the meaning specified in Section 501.

     “Exchange Act” means the Securities Exchange Act of 1934 and any statute successor
thereto, in each case as amended from time to time.

     “Expiration Date” has the meaning specified in Section 104.

     “Global Security” means a Security that evidences all or part of the Securities of any
series and bears the legend set forth in Section 204 (or such legend as may be specified as
contemplated by Section 301 for such Securities).

     “Holder” means a Person in whose name a Security is registered in the Security
Register.

     “Indenture” means this instrument as originally executed and as it may from time to
time be supplemented or amended by one or more indentures supplemental hereto

-3-

 

entered into pursuant to the applicable provisions hereof, including, for all purposes of this
instrument and any such supplemental indenture, the provisions of the Trust Indenture Act that are
deemed to be a part of and govern this instrument and any such supplemental indenture,
respectively. The term “Indenture” shall also include the terms of particular series of Securities
established as contemplated by Section 301.

     “Interest”, when used with respect to an Original Issue Discount Security which by its
terms bears interest only after Maturity, means interest payable after Maturity.

     “Interest Payment Date”, when used with respect to any Security, means the Stated
Maturity of an installment of interest on such Security.

     “Investment Company Act” means the Investment Company Act of 1940 and any statute
successor thereto, in each case as amended from time to time.

     “Management Board” means either the Management Board of the Company or any duly
authorized committee of that board.

     “Maturity”, when used with respect to any Security, means the date on which the
principal of such Security or an installment of principal becomes due and payable as therein or
herein provided, whether at the Stated Maturity or by declaration of acceleration, call for
redemption or otherwise.

     “New Issuer” has the meaning specified in Section 803.

     “Notice of Default” means a written notice of the kind specified in Section 501(4).

     “Officers’ Certificate” means a certificate signed by any member of the Management
Board or any other officer or officers (Prokuristen) of the Company designated in a writing by or
pursuant to authority of the Management Board and delivered to the Trustee from time to time. One
of the officers signing an Officers’ Certificate given pursuant to Section 1004 shall be the
principal executive, financial or accounting officer of the Company.

     “Opinion of Counsel” means a written opinion of counsel, who may be an employee of the
Company.

     “Original Issue Discount Security” means any Security which provides for an amount
less than the principal amount thereof to be due and payable upon a declaration of acceleration of
the Maturity thereof pursuant to Section 502.

     “Outstanding”, when used with respect to the Securities, means, as of the date of
determination, all Securities theretofore authenticated and delivered under this Indenture, except:

     (1) Securities theretofore canceled by the Trustee or delivered to the Trustee for
cancellation;

     (2) Securities for whose payment or redemption money in the necessary amount has been
theretofore deposited with the Trustee or any Paying

-4-

 

Agent (other than the Company) in trust or set aside and segregated in trust by the
Company (if the Company shall act as its own Paying Agent) for the Holders of such
Securities; provided, however, that, if such Securities are to be redeemed, notice of such
redemption has been duly given pursuant to this Indenture or provision therefor
satisfactory to the Trustee has been made;

     (3) Securities as to which Defeasance has been effected pursuant to Section 1302;

     (4) Securities which have been paid pursuant to Section 306 or in exchange for or in
lieu of which other Securities have been authenticated and delivered pursuant to this
Indenture, other than any such Securities in respect of which there shall have been
presented to the Trustee proof satisfactory to it that such Securities are held by a
protected purchaser in whose hands such Securities are valid obligations of the Company;
and

     (5) Securities as to which any property deliverable upon conversion thereof has been
delivered (or such delivery has been duly provided for), or as to which any other
particular conditions have been satisfied, in each case as may be provided for such
Securities as contemplated in Section 301;

provided, however, that in determining whether the Holders of the requisite principal amount of the
Outstanding Securities have given, made or taken any request, demand, authorization, direction,
notice, consent, waiver or other action hereunder as of any date, (A) the principal amount of an
Original Issue Discount Security which shall be deemed to be Outstanding shall be the amount of the
principal thereof which would be due and payable as of such date upon acceleration of the Maturity
thereof to such date pursuant to Section 502, (B) if, as of such date, the principal amount payable
at the Stated Maturity of a Security is not determinable, the principal amount of such Security
which shall be deemed to be Outstanding shall be the amount as specified or determined as
contemplated by Section 301, (C) the principal amount of a Security denominated in one or more
foreign currencies, composite currencies or currency units which shall be deemed to be Outstanding
shall be the U.S. dollar equivalent, determined as of such date in the manner provided as
contemplated by Section 301, of the principal amount of such Security (or, in the case of a
Security described in Clause (A) or (B) above, of the amount determined as provided in such
Clause), and (D) Securities owned by the Company or any other obligor upon the Securities or any
Affiliate of the Company or of such other obligor shall be disregarded and deemed not to be
Outstanding, except that, in determining whether the Trustee shall be protected in relying upon any
such request, demand, authorization, direction, notice, consent, waiver or other action, only
Securities which a Responsible Officer of the Trustee actually knows to be so owned shall be so
disregarded. Securities so owned which have been pledged in good faith may be regarded as
Outstanding if the pledgee establishes to the satisfaction of the Trustee the pledgee’s right so to
act with respect to such Securities and that the pledgee is not the Company or any other obligor
upon the Securities or any Affiliate of the Company or of such other obligor.

     “Paying Agent” means any Person authorized by the Company to pay the principal of or
any premium or interest on any Securities on behalf of the Company.

-5-

 

     “Person” means any individual, corporation, limited liability company, partnership,
joint venture, trust, unincorporated organization or government or any agency or political
subdivision thereof.

     “Place of Payment”, when used with respect to the Securities of any series and subject
to Section 1002, means the place or places where the principal of and any premium and interest on
the Securities of that series are payable as specified as contemplated by Section 301.

     “Predecessor Security” of any particular Security means every previous Security
evidencing all or a portion of the same debt as that evidenced by such particular Security; and,
for the purposes of this definition, any Security authenticated and delivered under Section 306 in
exchange for or in lieu of a mutilated, destroyed, lost or stolen Security shall be deemed to
evidence the same debt as the mutilated, destroyed, lost or stolen Security.

     “Redemption Date”, when used with respect to any Security to be redeemed, means the
date fixed for such redemption by or pursuant to this Indenture.

     “Redemption Price”, when used with respect to any Security to be redeemed, means the
price at which it is to be redeemed pursuant to this Indenture.

     “Regular Record Date” for the interest payable on any Interest Payment Date on the
Securities of any series means the date specified for that purpose as contemplated by Section 301.

     “Relevant Jurisdiction” has the meaning specified in Section 1006.

     “Responsible Officer”, when used with respect to the Trustee, means any officer of the
Trustee having direct responsibility for the administration of this Indenture and also means, with
respect to a particular corporate trust matter, any other officer to whom such matter is referred
because of his knowledge of and familiarity with the particular subject.

     “Securities” has the meaning stated in the first recital of this Indenture and more
particularly means any Securities authenticated and delivered under this Indenture.

     “Securities Act” means the Securities Act of 1933 and any statute successor thereto,
in each case as amended from time to time.

     “Security Register” and “Security Registrar” have the respective meanings
specified in Section 305.

     “Special Record Date” for the payment of any Defaulted Interest means a date fixed by
the Trustee pursuant to Section 307.

     “Stated Maturity”, when used with respect to any Security or any installment of
principal thereof or interest thereon, means the date specified in such Security as the fixed date
on which the principal of such Security or such installment of principal or interest is due and
payable.

-6-

 

     “Subsidiary” means any Person a majority of the combined voting power of the total
outstanding ownership interests in which is, at the time of determination, beneficially owned or
held, directly or indirectly, by the Company or one or more other Subsidiaries. For this purpose,
“voting power” means power to vote in an ordinary election of directors (or, in the case of a
Person that is not a corporation, ordinarily to appoint or approve the appointment of Persons
holding similar positions), whether at all times or only as long as no senior class of ownership
interests has such voting power by reason of any contingency.

     “Taxes” has the meaning specified in Section 1006.

     “Trust Indenture Act” means the Trust Indenture Act of 1939, as amended by the Trust
Indenture Reform Act of 1990, and as in force at the date as of which this instrument was executed;
provided, however, that in the event the Trust Indenture Act of 1939 is amended after such date,
“Trust Indenture Act” means, to the extent required by any such amendment, the Trust Indenture Act
of 1939 as so amended.

     “Trustee” means the Person named as the “Trustee” in the first paragraph of this
instrument until a successor Trustee shall have become such pursuant to the applicable provisions
of this Indenture, and thereafter “Trustee” shall mean or include each Person who is then a Trustee
hereunder, and if at any time there is more than one such Person, “Trustee” as used with respect to
the Securities of any series shall mean the Trustee with respect to Securities of that series.

     “U.S. Government Obligation” has the meaning specified in Section 1304.

Section 102. Compliance Certificates and Opinions.

     Upon any application or request by the Company to the Trustee to take any action under any
provision of this Indenture, the Company shall furnish to the Trustee such certificates and
opinions as may be required under the Trust Indenture Act; provided, however, that no such
certificates or opinion shall be required in connection with the issuance of Securities of any
series. Each such certificate or opinion shall be given in the form of an Officers’ Certificate, if
to be given by an officer of the Company, or an Opinion of Counsel, if to be given by counsel, and
shall comply with the requirements of the Trust Indenture Act and any other requirements set forth
in this Indenture.

     Every certificate or opinion with respect to compliance with a condition or covenant provided
for in this Indenture shall include:

     (1) a statement that each individual signing such certificate or opinion has read
such covenant or condition and the definitions herein relating thereto;

     (2) a brief statement as to the nature and scope of the examination or investigation
upon which the statements or opinions contained in such certificate or opinion are based;

     (3) a statement that, in the opinion of each such individual, he has made such
examination or investigation as is necessary to enable him to express

-7-

 

an informed opinion as to whether or not such covenant or condition has been complied
with; and

     (4) a statement as to whether, in the opinion of each such individual, such condition
or covenant has been complied with.

Section 103. Form of Documents Delivered to Trustee.

     In any case where several matters are required to be certified by, or covered by an opinion
of, any specified Person, it is not necessary that all such matters be certified by, or covered by
the opinion of, only one such Person, or that they be so certified or covered by only one document,
but one such Person may certify or give an opinion with respect to some matters and one or more
other such Persons as to other matters, and any such Person may certify or give an opinion as to
such matters in one or several documents.

     Any certificate or opinion of an officer of the Company may be based, insofar as it relates to
legal matters, upon a certificate or opinion of, or representations by, counsel, unless such
officer knows, or in the exercise of reasonable care should know, that the certificate or opinion,
or representations with respect to the matters upon which his certificate or opinion is based, are
erroneous. Any such certificate or opinion of, or representation by, counsel may be based, insofar
as it relates to factual matters, upon a certificate or opinion of, or representations by, an
officer or officers of the Company stating that the information with respect to such factual
matters is in the possession of the Company, unless such counsel knows, or in the exercise of
reasonable care should know, that the certificate or opinion or representations with respect to
such matters are erroneous.

     Where any Person is required to make, give or execute two or more applications, requests,
consents, certificates, statements, opinions or other instruments under this Indenture, they may,
but need not, be consolidated and form one instrument.

Section 104. Acts of Holders; Record Dates.

     Any request, demand, authorization, direction, notice, consent, waiver or other action
provided or permitted by this Indenture to be given, made or taken by Holders may be embodied in
and evidenced by one or more instruments of substantially similar tenor signed by such Holders in
person or by agent duly appointed in writing; and, except as herein otherwise expressly provided,
such action shall become effective when such instrument or instruments are delivered to the Trustee
and, where it is hereby expressly required, to the Company. Such instrument or instruments (and the
action embodied therein and evidenced thereby) are herein sometimes referred to as the
“Act” of the Holders signing such instrument or instruments. Proof of execution of any such
instrument or of a writing appointing any such agent shall be sufficient for any purpose of this
Indenture and (subject to Section 601) conclusive in favor of the Trustee and the Company, if made
in the manner provided in this Section.

     The fact and date of the execution by any Person of any such instrument or writing may be
proved by the affidavit of a witness of such execution or by a certificate of a notary public or
other officer authorized by law to take acknowledgments of deeds, certifying that the individual
signing such instrument or writing acknowledged to him the

-8-

 

execution thereof. Where such execution is by a signer acting in a capacity other than his
individual capacity, such certificate or affidavit shall also constitute sufficient proof of his
authority. The fact and date of the execution of any such instrument or writing, or the authority
of the Person executing the same, may also be proved in any other manner which the Trustee deems
sufficient.

     The ownership of Securities shall be proved by the Security Register.

     Any request, demand, authorization, direction, notice, consent, waiver or other Act of the
Holder of any Security shall bind every future Holder of the same Security and the Holder of every
Security issued upon the registration of transfer thereof or in exchange therefor or in lieu
thereof in respect of anything done, omitted or suffered to be done by the Trustee or the Company
in reliance thereon, whether or not notation of such action is made upon such Security.

     The Company may set any day as a record date for the purpose of determining the Holders of
Outstanding Securities of any series entitled to give, make or take any request, demand,
authorization, direction, notice, consent, waiver or other action provided or permitted by this
Indenture to be given, made or taken by Holders of Securities of such series; provided, that the
Company may not set a record date for, and the provisions of this paragraph shall not apply with
respect to, the giving or making of any notice, declaration, request or direction referred to in
the next paragraph. If any record date is set pursuant to this paragraph, the Holders of
Outstanding Securities of the relevant series on such record date, and no other Holders, shall be
entitled to take the relevant action, whether or not such Holders remain Holders after such record
date; provided, that no such action shall be effective hereunder unless taken on or prior to the
applicable Expiration Date by Holders of the requisite principal amount of Outstanding Securities
of such series on such record date. Nothing in this paragraph shall be construed to prevent the
Company from setting a new record date for any action for which a record date has previously been
set pursuant to this paragraph (whereupon the record date previously set shall automatically and
with no action by any Person be canceled and of no effect), and nothing in this paragraph shall be
construed to render ineffective any action taken by Holders of the requisite principal amount of
Outstanding Securities of the relevant series on the date such action is taken. Promptly after any
record date is set pursuant to this paragraph, the Company, at its own expense, shall cause notice
of such record date, the proposed action by Holders and the applicable Expiration Date to be given
to the Trustee in writing and to each Holder of Securities of the relevant series in the manner set
forth in Section 106.

     The Trustee may set any day as a record date for the purpose of determining the Holders of
Outstanding Securities of any series entitled to join in the giving or making of (i) any Notice of
Default, (ii) any declaration of acceleration referred to in Section 502, (iii) any request to
institute proceedings referred to in Section 507(2) or (iv) any direction referred to in Section
512, in each case with respect to Securities of such series. If any record date is set pursuant to
this paragraph, the Holders of Outstanding Securities of such series on such record date, and no
other Holders, shall be entitled to join in such notice, declaration, request or direction, whether
or not such Holders remain Holders after such record date; provided, that no such action shall be
effective hereunder unless taken on or prior to the applicable Expiration Date by Holders of the
requisite principal amount of Outstanding Securities of such series on such record date. Nothing in
this paragraph shall be construed to prevent the Trustee from setting a new record date for

-9-

 

any action for which a record date has previously been set pursuant to this paragraph
(whereupon the record date previously set shall automatically and with no action by any Person be
canceled and of no effect), and nothing in this paragraph shall be construed to render ineffective
any action taken by Holders of the requisite principal amount of Outstanding Securities of the
relevant series on the date such action is taken. Promptly after any record date is set pursuant to
this paragraph, the Trustee, at the Company’s expense, shall cause notice of such record date, the
proposed action by Holders and the applicable Expiration Date to be given to the Company in writing
and to each Holder of Securities of the relevant series in the manner set forth in Section 106.

     With respect to any record date set pursuant to this Section, the party hereto which sets such
record dates may designate any day as the “Expiration Date” and from time to time may change the
Expiration Date to any earlier or later day; provided, that no such change shall be effective
unless notice of the proposed new Expiration Date is given to the other party hereto in writing,
and to each Holder of Securities of the relevant series in the manner set forth in Section 106, on
or prior to the existing Expiration Date. If an Expiration Date is not designated with respect to
any record date set pursuant to this Section, the party hereto which set such record date shall be
deemed to have initially designated the 180th day after such record date as the Expiration Date
with respect thereto, subject to its right to change the Expiration Date as provided in this
paragraph. Notwithstanding the foregoing, no Expiration Date shall be later than the 180th day
after the applicable record date.

     Without limiting the foregoing, a Holder entitled hereunder to take any action hereunder with
regard to any particular Security may do so with regard to all or any part of the principal amount
of such Security or by one or more duly appointed agents each of which may do so pursuant to such
appointment with regard to all or any part of such principal amount of such Security.

Section 105. Notices, Etc., to Trustee and Company.

     Any request, demand, authorization, direction, notice, consent, waiver or Act of Holders or
other document provided or permitted by this Indenture to be made upon, given or furnished to, or
filed with:

     (1) the Trustee by any Holder or by the Company shall be sufficient for every purpose
hereunder if made, given, furnished or filed in writing (which may be via facsimile) and
mailed, first-class postage prepaid, to the Trustee to or with the Trustee at its
Corporate Trust Office, Attention: Global Finance Americas; or

     (2) the Company by the Trustee or by any Holder shall be sufficient for every purpose
hereunder (unless otherwise herein expressly provided) if in writing (which may be via
facsimile) and mailed, first-class postage prepaid, to the Company addressed to it at the
address of its principal office specified in the first paragraph of this instrument,
Attention: Director of Corporate Finance, or at any other address previously furnished in
writing to the Trustee by the Company.

-10-

 

Section 106. Notice to Holders; Waiver.

     Where this Indenture provides for notice to Holders of any event, such notice shall be
sufficiently given (unless otherwise herein expressly provided) if in writing and mailed,
first-class postage prepaid, to each Holder affected by such event, at his address as it appears in
the Security Register, not later than the latest date (if any), and not earlier than the earliest
date (if any), prescribed for the giving of such notice. In any case where notice to Holders is
given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to
any particular Holder shall affect the sufficiency of such notice with respect to other Holders.
Any notice mailed to a Holder in a manner herein prescribed shall be conclusively deemed to have
been received by such Holder, whether or not such Holder actually receives such notice. Where this
Indenture provides for notice in any manner, such notice may be waived in writing by the Person
entitled to receive such notice, either before or after the event, and such waiver shall be the
equivalent of such notice. Waivers of notice by Holders shall be filed with the Trustee, but such
filing shall not be a condition precedent to the validity of any action taken in reliance upon such
waiver.

     In case by reason of the suspension of regular mail service or by reason of any other cause it
shall be impracticable to give such notice by mail, then such notification as shall be made with
the approval of the Trustee shall constitute a sufficient notification for every purpose hereunder.

     Where this Indenture provides for Notice of any event to a Holder of a Global Security, such
notice shall be sufficiently given if given to the Depositary for such Security (or its designee),
pursuant to its Applicable Procedures, not later than the latest date (if any), and not earlier
than the earliest date (if any), prescribed for the giving of such notice.

Section 107. Conflict with Trust Indenture Act.

     If any provision hereof limits, qualifies or conflicts with a provision of the Trust Indenture
Act which is required under the Trust Indenture Act to be a part of and govern this Indenture, the
latter provision shall control. If any provision of this Indenture modifies or excludes any
provision of the Trust Indenture Act which may be so modified or excluded, the latter provision
shall be deemed to apply to this Indenture as so modified or to be excluded, as the case may be.

Section 108. Effect of Headings and Table of Contents.

     The Article and Section headings herein and the Table of Contents are for convenience only and
shall not affect the construction hereof.

Section 109. Successors and Assigns.

     All covenants and agreements in this Indenture by the Company shall bind its successors and
assigns, whether so expressed or not.

-11-

 

Section 110. Separability Clause.

     In case any provision in this Indenture or in the Securities shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby.

Section 111. Benefits of Indenture.

     Nothing in this Indenture or in the Securities, express or implied, shall give to any Person,
other than the parties hereto and their successors hereunder and the Holders, any benefit or any
legal or equitable right, remedy or claim under this Indenture.

Section 112. Governing Law.

     Unless otherwise specified in or pursuant to an indenture supplemental hereto, this Indenture
and the Securities shall be governed by and construed in accordance with the laws of the State of
New York.

Section 113. Submission to Jurisdiction; Appointment of Agent for Service of Process.

     The Company hereby appoints Corporation Service Company, acting through its office at 1133
Avenue of the Americas, Suite 3100, New York, New York 10036 (or such other address in the Borough
of Manhattan, The City of New York, as such agent shall furnish in writing to the Company and the
Trustee) as its authorized agent (the “Authorized Agent”) upon which process may be served
in any legal action or proceeding against it with respect to its obligations under this Indenture
or the Securities of any series, as the case may be, instituted in any federal or state court in
the Borough of Manhattan, The City of New York by the Holder of any Security, and agrees that
service of process upon the Authorized Agent, together with written notice of said service mailed
or delivered to the Company, addressed as provided in Section 105, shall be deemed in every respect
effective service of process upon the Company in any such legal action or proceeding, and the
Company hereby irrevocably submits to the non-exclusive jurisdiction of any such court in respect
of any such legal action or proceeding. Such appointment shall be irrevocable so long as the
Holders of Securities shall have any rights pursuant to the terms of the Securities or of this
Indenture until the appointment of a successor Authorized Agent by the Company and such successor’s
acceptance of such appointment. The Company reserves the right to appoint another person located,
or with an office, in the Borough of Manhattan, The City of New York, selected in its sole
discretion, as a successor Authorized Agent, and upon acceptance of such appointment by such a
successor the appointment of the prior Authorized Agent shall terminate. If for any reason
Corporation Service Company ceases to be able to act as the Authorized Agent or to have an address
in the Borough of Manhattan, The City of New York, the Company will appoint a successor Authorized
Agent in accordance with the preceding sentence. The Company further agrees to take any and all
action, including the filing of any and all documents and instruments as may be necessary to
continue such designation and appointment of such agent or successor in full force and effect for
as long as required hereunder.

-12-

 

Section 114. Legal Holidays.

     In any case where any Interest Payment Date, Redemption Date or Maturity of any Security, or
any date on which a Holder has the right to convert his Security, shall not be a Business Day at
any Place of Payment, then (notwithstanding any other provision of this Indenture or of the
Securities (other than a provision of any Security which specifically states that such provision
shall apply in lieu of this Section)) payment of interest or principal (and premium, if any), or
conversion of such Security need not be made at such Place of Payment on such date, but may be made
on the next succeeding Business Day at such Place of Payment with the same force and effect as if
made on the Interest Payment Date or Redemption Date, or at the Maturity, or on such date for
conversion, as the case may be.

Section 115. Waiver of Jury Trial.

     EACH OF THE COMPANY, THE TRUSTEE AND ANY HOLDER OR BENEFICIAL OWNER OF A SECURITY BY ITS
ACQUISITION OF AN INTEREST IN SUCH SECURITY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT
OF OR RELATING TO THIS INDENTURE, THE SECURITIES OR THE TRANSACTIONS CONTEMPLATED HEREBY.

ARTICLE TWO

 Security Forms

Section 201. Forms Generally.

     The Securities of each series shall be in substantially the form set forth in this Article, or
in such other form as shall be established by or pursuant to a Board Resolution or in one or more
indentures supplemental hereto, in each case with such appropriate insertions, omissions,
substitutions and other variations as are required or permitted by this Indenture, and may have
such letters, numbers or other marks of identification and such legends or endorsements placed
thereon as may be required to comply with the rules of any securities exchange or Depositary
therefor or as may, consistently herewith, be determined by the officers executing such Securities,
as evidenced by their execution thereof. If the form of Securities of any series is established by
action taken pursuant to a Board Resolution, a copy of an appropriate record of such action shall
be certified by any member of the Management Board and delivered to the Trustee at or prior to the
delivery of the Company Order contemplated by Section 303 for the authentication and delivery of
such Securities.

     The definitive Securities shall be printed, lithographed or engraved on steel engraved borders
or may be produced in any other manner, all as determined by the officers executing such
Securities, as evidenced by their execution of such Securities.

Section 202. Form of Face of Security.

     [Insert any legend required by the Internal Revenue Code and the regulations thereunder or
other selling restrictions.]

-13-

 

Allianz SE

                                                            

			
	 	 	 
	No.                     	 	 
	CUSIP No.                     
	 	$                    
	[ISIN                     ]	 	 
	[COMMON CODE                     ]	 	 

     Allianz SE, a European company incorporated in the Federal Republic of Germany and organized
and existing under the laws of the Federal Republic of Germany and the European Union, having its
corporate seat in Munich, Germany (herein called the “Company”, which term includes any successor
Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to
                                                  , or registered assigns, the principal
sum of            
             
            
           
   Dollars on          
             
    
               
               
     [if the Security is to bear
interest prior to Maturity, insert — , and to pay interest thereon from                      or from the most recent
Interest Payment Date to which interest has been paid or duly provided for, [semi-]annually on                      and                     
in each year, commencing                     , and at the Maturity thereof, at the rate of ___% per annum, until the
principal hereof is paid or made available for payment [if applicable, insert — , provided that
any principal and premium, and any such installment of interest, which is overdue shall bear
interest at the rate of
        % per annum (to the extent that the payment of such interest shall be
legally enforceable), from the dates such amounts are due until they are paid or made available for
payment, and such interest shall be payable on demand]. The interest so payable, and punctually
paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be
paid to the Person in whose name this Security (or one or more Predecessor Securities) is
registered at the close of business on the Regular Record Date for such interest, which shall be
the ___ or ___ (whether or not a Business Day), as the case may be, next preceding such Interest
Payment Date. Any such interest so payable, but not punctually paid or duly provided for, on any
Interest Payment Date will forthwith cease to be payable to the Holder on such Regular Record Date
and may either be paid to the Person in whose name this Security (or one or more Predecessor
Securities) is registered at the close of business on a Special Record Date for the payment of such
Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of
Securities of this series not less than 10 days prior to such Special Record Date, or be paid in
any other lawful manner not inconsistent with the requirements of any securities exchange on which
this Security may be listed, and upon such notice as may be required by such exchange, all as more
fully provided in said Indenture].

     [If the Security is not to bear interest prior to Maturity, insert — The principal of this
Security shall not bear interest except in the case of a default in payment of principal upon
acceleration, upon redemption or at Stated Maturity and in such case the overdue principal and any
overdue premium shall bear interest at the rate of % per annum (to the extent that the payment of
such interest shall be legally enforceable), from the dates such amounts are due until they are
paid or made available for payment. Interest on any overdue principal or premium shall be payable
on demand.]

     Payment of the principal of (and premium, if any) and [if applicable, insert — any such]
interest on this Security will be made at the office or agency of the Company maintained for that
purpose in New York, New York, in such coin or currency of the

-14-

 

United States of America as at the time of payment is legal tender for payment of public and
private debts, against surrender of this Security in the case of any payment due at the Maturity of
the principal thereof (other than any payment of interest that first becomes payable on a day other
than an Interest Payment Date); provided, however, that at the option of the Company, payment of
interest may be made by check mailed to the address of the Person entitled thereto as such address
shall appear in the Security Register; and provided, further, that if this Security is a Global
Security, payment may be made pursuant to the Applicable Procedures of the Depositary as permitted
in said Indenture.

     Reference is hereby made to the further provisions of this Security set forth on the reverse
hereof, which further provisions shall for all purposes have the same effect as if set forth at
this place.

     Unless the certificate of authentication hereon has been executed by the Trustee referred to
on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under
the Indenture or be valid or obligatory for any purpose.

     In Witness Whereof, the Company has caused this instrument to be duly executed.

	 	 	 	 	 
	 	Allianz SE

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

Attest:

 

Section 203. Form of Reverse of Security.

     This Security is one of a duly authorized issue of securities of the Company (herein called
the “Securities”), issued and to be issued in one or more series under a Senior Indenture, dated
as of                     , 200__ (herein called the “Indenture”, which term shall have the meaning
assigned to it in such instrument), between the Company and The Bank of New York, as Trustee
(herein called the “Trustee”, which term includes any successor trustee under the Indenture), and
reference is hereby made to the Indenture for a statement of the respective rights, limitations of
rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the
Securities and of the terms upon which the Securities are, and are to be, authenticated and
delivered. This Security is one of the series designated on the face hereof [if applicable, insert
— , limited in aggregate principal amount to $                    ].

     [If applicable, insert — The Securities of this series are subject to redemption upon not
less than 30 days’ notice, by mail, at any time [if applicable, insert — on or

-15-

 

after                     , 20__], as a whole or in part, at the election of the Company, at the following
Redemption Prices (expressed as percentages of the principal amount): If redeemed [if applicable,
insert — on or before                     , ___%, and if redeemed] during the 12-month period beginning                      of the
years indicated,

	 	 	 	 	 
	Year	 	Redemption Price

	 	 	 	 	 
	Year	 	Redemption Price

and thereafter at a Redemption Price equal to .% of the principal amount, together in the case of
any such redemption with accrued interest to the Redemption Date, but interest installments whose
Stated Maturity is on or prior to such Redemption Date will be payable to the Holders of such
Securities, or one or more Predecessor Securities, of record at the close of business on the
relevant Record Dates referred to on the face hereof, all as provided in the Indenture.]

     [If the Security is subject to redemption of any kind, insert — In the event of redemption of
this Security in part only, a new Security or Securities of this series and of like tenor for the
unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation
hereof.]

     [If applicable, insert — The Indenture contains provisions for defeasance at any time of the
entire indebtedness of this Security or certain restrictive covenants and Events of Default with
respect to this Security, in each case upon compliance with certain conditions set forth in the
Indenture.]

     [If the Security is not an Original Issue Discount Security, insert — If an Event of Default
with respect to Securities of this series shall occur and be continuing, the principal of the
Securities of this series may be declared due and payable in the manner and with the effect
provided in the Indenture.]

     [If the Security is an Original Issue Discount Security, insert — If an Event of Default with
respect to Securities of this series shall occur and be continuing, an amount of principal of the
Securities of this series may be declared due and payable in the manner and with the effect
provided in the Indenture. Such amount shall be equal to — insert formula for determining the
amount. Upon payment (i) of the amount of principal so declared due and payable and (ii) of
interest on any overdue principal, premium and interest (in each case to the extent that the
payment of such interest shall be legally enforceable), all of the Company’s obligations in respect
of the payment of the principal of and premium and interest, if any, on the Securities of this
series shall terminate.]

     Payments under the Securities will be made free and clear of and without withholding or
deduction for any taxes, duties, assessments or governmental charges of whatever nature
(“Taxes”) imposed, levied, collected, withheld or assessed by the Federal Republic of
Germany or the government of a jurisdiction in which a successor to the Company is organized or
resident for tax purposes or any political subdivision or authority thereof or therein that has the
power to tax (each, a “Relevant Jurisdiction”), unless required by law. To the extent any
such Taxes are so levied or imposed, the

-16-

 

Company will, subject to the exceptions and limitations set forth in Section 1006 of the
Indenture, pay such additional amounts (“Additional Amounts”) to the Holder of any Security
who is not a resident of a Relevant Jurisdiction as may be necessary in order that every net
payment of the principal of and interest on such Security and any other amounts payable on such
Security, after withholding for or on account of such Taxes imposed upon or as a result of such
payment, will not be less than the amount provided for in such Security to be then due and payable.

     [If
applicable insert — In addition to its ability to redeem this Security pursuant to the
foregoing,] [i]f at any time as a result of any change in or amendment to the laws or regulations
of a Relevant Jurisdiction affecting taxation, or a change in any application or interpretation of
such laws or regulations (including the decision of any court or tribunal) either generally or in
relation to any particular Securities, which change, amendment, application or interpretation
becomes effective on or after
_________, 20___ in making any payment of, or in respect of, the
principal amount of, or any premium or interest on, the Securities, the Company would be required
to pay any Additional Amounts with respect thereto, then the Securities will be redeemable upon not
less than 45 nor more than 60 days’ notice by mail, at any time thereafter, in whole but not in
part, at the election of the Company as provided in the Indenture at [their principal amount] [if
the Security is an Original Issue Discount Security, insert an amount equal to _________, insert
formula for determining the amount], together in the case of any such redemption with any accrued
but unpaid interest to, the Redemption Date.

     The Indenture permits, with certain exceptions as therein provided, the amendment thereof and
the modification of the rights and obligations of the Company and the rights of the Holders of the
Securities of each series to be affected under the Indenture at any time by the Company and the
Trustee with the consent of the Holders of a majority in principal amount of the Securities at the
time Outstanding of all series to be affected (considered together as one class for this purpose).
The Indenture also contains provisions (i) permitting the Holders of a majority in principal amount
of the Securities of each series at the time Outstanding, on behalf of the Holders of all
Securities of such series, to waive compliance by the Company with certain provisions of the
Indenture and (ii) permitting the Holders of a majority in principal amount of the Securities at
the time Outstanding of any series to be affected under the Indenture (with each such series
considered separately for this purpose), on behalf of the Holders of all Securities of such series,
to waive certain past defaults under the Indenture and their consequences. Any such consent or
waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all
future Holders of this Security and of any Security issued upon the registration of transfer hereof
or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made
upon this Security.

     As provided in and subject to the provisions of the Indenture, the Holder of this Security
shall not have the right to institute any proceeding with respect to the Indenture, or for the
appointment of a receiver or trustee, or for any other remedy thereunder, unless such Holder shall
have previously given the Trustee written notice of a continuing Event of Default with respect to
the Securities of this series, the Holders of not less than 25% in principal amount of the
Securities of this series at the time Outstanding shall have made written request to the Trustee to
institute proceedings in respect of such Event of Default as Trustee and offered the Trustee
indemnity reasonably satisfactory to it, and the Trustee shall not have received from the Holders
of a majority in principal amount of Securities of this series at the time Outstanding a direction
inconsistent with such request, and shall

-17-

 

have failed to institute any such proceeding, for 60 days after receipt of such notice,
request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder
of this Security for the enforcement of any payment of principal hereof or any premium or interest
hereon on or after the respective due dates expressed herein.

     No reference herein to the Indenture and no provision of this Security or of the Indenture
shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay
the principal of and any premium and interest on this Security at the times, place and rate, and in
the coin or currency, herein prescribed.

     As provided in the Indenture and subject to certain limitations therein set forth, the
transfer of this Security is registrable in the Security Register, upon surrender of this Security
for registration of transfer at the office or agency of the Company in any place where the
principal of and any premium and interest on this Security are payable, duly endorsed by, or
accompanied by a written instrument of transfer in form satisfactory to the Company and the
Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing,
and thereupon one or more new Securities of this series and of like tenor, of authorized
denominations and for the same aggregate principal amount, will be issued to the designated
transferee or transferees.

     The Securities of this series are issuable only in registered form without coupons in
denominations of $_________ and any integral multiple thereof. As provided in the Indenture and
subject to certain limitations therein set forth, Securities of this series are exchangeable for a
like aggregate principal amount of Securities of this series and of like tenor of a different
authorized denomination, as requested by the Holder surrendering the same.

     No service charge shall be made for any such registration of transfer or exchange, but the
Company or the Trustee may require payment of a sum sufficient to cover any tax or other
governmental charge payable in connection therewith.

     Prior to due presentment of this Security for registration of transfer, the Company, the
Trustee and any agent of the Company or the Trustee may treat the Person in whose name this
Security is registered as the owner hereof for all purposes, whether or not this Security be
overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the
contrary.

     This Security is a Global Security and is subject to the provisions of the Indenture relating
to Global Securities, including the limitations in Section 305 thereof on transfers and exchanges
of Global Securities.

     This Security and the Indenture shall be governed by and construed in accordance with the laws
of the State of New York.

     All terms used in this Security which are defined in the Indenture shall have the meanings
assigned to them in the Indenture.

-18-

 

Section 204. Form of Legend for Global Securities.

     Unless otherwise specified as contemplated by Section 301 for the Securities evidenced
thereby, every Global Security authenticated and delivered hereunder shall bear a legend in
substantially the following form:

This Security is a Global Security within the meaning of the Indenture hereinafter referred to
and is registered in the name of a Depositary or a nominee thereof. This Security may not be
exchanged in whole or in part for a Security registered, and no transfer of this Security in whole
or in part may be registered, in the name of any Person other than such Depositary or a nominee
thereof, except in the limited circumstances described in the Indenture.

Section 205. Form of Trustee’s Certificate of Authentication.

     The Trustee’s certificates of authentication shall be in substantially the following form:

     This is one of the Securities of the series designated herein and referred to in the
within-mentioned Indenture.

Dated:

	 	 	 	 	 
	 	The Bank of New York,

As Trustee

 	 
	 	By:  	 	 
	 	 	Authorized Officer 	 
	 	 	 	 
	 

ARTICLE THREE

The Securities

Section 301. Amount Unlimited; Issuable in Series.

     The aggregate principal amount of Securities which may be authenticated and delivered under
this Indenture is unlimited.

     The Securities may be issued in one or more series. There shall be established in or pursuant
to a Board Resolution and, subject to Section 303, set forth, or determined in the manner provided,
in an Officers’ Certificate, or established in one or more indentures supplemental hereto, prior to
the issuance of Securities of any series:

     (1) the title of the Securities of the series, including CUSIP numbers (which shall
distinguish the Securities of the series from Securities of any other series);

     (2) any limit upon the aggregate principal amount of the Securities of the series
which may be authenticated and delivered under this Indenture

-19-

 

(except for Securities authenticated and delivered upon registration of transfer of,
or in exchange for, or in lieu of, other Securities of the series pursuant to Section 304,
305, 306, 906 or 1107 and except for any Securities which, pursuant to Section 303, are
deemed never to have been authenticated and delivered hereunder);

     (3) the Person to whom any interest on a Security of the series shall be payable, if
other than the Person in whose name that Security (or one or more Predecessor Securities)
is registered at the close of business on the Regular Record Date for such interest;

     (4) the date or dates on which the principal of any Securities of the series is
payable;

     (5) the rate or rates at which any Securities of the series shall bear interest, if
any, the date or dates from which any such interest shall accrue, the Interest Payment
Dates on which any such interest shall be payable and any right to extend or defer the
interest payment periods and the duration of the extension and the Regular Record Date for
any such interest payable on any Interest Payment Date;

     (6) the place or places where the principal of and any premium and interest on any
Securities of the series shall be payable and the manner in which any payment may be made;

     (7) the period or periods within which, the price or prices at which and the terms
and conditions upon which any Securities of the series may be redeemed, in whole or in
part, at the option of the Company and, if other than by a Board Resolution, the manner in
which any election by the Company to redeem the Securities shall be evidenced;

     (8) the obligation, if any, of the Company to redeem or purchase any Securities of
the series pursuant to any sinking fund or analogous provisions of the Security or at the
option of the Holder thereof and the period or periods within which, the price or prices
at which and the terms and conditions upon which any Securities of the series shall be
redeemed or purchased, in whole or in part, pursuant to such obligation;

     (9) if other than denominations of $1,000 and any multiple thereof, the denominations
in which any Securities of the series shall be issuable;

     (10) if the amount of principal of or any premium or interest on any Securities of
the series may be determined with reference to an index, other security (whether equity or
debt) or pursuant to a formula, the manner in which such amounts shall be determined;

     (11) if other than the currency of the United States of America, the currency,
currencies, composite currency, composite currencies or currency units in which the
principal of or any premium or interest on any Securities of the series shall be payable
and the manner of determining the equivalent thereof in the currency of the United States
of America for any purpose, including for the

-20-

 

purposes of making payment in the currency of the United States of America and
applying the definition of “Outstanding” in Section 101;

     (12) if the principal of or any premium or interest on any Securities of the series
is to be payable, at the election of the Company or the Holder thereof, in one or more
currencies, composite currencies or currency units other than that or those in which such
Securities are stated to be payable, the currency, currencies, composite currency,
composite currencies or currency units in which the principal of or any premium or
interest on such Securities as to which such election is made shall be payable, the
periods within which and the terms and conditions upon which such election is to be made
and the amount so payable (or the manner in which such amount shall be determined);

     (13) if other than the entire principal amount thereof, the portion of the principal
amount of any Securities of the series which shall be payable upon declaration of
acceleration of the Maturity thereof pursuant to Section 502;

     (14) if other than as provided in Section 201, the form or forms of the Securities;

     (15) if the principal amount payable at the Stated Maturity of any Securities of the
series will not be determinable as of any one or more dates prior to the Stated Maturity,
the amount which shall be deemed to be the principal amount of such Securities as of any
such date for any purpose thereunder or hereunder, including the principal amount thereof
which shall be due and payable upon any Maturity other than the Stated Maturity or which
shall be deemed to be Outstanding as of any date prior to the Stated Maturity (or, in any
such case, the manner in which such amount deemed to be the principal amount shall be
determined);

     (16) if applicable, that the Securities of the series, in whole or any specified
part, shall be defeasible pursuant to Section 1302 or Section 1303 or both such Sections,
any provisions to permit a pledge of obligations other than U.S. Government Obligations
(or the establishment of other arrangements) to satisfy the requirements of Section
1304(1) for defeasance of such Securities and, if other than by a Board Resolution, the
manner in which any election by the Company to defease such Securities shall be evidenced;

     (17) if applicable, that any Securities of the series shall be issuable in whole or
in part in the form of one or more Global Securities and, in such case, the respective
Depositaries for such Global Securities, the form of any legend or legends which shall be
borne by any such Global Security in addition to or in lieu of that set forth in Section
204, any addition to, elimination of or other change in the circumstances set forth in
Clause (2) of the last paragraph of Section 305 in which any such Global Security may be
exchanged in whole or in part for Securities registered, and any transfer of such Global
Security in whole or in part may be registered, in the name or names of Persons other than
the Depositary for such Global Security or a nominee thereof and any other provisions
governing exchanges or transfers of any such Global Security;

-21-

 

     (18) any addition to, elimination of or other change in the Events of Default or any
other remedies which applies to any Securities of the series and any change in the right
of the Trustee or the requisite Holders of such Securities to declare the principal amount
thereof due and payable pursuant to Section 502;

     (19) any addition to, elimination of or other change in the covenants set forth in
Article Ten which applies to Securities of the series;

     (20) any provisions necessary to permit or facilitate the issuance, payment or
conversion of any Securities of the series that may be converted into securities or other
property other than Securities of the same series and of like tenor, whether in addition
to, or in lieu of, any payment of principal or other amount and whether at the option of
the Company or otherwise;

     (21) any optional redemption of the series, whether pursuant to Section 1108 or
another manner as may be determined by the Company; and

     (22) any other terms of the series (which terms shall not be inconsistent with the
provisions of this Indenture, except as permitted by Section 901(5)).

     All Securities of any one series shall be substantially identical except as to denomination
and except as may otherwise be provided in or pursuant to the Board Resolution referred to above
and (subject to Section 303) set forth, or determined in the manner provided, in the Officers’
Certificate referred to above or in any such indenture supplemental hereto. All Securities of any
series need not be issued at the same time, and unless otherwise provided, a series may be reopened
for issuance of additional Securities of such series.

     If any of the terms of the series are established by action taken pursuant to a Board
Resolution, a copy of an appropriate record of such action shall be certified by any member of the
Management Board and delivered to the Trustee at or prior to the delivery of the Officers’
Certificate setting forth the terms of the series.

Section 302. Denominations.

     The Securities of each series shall be issuable only in registered form without coupons and
only in such denominations as shall be specified as contemplated by Section 301. In the absence of
any such specified denomination with respect to the Securities of any series, the Securities of
such series shall be issuable in denominations of $1,000 and any multiple thereof.

Section 303. Execution, Authentication, Delivery and Dating.

     The Securities shall be executed on behalf of the Company by any member of the Management
Board (or any other officer of the Company designated in writing by or pursuant to authority of the
Management Board and delivered to the Trustee from time to time). The signature of any of these
officers on the Securities may be manual or facsimile.

-22-

 

     Securities bearing the manual or facsimile signatures of individuals who were at any time the
proper officers of the Company shall bind the Company, notwithstanding that such individuals or any
of them have ceased to hold such offices prior to the authentication and delivery of such
Securities or did not hold such offices at the date of such Securities.

     At any time and from time to time after the execution and delivery of this Indenture, the
Company may deliver Securities of any series executed by the Company to the Trustee for
authentication, together with a Company Order for the authentication and delivery of such
Securities, and the Trustee in accordance with the Company Order shall authenticate by its manual
signature and deliver such Securities. If the form or terms of the Securities of the series have
been established by or pursuant to one or more Board Resolutions as permitted by Sections 201 and
301, in authenticating such Securities, and accepting the additional responsibilities under this
Indenture in relation to such Securities, the Trustee shall be entitled to receive, and (subject to
Section 601) shall be fully protected in relying upon, an Opinion of Counsel stating:

     (1) if the form of such Securities has been established by or pursuant to Board
Resolution as permitted by Section 201, that such form has been established in conformity
with the provisions of this Indenture;

     (2) if the terms of such Securities have been established by or pursuant to Board
Resolution as permitted by Section 301, that such terms have been established in
conformity with the provisions of this Indenture; and

     (3) that such Securities, when authenticated and delivered by the Trustee and issued
by the Company in the manner and subject to any conditions specified in such Opinion of
Counsel, will constitute valid and legally binding obligations of the Company enforceable
in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar laws of general applicability relating to or
affecting creditors’ rights and to general equity principles.

If such form or terms have been so established, the Trustee shall not be required to authenticate
such Securities if the issue of such Securities pursuant to this Indenture will affect the
Trustee’s own rights, duties or immunities under the Securities and this Indenture or otherwise in
a manner which is not reasonably acceptable to the Trustee.

     Notwithstanding the provisions of Section 301 and of the preceding paragraph, if all
Securities of a series are not to be originally issued at one time, it shall not be necessary to
deliver the Officers’ Certificate otherwise required pursuant to Section 301 or the Company Order
and Opinion of Counsel otherwise required pursuant to such preceding paragraph at or prior to the
authentication of each Security of such series if such documents are delivered at or prior to the
authentication upon original issuance of the first Security of such series to be issued.

     Each Security shall be dated the date of its authentication.

     No Security shall be entitled to any benefit under this Indenture or be valid or obligatory
for any purpose unless there appears on such Security a certificate of authentication substantially
in the form provided for herein executed by the Trustee by

-23-

 

manual signature, and such certificate upon any Security shall be conclusive evidence, and the
only evidence, that such Security has been duly authenticated and delivered hereunder.
Notwithstanding the foregoing, if any Security shall have been authenticated and delivered
hereunder but never issued and sold by the Company, and the Company shall deliver such Security to
the Trustee for cancellation as provided in Section 309, for all purposes of this Indenture such
Security shall be deemed never to have been authenticated and delivered hereunder and shall never
be entitled to the benefits of this Indenture.

Section 304. Temporary Securities.

     Pending the preparation of definitive Securities of any series, the Company may execute, and
upon Company Order the Trustee shall authenticate and deliver, temporary Securities which are
printed, lithographed, typewritten, mimeographed or otherwise produced, in any authorized
denomination, substantially of the tenor of the definitive Securities in lieu of which they are
issued and with such appropriate insertions, omissions, substitutions and other variations as the
officers executing such Securities may determine, as evidenced by such execution.

     If temporary Securities of any series are issued, the Company will cause definitive Securities
of that series to be prepared without unreasonable delay. After the preparation of definitive
Securities of such series, the temporary Securities of such series shall be exchangeable for
definitive Securities of such series upon surrender of the temporary Securities of such series at
the office or agency of the Company in a Place of Payment for that series, without charge to the
Holder. Upon surrender for cancellation of any one or more temporary Securities of any series, the
Company shall execute and the Trustee shall authenticate and deliver in exchange therefor one or
more definitive Securities of the same series, of any authorized denominations and of like tenor
and aggregate principal amount. Until so exchanged, the temporary Securities of any series shall in
all respects be entitled to the same benefits under this Indenture as definitive Securities of such
series and tenor.

Section 305. Registration, Registration of Transfer and Exchange.

     (a) The Company shall cause to be kept at the Corporate Trust Office of the Trustee a register
(the register maintained in such office and in any other office or agency of the Company in a Place
of Payment being herein sometimes collectively referred to as the “Security Register”) in
which, subject to such reasonable regulations as it may prescribe, the Company shall provide for
the registration of Securities and transfers and exchanges of Securities. The Trustee is hereby
appointed “Security Registrar” for the purpose of registering Securities and transfers of
Securities as herein provided.

     (b) Upon surrender for registration of transfer of any Security of a series at the office or
agency of the Company in a Place of Payment for that series, the Company shall execute, and the
Trustee shall authenticate and deliver, in the name of the designated transferee or transferees,
one or more new Securities of the same series, of any authorized denominations and of like tenor
and aggregate principal amount.

     (c) At the option of the Holder, Securities of any series may be exchanged for other
Securities of the same series, of any authorized denominations and of like tenor and aggregate
principal amount, upon surrender of the Securities to be exchanged at such

-24-

 

office or agency. Whenever any Securities are so surrendered for exchange, and subject to the
other provisions of this Section, the Company shall execute, and the Trustee shall authenticate and
deliver, the Securities which the Holder making the exchange is entitled to receive.

     All Securities issued upon any registration of transfer or exchange of Securities shall be the
valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under
this Indenture, as the Securities surrendered upon such registration of transfer or exchange.

     Every Security presented or surrendered for registration of transfer or for exchange shall (if
so required by the Company or the Trustee) be duly endorsed, or be accompanied by a written
instrument of transfer in form satisfactory to the Company and the Security Registrar duly
executed, by the Holder thereof or his attorney duly authorized in writing.

     (d) No service charge shall be made for any registration of transfer or exchange of
Securities, but the Company or the Trustee may require payment of a sum sufficient to cover any tax
or other governmental charge that may be imposed in connection with any registration of transfer or
exchange of Securities, other than exchanges pursuant to Section 304, 906 or 1107 not involving any
transfer.

     (e) If the Securities of any series (or of any series and specified tenor) are to be redeemed
in part, the Company shall not be required (A) to issue, register the transfer of or exchange any
Securities of that series (or of that series and specified tenor, as the case may be) during a
period beginning at the opening of business 15 days before the day of the mailing of a notice of
redemption of any such Securities selected for redemption under Section 1103 and ending at the
close of business on the day of such mailing, or (B) to register the transfer of or exchange any
Security so selected for redemption in whole or in part, except the unredeemed portion of any
Security being redeemed in part.

     The provisions of Clauses (1), (2), (3) and (4) below shall apply only to Global Securities:

     (1) Each Global Security authenticated under this Indenture shall be registered in
the name of the Depositary designated for such Global Security or a nominee thereof and
delivered to such Depositary or a nominee thereof or custodian therefor, and each such
Global Security shall constitute a single Security for all purposes of this Indenture.

     (2) Notwithstanding any other provision in this Indenture, and subject to such
applicable provisions, if any, as may be specified as contemplated by Section 301, no
Global Security may be exchanged in whole or in part for Securities registered, and no
transfer of a Global Security in whole or in part may be registered, in the name of any
Person other than the Depositary for such Global Security or a nominee thereof unless (A)
such Depositary has notified the Company that it (i) is unwilling or unable to continue as
Depositary for such Global Security or (ii) has ceased to be a clearing agency registered
under the Exchange Act, (B) there shall have occurred and be continuing an Event of
Default with respect to such Global Security or (C) the Company has executed and delivered
to the Trustee a Company Order stating that such Global Security

-25-

 

shall be exchanged in whole for Securities that are not Global Securities (in which
case such exchange shall promptly be effected by the Trustee). If the Company receives a
notice of the kind specified in Clause (A) above or has delivered a Company Order of the
kind specified in Clause (C) above, it may, in its sole discretion, designate a successor
Depositary for such Global Security within 60 days after receiving such notice or delivery
of such order, as the case may be. If the Company designates a successor Depositary as
aforesaid, such Global Security shall promptly be exchanged in whole for one or more other
Global Securities registered in the name of the successor Depositary, whereupon such
designated successor shall be the Depositary for such successor Global Security or Global
Securities and the provisions of Clauses (1), (2), (3) and (4) of this Section shall
continue to apply thereto.

     (3) Subject to Clause (2) above and to such applicable provisions, if any, as may be
specified as contemplated by Section 301, any exchange of a Global Security for other
Securities may be made in whole or in part, and all Securities issued in exchange for a
Global Security or any portion thereof shall be registered in such names as the Depositary
for such Global Security shall direct.

     (4) Every Security authenticated and delivered upon registration of transfer of, or
in exchange for or in lieu of, a Global Security or any portion thereof, whether pursuant
to this Section, Section 304, 306, 906 or 1107 or otherwise, shall be authenticated and
delivered in the form of, and shall be, a Global Security, unless such Security is
registered in the name of a Person other than the Depositary for such Global Security or a
nominee thereof.

Section 306. Mutilated, Destroyed, Lost and Stolen Securities.

     If any mutilated Security is surrendered to the Trustee, the Company shall execute and the
Trustee shall authenticate and deliver in exchange therefor a new Security of the same series and
of like tenor and principal amount and bearing a number not contemporaneously outstanding.

     If there shall be delivered to the Company and the Trustee (i) evidence to their satisfaction
of the destruction, loss or theft of any Security and (ii) such security or indemnity as may be
required by them to save each of them and any agent of either of them harmless, then, in the
absence of notice to the Company or the Trustee that such Security has been acquired by a protected
purchaser, the Company shall execute and the Trustee shall authenticate and deliver, in lieu of any
such destroyed, lost or stolen Security, a new Security of the same series and of like tenor and
principal amount and bearing a number not contemporaneously outstanding.

     In case any such mutilated, destroyed, lost or stolen Security has become or is about to
become due and payable, the Company in its discretion may, instead of issuing a new Security, pay
such Security.

     Upon the issuance of any new Security under this Section, the Company may require the payment
of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation
thereto and any other expenses (including the fees and expenses of the Trustee) connected
therewith.

-26-

 

     Every new Security of any series issued pursuant to this Section in lieu of any destroyed,
lost or stolen Security shall constitute an original additional contractual obligation of the
Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by
anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately
with any and all other Securities of that series duly issued hereunder.

     The provisions of this Section are exclusive and shall preclude (to the extent lawful) all
other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost
or stolen Securities.

Section 307. Payment of Interest; Interest Rights Preserved.

     Except as otherwise provided as contemplated by Section 301 with respect to any Securities of
a series, the Company shall deposit with the Trustee or with the Paying Agent, no later than 10:00
a.m., New York City time, on any Interest Payment Date an amount of money sufficient to pay the
interest on any Security which is payable, and such interest shall be punctually paid or duly
provided for on such Interest Payment Date to the Person in whose name that Security (or one or
more Predecessor Securities) is registered at the close of business on the Regular Record Date for
such interest.

     Any interest on any Security of any series which is payable, but is not punctually paid or
duly provided for, on any Interest Payment Date (herein called “Defaulted Interest”) shall
forthwith cease to be payable to the Holder on the relevant Regular Record Date by virtue of having
been such Holder, and such Defaulted Interest may be paid by the Company, at its election in each
case, as provided in Clause (1) or (2) below:

     (1) The Company may elect to make payment of any Defaulted Interest payable on any
Securities of a series to the Persons in whose names such Securities (or their respective
Predecessor Securities) are registered at the close of business on a Special Record Date
for the payment of such Defaulted Interest, which shall be fixed in the following manner.
The Company shall notify the Trustee in writing of the amount of Defaulted Interest
proposed to be paid on each of such Securities and the date of the proposed payment, and
at the same time the Company shall deposit with the Trustee an amount of money equal to
the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall
make arrangements satisfactory to the Trustee for such deposit prior to the date of the
proposed payment, such money when deposited to be held in trust for the benefit of the
Persons entitled to such Defaulted Interest as in this Clause provided. Thereupon the
Trustee shall fix a Special Record Date for the payment of such Defaulted Interest which
shall be not more than 15 days and not less than 10 days prior to the date of the proposed
payment and not less than 10 days after the receipt by the Trustee of the notice of the
proposed payment. The Trustee shall promptly notify the Company of such Special Record
Date and, in the name and at the expense of the Company, shall cause notice of the
proposed payment of such Defaulted Interest and the Special Record Date therefor to be
given to each Holder of such Securities in the manner set forth in Section 106, not less
than 10 days prior to such Special Record Date. Notice of the proposed payment of such
Defaulted Interest and the Special Record Date therefor having been so mailed, such
Defaulted Interest shall be paid to the Persons in whose names such Securities (or their
respective Predecessor Securities) are registered at the close

-27-

 

of business on such Special Record Date and shall no longer be payable pursuant to
the following Clause (2).

     (2) The Company may make payment of any Defaulted Interest on any Securities of a
series in any other lawful manner not inconsistent with the requirements of any securities
exchange on which such Securities may be listed, and upon such notice as may be required
by such exchange, if, after notice given by the Company to the Trustee of the proposed
payment pursuant to this Clause, such manner of payment shall be deemed practicable by the
Trustee.

     Except as may otherwise be provided in this Section 307 or as contemplated in Section 301 with
respect to any Securities of a series, the Person to whom interest shall be payable on any Security
that first becomes payable on a day that is not an Interest Payment Date shall be the Holder of
such Security on the day such interest is paid.

     Subject to the foregoing provisions of this Section, each Security delivered under this
Indenture upon registration of transfer of or in exchange for or in lieu of any other Security
shall carry the rights to interest accrued and unpaid, and to accrue, which were carried by such
other Security.

     In the case of any Security which is converted after any Regular Record Date and on or prior
to the next succeeding Interest Payment Date (other than any Security whose Maturity is prior to
such Interest Payment Date), interest whose Stated Maturity is on such Interest Payment Date shall
be payable on such Interest Payment Date notwithstanding such conversion, and such interest
(whether or not punctually paid or duly provided for) shall be paid to the Person in whose name
that Security (or one or more Predecessor Securities) is registered at the close of business on
such Regular Record Date. Except as otherwise expressly provided in the immediately preceding
sentence, in the case of any Security which is converted, interest whose Stated Maturity is after
the date of conversion of such Security shall not be payable. Notwithstanding the foregoing, the
terms of any Security that may be converted may provide that the provisions of this paragraph do
not apply, or apply with such additions, changes or omissions as may be provided thereby, to such
Security.

Section 308. Persons Deemed Owners.

     Prior to due presentment of a Security for registration of transfer, the Company, the Trustee
and any agent of the Company or the Trustee may treat the Person in whose name such Security is
registered as the owner of such Security for the purpose of receiving payment of principal of and
any premium and (subject to Section 307) any interest on such Security and for all other purposes
whatsoever, whether or not such Security be overdue, and neither the Company, the Trustee nor any
agent of the Company or the Trustee shall be affected by notice to the contrary.

     No holder of any beneficial interest in any Global Security held on its behalf by a Depositary
shall have any rights under this Indenture with respect to such Global Security, and such
Depositary may be treated by the Company, the Trustee, and any agent of the Company or the Trustee
as the owner of such Global Security for all purposes whatsoever. Notwithstanding the foregoing,
nothing herein shall impair, as between a Depositary and such holders of beneficial interests, the
operation of customary practices governing the exercise of the rights of the Depositary as Holder
of any Security.

-28-

 

     None of the Company, the Trustee or any agent of the Company or the Trustee shall have any
responsibility or liability for any aspect of the records relating to or payments made on account
of beneficial ownership interests in a Global Security, for maintaining, supervising or reviewing
any records relating to such beneficial ownership interests, for any acts or omissions of a
Depositary or for any transactions between a Depositary and beneficial owners.

Section 309. Cancellation.

     All Securities surrendered for payment, redemption, registration of transfer or exchange or
conversion or for credit against any sinking fund payment shall, if surrendered to any Person other
than the Trustee, be delivered to the Trustee and shall be promptly canceled by it. The Company may
at any time deliver to the Trustee for cancellation any Securities previously authenticated and
delivered hereunder which the Company may have acquired in any manner whatsoever, and may deliver
to the Trustee (or to any other Person for delivery to the Trustee) for cancellation any Securities
previously authenticated hereunder which the Company has not issued and sold, and all Securities so
delivered shall be promptly canceled by the Trustee. No Securities shall be authenticated in lieu
of or in exchange for any Securities canceled as provided in this Section, except as expressly
permitted by this Indenture. All canceled Securities held by the Trustee shall be disposed of by
the Trustee in accordance with its customary practices or as directed by a Company Order; provided,
however, that the Trustee shall not be required to destroy such canceled Securities.

Section 310. Computation of Interest.

     Except as otherwise specified as contemplated by Section 301 for Securities of any series,
interest on the Securities of each series shall be computed on the basis of a 360-day year of
twelve 30-day months.

Section 311. CUSIP Numbers.

     The Company in issuing the Securities may use CUSIP numbers (if then generally in use) and, if
so, the Trustee shall use CUSIP numbers in notices of redemption as a convenience to Holders;
provided, that any such notice may state that no representation is made as to the correctness of
such numbers either as printed on the Securities or as contained in any notice of redemption and
that reliance may be placed only on the other identification numbers printed on the Securities.
Any such redemption shall not be affected by any defect in or omission of such numbers. The
Company shall promptly notify the Trustee in writing of any change in the CUSIP numbers.

ARTICLE FOUR

Satisfaction and Discharge

Section 401. Satisfaction and Discharge of Indenture.

     This Indenture shall upon Company Request cease to be of further effect (except as to any
surviving rights of conversion, registration of transfer or exchange of any Security expressly
provided for herein or in the terms of such Security), and the Trustee,

-29-

 

at the expense of the Company, shall execute proper instruments acknowledging satisfaction and
discharge of this Indenture, when:

     (1) either:

     (A) all Securities theretofore authenticated and delivered (other than (i)
Securities which have been destroyed, lost or stolen and which have been replaced
or paid as provided in Section 306 and (ii) Securities for whose payment money
has theretofore been deposited in trust or segregated and held in trust by the
Company and thereafter repaid to the Company or discharged from such trust, as
provided in Section 1003) have been delivered to the Trustee for cancellation; or

     (B) all such Securities not theretofore delivered to the Trustee for
cancellation:

     (i) have become due and payable; or

     (ii) will become due and payable at their Stated Maturity within
one year; or

     (iii) are to be called for redemption within one year under
arrangements satisfactory to the Trustee for the giving of notice of
redemption by the Trustee in the name, and at the expense, of the
Company;

and the Company, in the case of (i), (ii) or (iii) above, has deposited or caused
to be deposited with the Trustee as trust funds in trust for the purpose money in
an amount sufficient to pay and discharge the entire indebtedness on such
Securities not theretofore delivered to the Trustee for cancellation, for
principal and any premium and interest to the date of such deposit (in the case
of Securities which have become due and payable) or to the Stated Maturity or
Redemption Date, as the case may be;

     (2) the Company has paid or caused to be paid all other sums payable hereunder by the
Company; and

     (3) the Company has delivered to the Trustee an Officers’ Certificate and an Opinion
of Counsel, each stating that all conditions precedent herein provided for relating to the
satisfaction and discharge of this Indenture have been complied with.

     Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the
Company to the Trustee under Section 607 and, if money shall have been deposited with the Trustee
pursuant to subclause (B) of Clause (1) of this Section, the obligations of the Trustee under
Section 402 and the last paragraph of Section 1003 shall survive such satisfaction and discharge.

-30-

 

Section 402. Application of Trust Money.

     Subject to the provisions of the last paragraph of Section 1003, all money deposited with the
Trustee pursuant to Section 401 shall be held in trust and applied by it, in accordance with the
provisions of the Securities and this Indenture, to the payment, either directly or through any
Paying Agent (including the Company acting as its own Paying Agent) as the Trustee may determine,
to the Persons entitled thereto, of the principal and any premium and interest for whose payment
such money has been deposited with the Trustee. All moneys deposited with the Trustee pursuant to
Section 401 (and held by it or any Paying Agent) for the payment of Securities subsequently
converted shall be returned to the Company upon Company Request.

ARTICLE FIVE

 Remedies

Section 501. Events of Default.

     “Event of Default”, wherever used herein with respect to Securities of any series and
if applicable, means any one of the following events (whatever the reason for such Event of Default
and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to
any judgment, decree or order of any court or any order, rule or regulation of any administrative
or governmental body):

     (1) default in the payment of any interest upon any Security of that series when it
becomes due and payable, and continuance of such default for a period of 30 days; or

     (2) default in the payment of the principal of or any premium on any Security of that
series at its Maturity; or

     (3) default in the deposit of any sinking fund payment, when and as due by the terms
of a Security of that series; or

     (4) default in the performance, or breach, of any covenant or warranty of the Company
in this Indenture (other than a covenant or warranty a default in whose performance or
whose breach is elsewhere in this Section specifically dealt with or which has expressly
been included in this Indenture solely for the benefit of series of Securities other than
that series), and continuance of such default or breach for a period of 90 days after
there has been given, by registered or certified mail, to the Company by the Trustee or to
the Company and the Trustee by the Holders of at least 25% in principal amount of the
Outstanding Securities of that series a written notice specifying such default or breach
and requiring it to be remedied and stating that such notice is a “Notice of Default”
hereunder; or

     (5) the entry by a court having jurisdiction in the premises of (A) a decree or order
for relief in respect of the Company in an involuntary case or proceeding under any
applicable bankruptcy, insolvency, reorganization or other similar law in Germany or the
jurisdiction of the New Issuer, as the case may be, or (B) a decree or order adjudging the
Company a bankrupt or insolvent, or

-31-

 

approving as properly filed a petition seeking reorganization, arrangement,
adjustment or composition of or in respect of the Company under any applicable law in
Germany or the jurisdiction of the New Issuer, as the case may be, or appointing a
custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official
of the Company or of any substantial part of its property, or ordering the winding up or
liquidation of its affairs, and the continuance of any such decree or order for relief or
any such other decree or order unstayed and in effect for a period of 60 consecutive days;
or

     (6) the commencement by the Company of a voluntary case or proceeding under any
applicable bankruptcy, insolvency, reorganization or other similar law in Germany or the
jurisdiction of the New Issuer, as the case may be, or of any other case or proceeding to
be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree or
order for relief in respect of the Company in an involuntary case or proceeding under any
applicable bankruptcy, insolvency, reorganization or other similar law in Germany or the
jurisdiction of the New Issuer, as the case may be, or to the commencement of any
bankruptcy or insolvency case or proceeding against it, or the filing by it of a petition
or answer or consent seeking reorganization or relief under any applicable law in Germany
or the jurisdiction of the New Issuer, as the case may be, or the consent by it to the
filing of such petition or to the appointment of or taking possession by a custodian,
receiver, liquidator, assignee, trustee, sequestrator or other similar official of the
Company or of any substantial part of its property, or the making by it of an assignment
for the benefit of creditors, or the taking of corporate action by the Company in
furtherance of any such action; or

     (7) any other Event of Default provided with respect to Securities of that series.

Section 502. Acceleration of Maturity; Rescission and Annulment.

     If an Event of Default (other than an Event of Default specified in Section 501(5) or 501(6))
with respect to Securities of any series at the time Outstanding occurs and is continuing, then in
every such case the Trustee or the Holders of not less than 25% in principal amount of the
Outstanding Securities of that series may declare the principal amount of all the Securities of
that series (or, in the case of any Security of that series which specifies an amount to be due and
payable thereon upon acceleration of the Maturity thereof, such amount as may be specified by the
terms thereof) to be due and payable immediately, by a notice in writing to the Company (and to the
Trustee if given by Holders), and upon any such declaration such principal amount (or specified
amount) shall become immediately due and payable. If an Event of Default specified in Section
501(5) or 501(6) with respect to Securities of any series at the time Outstanding occurs, the
principal amount of all the Securities of that series (or, in the case of any Security of that
series which specifies an amount to be due and payable thereon upon acceleration of the Maturity
thereof, such amount as may be specified by the terms thereof) shall automatically, and without any
declaration or other action on the part of the Trustee or any Holder, become immediately due and
payable.

     At any time after such a declaration of acceleration with respect to Securities of any series
has been made and before a judgment or decree for payment of the money due has been obtained by the
Trustee as hereinafter in this Article provided, the Holders of a

-32-

 

majority in principal amount of the Outstanding Securities of that series, by written notice
to the Company and the Trustee, may rescind and annul such declaration and its consequences if:

     (1) the Company has paid or deposited with the Trustee a sum sufficient to pay:

     (A) all overdue interest on all Securities of that series;

     (B) the principal of (and premium, if any, on) any Securities of that series
which have become due otherwise than by such declaration of acceleration and any
interest thereon at the rate or rates prescribed therefor in such Securities;

     (C) to the extent that payment of such interest is lawful, interest upon
overdue interest at the rate or rates prescribed therefor in such Securities; and

     (D) all sums paid or advanced by the Trustee hereunder and the reasonable
compensation, expenses, disbursements and advances of the Trustee, its agents and
counsel; and

     (2) all Events of Default with respect to Securities of that series, other than the
non-payment of the principal of Securities of that series which have become due solely by
such declaration of acceleration, have been cured or waived as provided in Section 513.

No such rescission shall affect any subsequent default or impair any right consequent thereon.

Section 503. Collection of Indebtedness and Suits for Enforcement by Trustee.

     The Company covenants that if:

     (1) default is made in the payment of any interest on any Security when such interest
becomes due and payable and such default continues for a period of 30 days; or

     (2) default is made in the payment of the principal of (or premium, if any, on) any
Security at the Maturity thereof;

the Company will, upon demand of the Trustee, pay to it, for the benefit of the Holders of such
Securities, the whole amount then due and payable on such Securities for principal and any premium
and interest and, to the extent that payment of such interest shall be legally enforceable,
interest on any overdue principal and premium and on any overdue interest, at the rate or rates
prescribed therefor in such Securities, and, in addition thereto, such further amount as shall be
sufficient to cover the costs and expenses of collection, including the reasonable compensation,
expenses, disbursements and advances of the Trustee, its agents and counsel.

-33-

 

     If an Event of Default with respect to Securities of any series occurs and is continuing, the
Trustee may in its discretion proceed to protect and enforce its rights and the rights of the
Holders of Securities of such series by such appropriate judicial proceedings as the Trustee shall
deem most effectual to protect and enforce any such rights, whether for the specific enforcement of
any covenant or agreement in this Indenture or in aid of the exercise of any power granted herein,
or to enforce any other proper remedy.

Section 504. Trustee May File Proofs of Claim.

     In case of any judicial proceeding relative to the Company (or any other obligor upon the
Securities), its property or its creditors, the Trustee shall be entitled and empowered, by
intervention in such proceeding or otherwise, to take any and all actions authorized under the
Trust Indenture Act in order to have claims of the Holders and the Trustee allowed in any such
proceeding. In particular, the Trustee shall be authorized to collect and receive any moneys or
other property payable or deliverable on any such claims and to distribute the same; and any
custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any
such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee
and, in the event that the Trustee shall consent to the making of such payments directly to the
Holders, to pay to the Trustee any amount due it for the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the
Trustee under Section 607.

     No provision of this Indenture shall be deemed to authorize the Trustee to authorize or
consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement,
adjustment or composition affecting the Securities or the rights of any Holder thereof or to
authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding;
provided, however, that the Trustee may, on behalf of the Holders, vote for the election of a
trustee in bankruptcy or similar official and be a member of a creditors’ or other similar
committee.

Section 505. Trustee May Enforce Claims Without Possession of Securities.

     All rights of action and claims under this Indenture or the Securities may be prosecuted and
enforced by the Trustee without the possession of any of the Securities or the production thereof
in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be
brought in its own name as trustee of an express trust, and any recovery of judgment shall, after
provision for the payment of the reasonable compensation, expenses, disbursements and advances of
the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Securities in
respect of which such judgment has been recovered.

Section 506. Application of Money Collected.

     Any money collected by the Trustee pursuant to this Article shall be applied in the following
order, at the date or dates fixed by the Trustee and, in case of the distribution of such money on
account of principal or any premium or interest, upon presentation of the Securities and the
notation thereon of the payment if only partially paid and upon surrender thereof if fully paid:

-34-

 

     First: To the payment of all amounts due the Trustee (including any
predecessor Trustee) under Section 607; and

     Second: To the payment of the amounts then due and unpaid for principal of and
any premium and interest on the Securities in respect of which or for the benefit of which
such money has been collected, ratably, without preference or priority of any kind, according
to the amounts due and payable on such Securities for principal and any premium and interest,
respectively.

Section 507. Limitation on Suits.

     No Holder of any Security of any series shall have any right to institute any proceeding,
judicial or otherwise, with respect to this Indenture, or for the appointment of a receiver or
trustee, or for any other remedy hereunder, unless:

     (1) such Holder has previously given written notice to the Trustee of a continuing
Event of Default with respect to the Securities of that series;

     (2) the Holders of not less than 25% in principal amount of the Outstanding
Securities of that series shall have made written request to the Trustee to institute
proceedings in respect of such Event of Default in its own name as Trustee hereunder;

     (3) such Holder or Holders have offered to the Trustee indemnity reasonably
satisfactory to it against the costs, expenses and liabilities to be incurred in
compliance with such request;

     (4) the Trustee for 60 days after its receipt of such notice, request and offer of
indemnity has failed to institute any such proceeding; and

     (5) no direction inconsistent with such written request has been given to the Trustee
during such 60-day period by the Holders of a majority in principal amount of the
Outstanding Securities of that series;

it being understood and intended that no one or more of such Holders shall have any right
in any manner whatever by virtue of, or by availing of, any provision of this Indenture to
affect, disturb or prejudice the rights of any other of such Holders, or to obtain or to
seek to obtain priority or preference over any other of such Holders or to enforce any
right under this Indenture, except in the manner herein provided and for the equal and
ratable benefit of all of such Holders.

	Section 508. Unconditional Right of Holders to Receive Principal, Premium and Interest and to
Convert.

     Notwithstanding any other provision in this Indenture, the Holder of any Security shall have
the right, which is absolute and unconditional, to receive payment of the principal of and any
premium and (subject to Section 307) interest on such Security on the respective Stated Maturities
expressed in such Security (or, in the case of redemption, on the Redemption Date), and, if the
terms of such Security so provide, to convert such Security in accordance with its terms, and to
institute suit for the enforcement of any such

-35-

 

payment and, if applicable, any such right to convert, and such rights shall not be impaired
without the consent of such Holder.

Section 509. Restoration of Rights and Remedies.

     If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy
under this Indenture and such proceeding has been discontinued or abandoned for any reason, or has
been determined adversely to the Trustee or to such Holder, then and in every such case, subject to
any determination in such proceeding, the Company, the Trustee and the Holders shall be restored
severally and respectively to their former positions hereunder and thereafter all rights and
remedies of the Trustee and the Holders shall continue as though no such proceeding had been
instituted.

Section 510. Rights and Remedies Cumulative.

     Except as otherwise provided with respect to the replacement or payment of mutilated,
destroyed, lost or stolen Securities in the last paragraph of Section 306, no right or remedy
herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of
any other right or remedy, and every right and remedy shall, to the extent permitted by law, be
cumulative and in addition to every other right and remedy given hereunder or now or hereafter
existing at law or in equity or otherwise. The assertion or employment of any right or remedy
hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other
appropriate right or remedy.

Section 511. Delay or Omission Not Waiver.

     No delay or omission of the Trustee or of any Holder of any Securities to exercise any right
or remedy accruing upon any Event of Default shall impair any such right or remedy or constitute a
waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by
this Article or by law to the Trustee or to the Holders may be exercised from time to time, and as
often as may be deemed expedient, by the Trustee or by the Holders, as the case may be.

Section 512. Control by Holders.

     The Holders of a majority in principal amount of the Outstanding Securities of any series
shall have the right to direct the time, method and place of conducting any proceeding for any
remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with
respect to the Securities of such series, provided that:

     (1) such direction shall not be in conflict with any rule of law or with this
Indenture; and

     (2) the Trustee may take any other action deemed proper by the Trustee which is not
inconsistent with such direction.

Section 513. Waiver of Past Defaults.

     Subject to Section 502, the Holders of not less than a majority in principal amount of the
Outstanding Securities of any series may on behalf of the Holders of all the

-36-

 

Securities of such series waive any past default hereunder with respect to such series and its
consequences, except a default:

     (1) in the payment of the principal of or any premium or interest on any Security of
such series; or

     (2) in respect of a covenant or provision hereof which under Article Nine cannot be
modified or amended without the consent of the Holder of each Outstanding Security of such
series affected.

     Upon any such waiver, such default shall cease to exist, and any Event of Default arising
therefrom shall be deemed to have been cured, for every purpose of this Indenture; but no such
waiver shall extend to any subsequent or other default or impair any right consequent thereon.

Section 514. Undertaking for Costs.

     In any suit for the enforcement of any right or remedy under this Indenture, or in any suit
against the Trustee for any action taken, suffered or omitted by it as Trustee, a court may require
any party litigant in such suit to file an undertaking to pay the costs of such suit, and may
assess costs, including reasonable attorneys’ fees and expenses, against any such party litigant,
in the manner and to the extent provided in the Trust Indenture Act; provided that neither this
Section nor the Trust Indenture Act shall be deemed to authorize any court to require such an
undertaking or to make such an assessment in any suit instituted by the Company or the Trustee or,
if applicable, in any suit for the enforcement of the right to convert any Security in accordance
with its terms.

Section 515. Waiver of Usury, Stay or Extension Laws.

     The Company covenants (to the extent that it may lawfully do so) that it will not at any time
insist upon, or plead, or in any manner whatsoever claim or take the benefit or advantage of, any
usury, stay or extension law wherever enacted, now or at any time hereafter in force, which may
affect the covenants or the performance of this Indenture; and the Company (to the extent that it
may lawfully do so) hereby expressly waives all benefit or advantage of any such law and covenants
that it will not hinder, delay or impede the execution of any power herein granted to the Trustee,
but will suffer and permit the execution of every such power as though no such law had been
enacted.

ARTICLE SIX

The Trustee

Section 601. Certain Duties and Responsibilities.

     The duties and responsibilities of the Trustee shall be as provided by the Trust Indenture
Act. Notwithstanding the foregoing, no provision of this Indenture shall require the Trustee to
expend or risk its own funds or otherwise incur any financial liability in the performance of any
of its duties hereunder, or in the exercise of any of its rights or powers, if it shall have
reasonable grounds for believing that repayment of such funds or adequate indemnity against such
risk of liability is not reasonably assured to it. Whether or not therein expressly so provided,
every provision of this Indenture relating to the

-37-

 

conduct or affecting the liability of or affording protection to the Trustee shall be subject
to the provisions of this Section.

Section 602. Notice of Defaults.

     If a default occurs hereunder with respect to Securities of any series, the Trustee shall give
the Holders of Securities of such series notice of such default as and to the extent provided by
the Trust Indenture Act; provided, however, that in the case of any default of the character
specified in Section 501(4) with respect to Securities of such series, no such notice to Holders
shall be given until at least 30 days after the occurrence thereof. For the purpose of this
Section, the term “default” means any event which is, or after notice or lapse of time or both
would become, an Event of Default with respect to Securities of such series.

Section 603. Certain Rights of Trustee.

Subject to the provisions of Section 601:

     (1) the Trustee may conclusively rely and shall be fully protected in acting or
refraining from acting upon any resolution, certificate, statement, instrument, opinion,
report, notice, request, direction, consent, order, bond, debenture, note, other evidence
of indebtedness or other paper or document (whether in its original or facsimile form)
believed by it to be genuine and to have been signed or presented by the proper party or
parties;

     (2) any request or direction of the Company mentioned herein shall be sufficiently
evidenced by a Company Request or Company Order, and any resolution of the Management
Board shall be sufficiently evidenced by a Board Resolution;

     (3) whenever in the administration of this Indenture the Trustee shall deem it
desirable that a matter be proved or established prior to taking, suffering or omitting
any action hereunder, the Trustee (unless other evidence be herein specifically
prescribed) may, in the absence of bad faith on its part, rely upon an Officers’
Certificate;

     (4) the Trustee may consult with counsel of its selection and the written advice of
such counsel or any Opinion of Counsel shall be full and complete authorization and
protection in respect of any action taken, suffered or omitted by it hereunder in good
faith and in reliance thereon;

     (5) the Trustee shall be under no obligation to exercise any of the rights or powers
vested in it by this Indenture at the request or direction of any of the Holders pursuant
to this Indenture, unless such Holders shall have offered to the Trustee security or
indemnity reasonably satisfactory to it against the costs, expenses and liabilities which
might be incurred by it in compliance with such request or direction;

     (6) the Trustee shall not be bound to make any investigation into the facts or
matters stated in any resolution, certificate, statement, instrument, opinion, report,
notice, request, direction, consent, order, bond, debenture, note,

-38-

 

other evidence of indebtedness or other paper or document, but the Trustee, in its
discretion, may make such further inquiry or investigation into such facts or matters as
it may see fit, and, if the Trustee shall determine to make such further inquiry or
investigation, it shall be entitled to examine the relevant books, records and premises of
the Company, personally or by agent or attorney , with reasonable prior notice and at the
reasonable expense of the Company, provided that the Trustee shall not be entitled to such
information which the Company is prevented from disclosing as a matter of law or contract;

     (7) the Trustee may execute any of the trusts or powers hereunder or perform any
duties hereunder either directly or by or through agents or attorneys and the Trustee
shall not be responsible for any misconduct or negligence on the part of any agent or
attorney appointed with due care by it hereunder;

     (8) the Trustee shall not be liable for any action taken, suffered or omitted to be
taken by it in good faith and reasonably believed by it to be authorized or within the
discretion or rights or powers conferred upon it by this Indenture;

     (9) the Trustee shall not be deemed to have notice of any default (within the meaning
of such term as defined in Section 602) or Event of Default with respect to the Securities
of any series unless a Responsible Officer of the Trustee has actual knowledge thereof or
unless written notice of any event which is in fact such a default is received by the
Trustee at the Corporate Trust Office of the Trustee, and such notice references such
Securities and this Indenture;

     (10) the rights, privileges, protections, immunities and benefits herein given to the
Trustee, including its rights to be indemnified, are extended to, and shall be enforceable
by, the Trustee in each of its capacities hereunder;

     (11) the permissive rights of the Trustee enumerated herein shall not be construed as
duties of the Trustee;

     (12) in no event shall the Trustee be responsible or liable for special, indirect, or
consequential loss or damage of any kind whatsoever (including, but not limited to, loss
of profit) irrespective of whether the Trustee has been advised of the likelihood of such
loss or damage and regardless of the form of action, so long as it conforms to the
standard of care under this Indenture; and

     (13) the Trustee may request that the Company deliver an Officers’ Certificate
setting forth the names of individuals and/or titles of officers authorized at such time
to take specified actions pursuant to this Indenture, which Officers’ Certificate may be
signed by any person authorized to sign an Officers’ Certificate, including any person
specified as so authorized in any such certificate previously delivered and not
superseded.

Section 604. Not Responsible for Recitals or Issuance of Securities.

     The recitals contained herein and in the Securities, except the Trustee’s certificates of
authentication, shall be taken as the statements of the Company, and the Trustee does not assume
any responsibility for their correctness. The Trustee makes no

-39-

 

representations as to the validity or sufficiency of this Indenture or of the Securities. The
Trustee shall not be accountable for the use or application by the Company of Securities or the
proceeds thereof.

Section 605. May Hold Securities.

     The Trustee, any Paying Agent, any Security Registrar or any other agent of the Company, in
its individual or any other capacity, may become the owner or pledgee of Securities and, subject to
Sections 608 and 613, may otherwise deal with the Company with the same rights it would have if it
were not Trustee, Paying Agent, Security Registrar or such other agent.

Section 606. Money Held in Trust.

     Money held by the Trustee in trust hereunder need not be segregated from other funds except to
the extent required by law. The Trustee shall be under no liability for interest on any money
received by it hereunder except as otherwise agreed in writing with the Company.

Section 607. Compensation and Reimbursement.

     The Company agrees:

     (1) to pay to the Trustee from time to time such compensation as shall be agreed from
time to time in writing between the parties for all services rendered by it hereunder
(which compensation shall not be limited by any provision of law in regard to the
compensation of a trustee of an express trust);

     (2) except as otherwise expressly provided herein, to reimburse the Trustee upon its
request for all reasonable expenses, disbursements and advances incurred or made by the
Trustee in accordance with any provision of this Indenture (including the reasonable
compensation and the expenses and disbursements of its agents and counsel), except any
such expense, disbursement or advance as shall be determined by a court of competent
jurisdiction to have been caused by its own negligence, willful misconduct or bad faith;
and

     (3) to fully indemnify each of the Trustee or any predecessor Trustee for, and to
hold it harmless against, any and all losses (except loss of profit), liabilities,
damages, claims or expenses including taxes (other than taxes imposed on the income of
the Trustee) incurred without negligence, willful misconduct or bad faith on its part,
arising out of or in connection with the acceptance or administration of the trust or
trusts hereunder, including the reasonable costs and expenses of defending itself against
any claim (whether asserted by the Company, a Holder or any other Person) or liability in
connection with the exercise or performance of any of its powers or duties hereunder.

     When the Trustee incurs expenses or renders services in connection with an Event of Default
specified in Section 501(5) or Section 501(6), the expenses (including the reasonable charges and
expenses of its counsel) and the compensation for the services are intended to constitute expenses
of administration under any applicable German bankruptcy, insolvency or other similar law.

-40-

 

     The provisions of this Section shall survive the resignation or removal of the Trustee and the
termination of this Indenture.

     To secure the Company’s payment obligations in this Section, the Trustee shall have a lien
prior to the Securities on all money or property held or collected by the Trustee other than money
or property held in trust to pay principal of (and premium, if any) and interest on particular
Securities.

Section 608. Conflicting Interests.

     If the Trustee has or shall acquire a conflicting interest within the meaning of the Trust
Indenture Act, the Trustee shall, as soon as practicable and in any event within 90 days after
ascertaining that it has a conflicting interest, and if the Event of Default (as defined in Section
501 hereof) to which such conflicting interest relates has not been cured or duly waived or
otherwise eliminated before the end of such 90-day period, either eliminate such interest or
resign, to the extent and in the manner provided by, and subject to the provisions of, the Trust
Indenture Act and this Indenture. To the extent permitted by the Trust Indenture Act, the Trustee
shall not be deemed to have a conflicting interest by virtue of being a trustee under this
Indenture with respect to Securities of more than one series or by virtue of being a trustee under
this Indenture and under any indenture listed in Schedule A hereto.

Section 609. Corporate Trustee Required; Eligibility.

     There shall at all times be one (and only one) Trustee hereunder with respect to the
Securities of each series, which may be Trustee hereunder for Securities of one or more other
series. Each Trustee shall be a Person that is eligible pursuant to the Trust Indenture Act to act
as such, has a combined capital and surplus of at least $50,000,000 and has its Corporate Trust
Office in the Borough of Manhattan, The City of New York. If any such Person publishes reports of
condition at least annually, pursuant to law or to the requirements of its supervising or examining
authority, then for the purposes of this Section and to the extent permitted by the Trust Indenture
Act, the combined capital and surplus of such Person shall be deemed to be its combined capital and
surplus as set forth in its most recent report of condition so published. If at any time the
Trustee with respect to the Securities of any series shall cease to be eligible in accordance with
the provisions of this Section, it shall resign immediately in the manner and with the effect
hereinafter specified in this Article.

Section 610. Resignation and Removal; Appointment of Successor.

     No resignation or removal of the Trustee and no appointment of a successor Trustee pursuant to
this Article shall become effective until the acceptance of appointment by the successor Trustee in
accordance with the applicable requirements of Section 611.

     The Trustee may resign at any time with respect to the Securities of one or more series by
giving written notice thereof to the Company. If the instrument of acceptance by a successor
Trustee required by Section 611 shall not have been delivered to the Trustee within 60 days after
the giving of such notice of resignation, the resigning Trustee or the Company may, at the expense
of the Company, petition any court of competent

-41-

 

jurisdiction for the appointment of a successor Trustee with respect to the Securities of such
series.

     The Trustee may be removed at any time with respect to the Securities of any series by (1) Act
of the Holders of a majority in principal amount of the Outstanding Securities of such series,
delivered to the Trustee and to the Company or (2) the Company by action established in or pursuant
to a Board Resolution delivered to the Trustee, provided that if a default or an Event of Default
has occurred and is continuing, the Company shall not be able to remove the Trustee pursuant to
subclause (2) of this paragraph. If the instrument of acceptance by a successor Trustee required
by Section 611 shall not have been delivered to the Trustee within 30 days after the giving of a
notice of removal pursuant to this paragraph, the Trustee being removed or the Company may petition
any court of competent jurisdiction for the appointment of a successor Trustee with respect to the
Securities of such series.

     If at any time:

     (1) the Trustee shall fail to comply with Section 608 after written request therefor
by the Company or by any Holder who has been a bona fide Holder of a Security for at least
six months; or

     (2) the Trustee shall cease to be eligible under Section 609 and shall fail to resign
after written request therefor by the Company or by any such Holder; or

     (3) the Trustee shall become incapable of acting or shall be adjudged a bankrupt or
insolvent or a receiver of the Trustee or of its property shall be appointed or any public
officer shall take charge or control of the Trustee or of its property or affairs for the
purpose of rehabilitation, conservation or liquidation;

then, in any such case, (A) the Company by a Board Resolution may remove the Trustee with respect
to all Securities, or (B) subject to Section 514, any Holder who has been a bona fide Holder of a
Security for at least six months may, on behalf of himself and all others similarly situated,
petition any court of competent jurisdiction for the removal of the Trustee with respect to all
Securities and the appointment of a successor Trustee or Trustees.

     If the Trustee shall resign, be removed or become incapable of acting, or if a vacancy shall
occur in the office of Trustee for any cause, with respect to the Securities of one or more series,
the Company, by a Board Resolution, shall promptly appoint a successor Trustee or Trustees with
respect to the Securities of that or those series (it being understood that any such successor
Trustee may be appointed with respect to the Securities of one or more or all of such series and
that at any time there shall be only one Trustee with respect to the Securities of any particular
series) and shall comply with the applicable requirements of Section 611. If, within one year after
such resignation, removal or incapability, or the occurrence of such vacancy, a successor Trustee
with respect to the Securities of any series shall be appointed by Act of the Holders of a majority
in principal amount of the Outstanding Securities of such series delivered to the Company and the
retiring Trustee, the successor Trustee so appointed shall, forthwith upon its acceptance of such
appointment in accordance with the applicable requirements of Section 611, become the successor
Trustee with respect to the Securities of such series

-42-

 

and to that extent supersede the successor Trustee appointed by the Company. If no successor
Trustee with respect to the Securities of any series shall have been so appointed by the Company or
the Holders and accepted appointment in the manner required by Section 611, any Holder who has been
a bona fide Holder of a Security of such series for at least six months may, on behalf of himself
and all others similarly situated, petition any court of competent jurisdiction for the appointment
of a successor Trustee with respect to the Securities of such series.

     The Company shall give notice of each resignation and each removal of the Trustee with respect
to the Securities of any series and each appointment of a successor Trustee with respect to the
Securities of any series to all Holders of Securities of such series in the manner provided in
Section 106. Each notice shall include the name of the successor Trustee with respect to the
Securities of such series and the address of its Corporate Trust Office.

Section 611. Acceptance of Appointment by Successor.

     In case of the appointment hereunder of a successor Trustee with respect to all Securities,
every such successor Trustee so appointed shall execute, acknowledge and deliver to the Company and
to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or
removal of the retiring Trustee shall become effective and such successor Trustee, without any
further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties
of the retiring Trustee; but, on the request of the Company or the successor Trustee, such retiring
Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such
successor Trustee all the rights, powers and trusts of the retiring Trustee and shall duly assign,
transfer and deliver to such successor Trustee all property and money held by such retiring Trustee
hereunder.

     In case of the appointment hereunder of a successor Trustee with respect to the Securities of
one or more (but not all) series, the Company, the retiring Trustee and each successor Trustee with
respect to the Securities of one or more series shall execute and deliver an indenture supplemental
hereto wherein each successor Trustee shall accept such appointment and which (1) shall contain
such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each
successor Trustee all the rights, powers, trusts and duties of the retiring Trustee with respect to
the Securities of that or those series to which the appointment of such successor Trustee relates,
(2) if the retiring Trustee is not retiring with respect to all Securities, shall contain such
provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts
and duties of the retiring Trustee with respect to the Securities of that or those series as to
which the retiring Trustee is not retiring shall continue to be vested in the retiring Trustee, and
(3) shall add to or change any of the provisions of this Indenture as shall be necessary to provide
for or facilitate the administration of the trusts hereunder by more than one Trustee, it being
understood that nothing herein or in such supplemental indenture shall constitute such Trustees
co-trustees of the same trust and that each such Trustee shall be trustee of a trust or trusts
hereunder separate and apart from any trust or trusts hereunder administered by any other such
Trustee; and upon the execution and delivery of such supplemental indenture the resignation or
removal of the retiring Trustee shall become effective to the extent provided therein and each such
successor Trustee, without any further act, deed or conveyance, shall become vested with all the
rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or
those series to

-43-

 

which the appointment of such successor Trustee relates; but, on request of the Company or any
successor Trustee, such retiring Trustee shall duly assign, transfer and deliver to such successor
Trustee all property and money held by such retiring Trustee hereunder with respect to the
Securities of that or those series to which the appointment of such successor Trustee relates.

     Upon request of any such successor Trustee, the Company shall execute any and all instruments
for more fully and certainly vesting in and confirming to such successor Trustee all such rights,
powers and trusts referred to in the first or second preceding paragraph, as the case may be.

     No successor Trustee shall accept its appointment unless at the time of such acceptance such
successor Trustee shall be qualified and eligible under this Article.

Section 612. Merger, Conversion, Consolidation or Succession to Business.

     Any corporation into which the Trustee may be merged or converted or with which it may be
consolidated, or any corporation resulting from any merger, conversion or consolidation to which
the Trustee shall be a party, or any corporation succeeding to all or substantially all the
corporate trust business of the Trustee, shall be the successor of the Trustee hereunder, provided
such corporation shall be otherwise qualified and eligible under this Article, without the
execution or filing of any paper or any further act on the part of any of the parties hereto. In
case any Securities shall have been authenticated, but not delivered, by the Trustee then in
office, any successor by merger, conversion or consolidation to such authenticating Trustee may
adopt such authentication and deliver the Securities so authenticated with the same effect as if
such successor Trustee had itself authenticated such Securities.

Section 613. Preferential Collection of Claims Against Company.

     If and when the Trustee shall be or become a creditor of the Company (or any other obligor
upon the Securities), the Trustee shall be subject to the provisions of the Trust Indenture Act
regarding the collection of claims against the Company (or any such other obligor) and, if
applicable, to mandatory provisions of the laws of foreign jurisdictions regarding the collection
of such claims.

Section 614. Appointment of Authenticating Agent.

     The Trustee may appoint an authenticating agent or agents (“Authenticating
Agent” or “Agent”) with respect to one or more series of Securities which shall be
authorized to act on behalf of the Trustee to authenticate Securities of such series issued upon
original issue and upon exchange, registration of transfer or partial redemption thereof or
pursuant to Section 306, and Securities so authenticated shall be entitled to the benefits of this
Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee
hereunder. Wherever reference is made in this Indenture to the authentication and delivery of
Securities by the Trustee or the Trustee’s certificate of authentication, such reference shall be
deemed to include authentication and delivery on behalf of the Trustee by an Authenticating Agent
and a certificate of authentication executed on behalf of the Trustee by an Authenticating Agent.
Each Authenticating Agent shall be acceptable to the Company and shall at all times be a
corporation organized and doing business under the laws of the United States of America, any State

-44-

 

thereof or the District of Columbia, authorized under such laws to act as Authenticating
Agent, having a combined capital and surplus of not less than $50,000,000 and subject to
supervision or examination by Federal or State authority. If such Authenticating Agent publishes
reports of condition at least annually, pursuant to law or to the requirements of said supervising
or examining authority, then for the purposes of this Section, the combined capital and surplus of
such Authenticating Agent shall be deemed to be its combined capital and surplus as set forth in
its most recent report of condition so published. If at any time an Authenticating Agent shall
cease to be eligible in accordance with the provisions of this Section, such Authenticating Agent
shall resign immediately in the manner and with the effect specified in this Section.

     Any corporation into which an Authenticating Agent may be merged or converted or with which it
may be consolidated, or any corporation resulting from any merger, conversion or consolidation to
which such Authenticating Agent shall be a party, or any corporation succeeding to the corporate
agency or corporate trust business of an Authenticating Agent, shall continue to be an
Authenticating Agent, provided such corporation shall be otherwise eligible under this Section,
without the execution or filing of any paper or any further act on the part of the Trustee or the
Authenticating Agent.

     An Authenticating Agent may resign at any time by giving written notice thereof to the Trustee
and to the Company. The Trustee may at any time terminate the agency of an Authenticating Agent by
giving written notice thereof to such Authenticating Agent and to the Company. Upon receiving such
a notice of resignation or upon such a termination, or in case at any time such Authenticating
Agent shall cease to be eligible in accordance with the provisions of this Section, the Trustee may
appoint a successor Authenticating Agent which shall be acceptable to the Company and shall give
notice of such appointment in the manner provided in Section 106 to all Holders of Securities of
the series with respect to which such Authenticating Agent will serve. Any successor Authenticating
Agent upon acceptance of its appointment hereunder shall become vested with all the rights, powers
and duties of its predecessor hereunder, with like effect as if originally named as an
Authenticating Agent. No successor Authenticating Agent shall be appointed unless eligible under
the provisions of this Section.

     The Company agrees to pay to each Authenticating Agent from time to time reasonable
compensation for its services under this Section.

     If an appointment with respect to one or more series is made pursuant to this Section, the
Securities of such series may have endorsed thereon, in addition to the Trustee’s certificate of
authentication, an alternative certificate of authentication in the following form:

-45-

 

     This is one of the Securities of the series designated therein referred to in the
within-mentioned Indenture.

	 	 	 	 	 
	 	THE BANK OF NEW YORK,

As Trustee

 	 
	 	By  	
 	, 
	 	 	As Authenticating Agent 	 
	 
	 	 	 
	 	By  	
 	 
	 	 	Authorized Officer 	 
	 	 	 	 
	 

Section 615. Appointment of Co-Trustee.

     (a) Notwithstanding any other provisions of this Indenture, following the occurrence of, and
during the continuation of, an Event of Default, hereunder, if the Trustee reasonably believes that
such action is required by law, rule or regulation of the jurisdiction of incorporation of the
Company or the jurisdiction in which the Company’s principal place of business is located, the
Trustee shall have the power and may execute and deliver all instruments necessary to appoint one
or more Persons to act as a co-trustee or co-trustees hereunder, or separate trustee or separate
trustees hereunder, in each case exclusively in such jurisdiction or jurisdictions, and to vest in
such Person or Persons, in such capacity and for the benefit of the Holders, such title hereunder,
or any part hereof, in each case exclusively in such jurisdiction or jurisdictions, and subject to
the other provisions of this Section, such powers, duties, obligations, rights and trusts in such
jurisdiction or jurisdictions as the Trustee may reasonably consider necessary or desirable. Each
co-trustee and separate trustee hereunder shall be authorized under applicable law to act as a
co-trustee or a separate trustee, as the case may be, and shall each have a combined capital and
surplus (computed in accordance with Section 310(a)(2) of the Trust Indenture Act) of at least
US$25,000,000. If at any time a co-trustee or a separate trustee shall cease to be eligible in
accordance with the provisions of this Section, it shall resign immediately in the manner and with
the effect specified in this Section.

     (b) Every separate trustee and co-trustee shall, to the extent permitted by law, be appointed
and act subject to the following provisions and conditions:

     (1) all rights, powers, duties and obligations conferred or imposed upon the Trustee
shall be conferred or imposed upon and exercised or performed by the Trustee and such
separate trustee or co-trustee jointly (it being understood that such separate trustee or
co-trustee is not authorized to act (i) outside the jurisdiction or jurisdictions set
forth in Section 615(a) hereof or (ii) separately without the Trustee joining in such
act), except to the extent that under any law of any such jurisdiction in which any
particular act or acts are to be performed the Trustee shall be incompetent or unqualified
to perform such act or acts, in which event such rights, powers, duties and obligations
shall be exercised and performed singly by such separate trustee or co-trustee, but solely
in such jurisdiction or jurisdictions and solely at the direction of the Trustee;

-46-

 

     (2) no trustee hereunder shall be personally liable by reason of any act or omission
of any other trustee hereunder; and

     (3) the Trustee may at any time accept the resignation of or remove any separate
trustee or co-trustee, and the Indenture Trustee shall, following the waiver or cure of
the Event of Default pursuant to the terms hereof remove any separate trustee or
co-trustee appointed pursuant to Section 615(a) hereof in connection with such Event of
Default.

     (c) Any notice, request or other writing given to the Trustee shall be deemed to have been
given to each of the then separate trustees and co-trustees, as effectively as if given to each of
them. Every instrument appointing any separate trustee or co-trustee shall refer to this Indenture
and the conditions of this Article Six. Each separate trustee and co-trustee, upon its acceptance
of the trusts conferred, shall, subject to the provisions of Section 615(a) and Section 615(b)
hereof, be vested with the estates or property specified in its instrument of appointment, either
jointly with the Trustee or separately, as may be provided therein, subject to all the provisions
of this Indenture specifically including every provision of this Indenture relating to the conduct
of, affecting the liability of, or affording protection or rights (including the rights to
compensation, reimbursement and indemnification hereunder) to the Trustee. Every such instrument
shall be filed with the Trustee.

     (d) Any separate trustee or co-trustee appointed pursuant to Section 615(a) hereof may at any
time constitute the Trustee, in the jurisdiction or jurisdictions set forth in Section 615(a)
hereof, its agent or attorney-in-fact in such jurisdiction or jurisdictions with full power and
authority, to the extent not prohibited by law in such jurisdiction or jurisdictions, to do any
lawful act under or in respect of this Indenture on its behalf and in its name. If any separate
trustee or co-trustee shall die, become incapable of acting, resign or be removed, all of its
estates, properties, rights, remedies and trusts shall vest in and be exercised by the Trustee to
the extent permitted by law, without the appointment of a new or successor trustee.

ARTICLE SEVEN

Holders’ Lists and Reports by Trustee and Company

Section 701. Company to Furnish Trustee Names and Addresses of Holders.

     The Company will furnish or cause to be furnished to the Trustee:

     (1) semi-annually, not later than May 15 and November 15 in each year, a list, in
such form as the Trustee may reasonably require, of the names and addresses of the Holders
of Securities of each series as of the immediately preceding May 1 or November 1, as the
case may be; and

     (2) at such other times as the Trustee may request in writing, within 30 days after
the receipt by the Company of any such request, a list of similar form and content as of a
date not more than 15 days prior to the time such list is furnished;

-47-

 

excluding from any such list names and addresses received by the Trustee in its capacity as
Security Registrar.

Section 702. Preservation of Information; Communications to Holders.

     The Trustee shall preserve, in as current a form as is reasonably practicable, the names and
addresses of Holders contained in the most recent list furnished to the Trustee as provided in
Section 701 and the names and addresses of Holders received by the Trustee in its capacity as
Security Registrar. The Trustee may destroy any list furnished to it as provided in Section 701
upon receipt of a new list so furnished.

     The rights of Holders to communicate with other Holders with respect to their rights under
this Indenture or under the Securities, and the corresponding rights and privileges of the Trustee,
shall be as provided by the Trust Indenture Act.

     Every Holder of Securities, by receiving and holding the same, agrees with the Company and the
Trustee that neither the Company nor the Trustee nor any agent of either of them shall be held
accountable by reason of any disclosure of information as to names and addresses of Holders made
pursuant to the Trust Indenture Act.

Section 703. Reports by Trustee.

     The Trustee shall transmit to Holders such reports concerning the Trustee and its actions
under this Indenture as may be required pursuant to the Trust Indenture Act at the times and in the
manner provided pursuant thereto.

     Reports so required to be transmitted at stated intervals of not more than 12 months shall be
transmitted no later than July 15 and shall be dated as of May 15 in each calendar year, commencing
in 20_.

     A copy of each such report shall, at the time of such transmission to Holders, be filed by the
Trustee with each stock exchange upon which any Securities are listed, if applicable, with the
Commission and with the Company. If applicable, the Company will notify the Trustee when any
Securities are listed on any stock exchange and of any delisting thereof.

Section 704. Reports by Company.

     The Company shall file with the Trustee and the Commission, and transmit to Holders, such
information, documents and other reports, and such summaries thereof, as may be required pursuant
to the Trust Indenture Act at the times and in the manner provided pursuant to the Trust Indenture
Act; provided that any such information, documents or reports required to be filed with the
Commission pursuant to Section 13 or 15(d) of the Exchange Act shall be filed with the Trustee
within 15 days after the same is so required to be filed with the Commission. Delivery of such
reports, information and documents to the Trustee is for informational purposes only and the
Trustee’s receipt of such shall not constitute constructive notice of any information contained
therein or determinable from information contained therein, including the Company’s compliance with
any of its covenants hereunder (as to which the Trustee is entitled to rely exclusively on
Officers’ Certificates).

-48-

 

ARTICLE EIGHT

Consolidation, Merger, Conveyance, Transfer or Lease

Section 801. Company May Consolidate, Etc., Only on Certain Terms.

     The Company shall not consolidate with or merge into any other Person (excluding, for the
avoidance of doubt, any merger of a wholly-owned subsidiary of the Company having the function of
an intermediate holding company under German law (referred to as Vermögensveraltungs GmbHs) with
and into the Company in the ordinary course of the Company’s holding management activities) or
convey, transfer or lease its properties and assets substantially as an entirety to any Person
(excluding, for the avoidance of doubt, any transfer by the Company of assets to one or more of its
Subsidiaries in connection with an internal restructuring whereby, following such transfer and
restructuring, such assets remain within the Company’s scope of consolidation for accounting
purposes), and the Company shall not permit any Person to consolidate with or merge into the
Company, unless:

     (1) in case the Company shall consolidate with or merge into another Person or
convey, transfer or lease its properties and assets substantially as an entirety to any
Person, the Person formed by such consolidation or into which the Company is merged or the
Person which acquires by conveyance or transfer, or which leases, the properties and
assets of the Company substantially as an entirety shall be a corporation, partnership,
trust, limited liability company or similar entity, shall be organized and validly
existing under the laws of any domestic or foreign jurisdiction and shall expressly
assume, by an indenture supplemental hereto, executed and delivered to the Trustee, in
form satisfactory to the Trustee, the due and punctual payment of the principal of and any
premium and interest on all the Securities in accordance with their terms and the
performance or observance of every covenant of this Indenture on the part of the Company
to be performed or observed and, for each Security that by its terms provides for
conversion, shall have provided for the right to convert such Security in accordance with
its terms;

     (2) immediately after giving effect to such transaction and treating any indebtedness
which becomes an obligation of the Company or any of its Subsidiaries as a result of such
transaction as having been incurred by the Company or such Subsidiary at the time of such
transaction, no Event of Default, and no event which, after notice or lapse of time or
both, would become an Event of Default, shall have happened and be continuing; and

     (3) the Company has delivered to the Trustee an Officers’ Certificate and an Opinion
of Counsel, each stating that such consolidation, merger, conveyance, transfer or lease
and, if a supplemental indenture is required in connection with such transaction, such
supplemental indenture comply with this Article and that all conditions precedent herein
provided for relating to such transaction have been complied with.

-49-

 

Section 802. Successor Substituted.

     Upon any consolidation of the Company with, or merger of the Company into, any other Person or
any conveyance, transfer or lease of the properties and assets of the Company substantially as an
entirety in accordance with Section 801, the successor Person formed by such consolidation or into
which the Company is merged or to which such conveyance, transfer or lease is made shall succeed
to, and be substituted for, and may exercise every right and power of, the Company under this
Indenture with the same effect as if such successor Person had been named as the Company herein,
and thereafter, except in the case of a lease, the predecessor Person shall be relieved of all
obligations and covenants under this Indenture and the Securities.

Section 803. Substitution of the Company on Certain Terms.

     Except as otherwise provided as contemplated in Section 301 with respect to Securities of a
series, any Subsidiary of the Company (other than an insurance undertaking) (the “New
Issuer”) may assume all the obligations of the Company under any of the Securities, and the
Company shall, with respect to such Securities, be relieved of all its obligations and covenants
under this Indenture and the Securities, provided that:

     (1) the New Issuer assumes any and all of the Company’s obligations under or in
connection with such Securities and, if the service of process vis-à-vis the New Issuer
would have to be effected outside the United States of America, appoints a process agent
within the United States of America;

     (2) the Company and the New Issuer have obtained all authorizations and approvals
necessary for the substitution and the fulfillment of obligations arising under or in
connection with such Securities; the New Issuer is in the position to pay the Trustee in
U.S. dollars and without deducting or withholding any taxes or other duties of whatever
nature imposed, levied or deducted by the country (or countries) in which the New Issuer
has its domicile or tax residence all amounts required for the performance of the payment
obligations arising from or in connection with such Securities;

     (3) immediately after giving effect to such transaction and treating any indebtedness
which becomes an obligation of the Company or any of its Subsidiaries as a result of such
transaction as having been incurred by the Company or such Subsidiary at the time of such
transaction, no Event of Default, and no event which, after notice or lapse of time or
both, would become an Event of Default, shall have happened and be continuing;

     (4) the Company has delivered to the Trustee an Officer’s Certificate and an Opinion
of Counsel, each stating that such substitution of the Company and, if a supplemental
indenture is required in connection with such transaction, such supplemental indenture,
complies with this Article and that all conditions precedent herein provided for relating
to such transaction have been complied with; and

     (5) the obligations of the New Issuer are guaranteed on the same terms as the
Company’s guarantees of the debt securities of Allianz Finance

-50-

 

Corporation and Allianz Finance III B.V. pursuant to the guarantees and indentures
dated to the date hereof.

     For the avoidance of doubt, following the substitution of the Company by a New Issuer pursuant
to this Section 803, any reference to the Company in the terms and conditions of the Securities and
this Indenture shall constitute a reference to the New Issuer.

ARTICLE NINE

Supplemental Indentures

Section 901. Supplemental Indentures Without Consent of Holders.

     Without the consent of any Holders, the Company, when authorized by a Board Resolution, and
the Trustee, at any time and from time to time, may enter into one or more indentures supplemental
hereto, in form satisfactory to the Trustee, for any of the following purposes:

     (1) to evidence the succession of another Person to the Company and the assumption by
any such successor of the covenants of the Company herein and in the Securities; or

     (2) to add to the covenants of the Company for the benefit of the Holders of all or
any series of Securities (and if such covenants are to be for the benefit of less than all
series of Securities, stating that such covenants are expressly being included solely for
the benefit of such series) or to surrender any right or power herein conferred upon the
Company; or

     (3) to add any additional Events of Default for the benefit of the Holders of all or
any series of Securities (and if such additional Events of Default are to be for the
benefit of less than all series of Securities, stating that such additional Events of
Default are expressly being included solely for the benefit of such series); or

     (4) to add to or change any of the provisions of this Indenture to such extent as
shall be necessary to permit or facilitate the issuance of Securities in bearer form,
registrable or not registrable as to principal, and with or without interest coupons, or
to permit or facilitate the issuance of Securities in uncertificated form; or

     (5) to add to, change or eliminate any of the provisions of this Indenture in respect
of one or more series of Securities, provided that any such addition, change or
elimination (A) shall neither (i) apply to any Security of any series created prior to the
execution of such supplemental indenture and entitled to the benefit of such provision nor
(ii) modify the rights of the Holder of any such Security with respect to such provision
or (B) shall become effective only when there is no such Security Outstanding; or

     (6) to establish the form or terms of Securities of any series as permitted by
Sections 201 and 301; or

-51-

 

     (7) to evidence and provide for the acceptance of appointment hereunder by a
successor Trustee with respect to the Securities of one or more series and to add to or
change any of the provisions of this Indenture as shall be necessary to provide for or
facilitate the administration of the trusts hereunder by more than one Trustee, pursuant
to the requirements of Section 611; or

     (8) to add to or change any of the provisions of this Indenture with respect to any
Securities that by their terms may be converted into securities or other property other
than Securities of the same series and of like tenor, in order to permit or facilitate the
issuance, payment or conversion of such Securities; or

     (9) to cure any ambiguity, to correct or supplement any provision herein which may be
defective or inconsistent with any other provision herein, or to make any other provisions
with respect to matters or questions arising under this Indenture, provided that such
action pursuant to this Clause (9) shall not adversely affect the interests of the Holders
of Securities of any series in any material respect; or

     (10) to amend or supplement any provision contained herein or in any supplemental
indenture, provided that no such amendment or supplement shall adversely affect the
interest of the Holders of the Securities in any material respect.

Section 902. Supplemental Indentures With Consent of Holders.

     With the consent of the Holders of a majority in principal amount of the Outstanding
Securities of all series affected by such supplemental indenture (considered together as one class
for this purpose), by Act of said Holders delivered to the Company and the Trustee, the Company,
when authorized by a Board Resolution, and the Trustee may enter into an indenture or indentures
supplemental hereto for the purpose of adding any provisions to or changing in any manner or
eliminating any of the provisions of this Indenture or of modifying in any manner the rights of the
Holders of Securities of such series under this Indenture; provided, however, that no such
supplemental indenture shall, without the consent of the Holder of each Outstanding Security
affected thereby:

     (1) change the stated maturity or the time of the payment of any installment of
interest on, any Security, or reduce the rate of interest thereon or any premium payable
upon the redemption thereof, or reduce the amount of the principal of an Original Issue
Discount Security or any other Security which would be due and payable upon a declaration
of acceleration of the Maturity thereof pursuant to Section 502, or permit the Company to
redeem any Security if, absent such supplemental indenture, the Company would not be
permitted to do so, or change any Place of Payment where, or the coin or currency in
which, any Security or any premium or interest thereon is payable; or

     (2) impair the right of any Holder to receive any principal payment or interest
payment on such Security in a manner other than that stated in the terms of the relevant
Security, on or after the applicable Interest Payment Date thereof, or to institute suit
for the enforcement of any such payment; or

-52-

 

     (3) reduce the principal amount or the amount payable upon the redemption of any
Security or change the times at which any Security may be redeemed or, once notice of
redemption has been given, the time at which it must thereupon be redeemed; or

     (4) change the obligation of the Company or of a New Issuer to pay Additional Amounts
and interest (including any deferred interest, if applicable), if any; or

     (5) modify or change any provision of this Indenture affecting the ranking of the
Securities of any series in a manner adverse to the Holders of the Securities; or

     (6) if any Security provides that the Holder may require the Company to repurchase or
convert such Security, impair such Holder’s right to require repurchase or conversion of
such Security on the terms provided therein; or

     (7) reduce the percentage in principal amount of the Outstanding Securities of any
one or more series (considered separately or together as one class, as applicable), the
consent of whose Holders is required for any such supplemental indenture, or the consent
of whose Holders is required for any waiver (of compliance with certain provisions of this
Indenture or certain defaults hereunder and their consequences) provided for in this
Indenture; or

     (8) modify any of the provisions of this Section, Section 513 or Section 1005, except
to increase any such percentage or to provide that certain other provisions of this
Indenture cannot be modified or waived without the consent of the Holder of each
Outstanding Security affected thereby; provided, however, that this Clause shall not be
deemed to require the consent of any Holder with respect to changes in the references to
“the Trustee” and concomitant changes in this Section and Section 1005, or the deletion of
this proviso, in accordance with the requirements of Sections 611 and 901(8).

A supplemental indenture which changes or eliminates any covenant or other provision of this
Indenture which has expressly been included solely for the benefit of one or more particular series
of Securities, or which modifies the rights of the Holders of Securities of such series with
respect to such covenant or other provision, shall be deemed not to affect the rights under this
Indenture of the Holders of Securities of any other series.

     It shall not be necessary for any Act of Holders under this Section to approve the particular
form of any proposed supplemental indenture, but it shall be sufficient if such Act shall approve
the substance thereof.

Section 903. Execution of Supplemental Indentures.

     In executing, or accepting the additional trusts created by, any supplemental indenture
permitted by this Article or the modifications thereby of the trusts created by this Indenture, the
Trustee shall be entitled to receive, in addition to the documents required by Section 102, and
(subject to Section 601) shall be fully protected in relying upon, an Opinion of Counsel stating
that the execution of such supplemental indenture is

-53-

 

authorized or permitted by this Indenture. The Trustee may, but shall not be obligated to,
enter into any such supplemental indenture which affects the Trustee’s own rights, duties or
immunities under this Indenture or otherwise.

Section 904. Effect of Supplemental Indentures.

     Upon the execution of any supplemental indenture under this Article, this Indenture shall be
modified in accordance therewith, and such supplemental indenture shall form a part of this
Indenture for all purposes; and every Holder of Securities theretofore or thereafter authenticated
and delivered hereunder shall be bound thereby.

Section 905. Conformity with Trust Indenture Act.

     Every supplemental indenture executed pursuant to this Article shall conform to the
requirements of the Trust Indenture Act.

Section 906. Reference in Securities to Supplemental Indentures.

     Securities of any series authenticated and delivered after the execution of any supplemental
indenture pursuant to this Article may, and shall if required by the Trustee, bear a notation in
form approved by the Trustee as to any matter provided for in such supplemental indenture. If the
Company shall so determine, new Securities of any series so modified as to conform, in the opinion
of the Trustee and the Company, to any such supplemental indenture may be prepared and executed by
the Company and authenticated and delivered by the Trustee in exchange for Outstanding Securities
of such series.

ARTICLE TEN

Covenants

Section 1001. Payment of Principal, Premium and Interest.

     The Company covenants and agrees for the benefit of each series of Securities that it will
duly and punctually pay the principal of and any premium and interest on the Securities of that
series in accordance with the terms of the Securities and this Indenture.

Section 1002. Maintenance of Office or Agency.

     The Company will maintain in each Place of Payment for any series of Securities an office or
agency where Securities of that series may be presented or surrendered for payment, where
Securities of that series may be surrendered for registration of transfer or exchange, where
Securities may be surrendered for conversion and where notices and demands to or upon the Company
in respect of the Securities of that series and this Indenture may be served. The Company will give
prompt written notice to the Trustee of the location, and any change in the location, of such
office or agency. If at any time the Company shall fail to maintain any such required office or
agency or shall fail to furnish the Trustee with the address thereof, such presentations,
surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee,
and the Company hereby appoints the Trustee as its agent to receive all such presentations,
surrenders, notices and demands.

-54-

 

     The Company may also from time to time designate one or more other offices or agencies where
the Securities of one or more series may be presented or surrendered for any or all such purposes
and may from time to time rescind such designations; provided, however, that no such designation or
rescission shall in any manner relieve the Company of its obligation to maintain an office or
agency in each Place of Payment for Securities of any series for such purposes. The Company will
give prompt written notice to the Trustee of any such designation or rescission and of any change
in the location of any such other office or agency.

     With respect to any Global Security, and except as otherwise may be specified for such Global
Security as contemplated by Section 301, the Corporate Trust Office of the Trustee shall be the
Place of Payment where such Global Security may be presented or surrendered for payment or for
registration of transfer or exchange, or where successor Securities may be delivered in exchange
therefor; provided, however, that any such payment, presentation, surrender or delivery effected
pursuant to the Applicable Procedures of the Depositary for such Global Security shall be deemed to
have been effected at the Place of Payment for such Global Security in accordance with the
provisions of this Indenture.

Section 1003. Money for Securities Payments to Be Held in Trust.

     If the Company shall at any time act as its own Paying Agent with respect to any series of
Securities, it will, on or before each due date of the principal of or any premium or interest on
any of the Securities of that series, segregate and hold in trust for the benefit of the Persons
entitled thereto a sum sufficient to pay the principal and any premium and interest so becoming due
until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will
promptly notify the Trustee of its action or failure so to act.

     Whenever the Company shall have one or more Paying Agents for any series of Securities, it
will, by each due date of the principal of or any premium or interest on any Securities of that
series, deposit (or, if the Company has deposited any trust funds with a trustee pursuant to
Section 1304(1), cause such trustee to deposit) with a Paying Agent a sum sufficient to pay such
amount, such sum to be held as provided by the Trust Indenture Act, and (unless such Paying Agent
is the Trustee) the Company will promptly notify the Trustee of its action or failure so to act.

     The Company will cause each Paying Agent for any series of Securities (other than the Trustee)
to execute and deliver to the Trustee an instrument in which such Paying Agent shall agree with the
Trustee, subject to the provisions of this Section, that such Paying Agent will (1) comply with the
provisions of the Trust Indenture Act applicable to it as a Paying Agent and (2) during the
continuance of any default by the Company (or any other obligor upon the Securities of that series)
in the making of any payment in respect of the Securities of that series, upon the written request
of the Trustee, forthwith pay to the Trustee all sums held in trust by such Paying Agent for
payment in respect of the Securities of that series.

     The Company may at any time, for the purpose of obtaining the satisfaction and discharge of
this Indenture or for any other purpose, pay, or by Company Order direct any Paying Agent to pay,
to the Trustee all sums held in trust by the Company or such Paying Agent, such sums to be held by
the Trustee upon the same trusts as those upon

-55-

 

which such sums were held by the Company or such Paying Agent; and, upon such payment by any
Paying Agent to the Trustee, such Paying Agent shall be released from all further liability with
respect to such money.

     Any money deposited with the Trustee or any Paying Agent, or then held by the Company, in
trust for the payment of the principal of or any premium or interest on any Security of any series
and remaining unclaimed for two years after such principal, premium or interest has become due and
payable shall be paid to the Company on Company Request, or (if then held by the Company) shall be
discharged from such trust; and the Holder of such Security shall thereafter, as an unsecured
general creditor, look only to the Company for payment thereof, and all liability of the Trustee or
such Paying Agent with respect to such trust money, and all liability of the Company as trustee
thereof, shall thereupon cease; provided, however, that the Trustee or such Paying Agent, before
being required to make any such repayment, may, at the expense of the Company, cause to be
published once, in a newspaper published in the English language, customarily published on each
Business Day and of general circulation in The City of New York, notice that such money remains
unclaimed and that, after a date specified therein, which shall not be less than 30 days from the
date of such publication, any unclaimed balance of such money then remaining will be repaid to the
Company.

Section 1004. Statement by Officers as to Default.

     The Company will deliver to the Trustee, within 120 days after the end of each fiscal year of
the Company ending after the date hereof, an Officers’ Certificate, stating whether or not to the
best knowledge of the signers thereof the Company is in default in the performance and observance
of any of the terms, provisions and conditions of this Indenture (without regard to any period of
grace or requirement of notice provided hereunder) and, if the Company shall be in default,
specifying all such defaults and the nature and status thereof of which they may have knowledge.

     The Company shall deliver to the Trustee, as soon as possible and in any event within five
days after the Company becomes aware of the occurrence of any Event of Default or an event which,
with notice or the lapse of time or both, would constitute an Event of Default, an Officers’
Certificate setting forth the details of such Event of Default or default and the action which the
Company proposes to take with respect thereto.

Section 1005. Waiver of Certain Covenants.

     Except as otherwise specified as contemplated by Section 301 for Securities of a specific
series, the Company may, with respect to the Securities of any one or more series, omit in any
particular instance to comply with any term, provision or condition set forth in any covenant
provided pursuant to Section 301(19), 901(2) or 901(6) for the benefit of the Holders of such
series or in Article Eight if, before the time for such compliance, the Holders of a majority in
principal amount of the Outstanding Securities of all series affected by such waiver (considered
together as one class for this purpose) shall, by Act of such Holders, either waive such compliance
in such instance or generally waive compliance with such term, provision or condition, but no such
waiver shall extend to or affect such term, provision or condition except to the extent so
expressly waived, and, until such waiver shall become effective, the obligations of the Company and
the duties of the Trustee in respect of any such term, provision or condition shall remain in full
force and effect.

-56-

 

Section 1006. Payment of Additional Amounts.

     The Company shall make all payments of principal, interest and premium in respect of the Securities
free and clear of, and without withholding or deduction for, any taxes, duties, assessments or
governmental charges of whatever nature (“Taxes”) imposed, levied, collected, withheld or
assessed by the Federal Republic of Germany or any political subdivision or any authority of or in
the Federal Republic of Germany that has power to tax (a “Relevant Jurisdiction”), unless
the Company is compelled by law to make such withholding or deduction. In the event of such
withholding or deduction, the Company will pay such additional amounts (the “Additional
Amounts”) as are necessary for each Holder to receive, after deduction or withholding of such
Taxes, the full amount that the Holder would have received if no such withholding or deduction had
been required; provided that no such Additional Amounts shall be payable with respect to such Taxes
in respect of any amount payable on any Securities:

     (i) to a Holder which is liable for such Taxes in respect of such
Securities by reason of such Holder having some connection with a
Relevant Jurisdiction (as the case may be) other than the mere holding
of such Securities;

     (ii) to a Holder which would be able to avoid such withholding or
deduction under the laws of a Relevant Jurisdiction by presenting any
form or certificate and/or making a declaration of non-residence or
similar claim for exemption or refund but fails to do so after proper
notice has been sent to such Holder by the Issuer;

     (iii) in respect of any deduction or withholding imposed on a
payment to an individual and required to be made pursuant to European
Council Directive 2003/48/EC or any other European Union Directive
implementing the conclusions of the ECOFIN Council meeting of 26-27
November 2000 on the taxation of savings income or any law implementing
or complying with, or introduced in order to conform to, such Directive;
or

     (iv) to a Holder which would have been able to avoid such
withholding or deduction by presenting (where presentation is required)
the Security to a Paying Agent in another Member State of the European
Union.

     For purposes of this Indenture, any references to principal of and/or interest on Securities
shall be deemed to include a reference to any relevant premium and/or Additional Amounts payable in
respect of such Securities.

     In the event that a New Issuer assumes the obligations of the Company pursuant to Section 803
and the New Issuer is organized or resident in any jurisdiction other than the Federal Republic of
Germany for tax purposes, such other jurisdiction will be deemed to be a Relevant Jurisdiction.

-57-

 

ARTICLE ELEVEN

 Redemption of Securities

Section 1101. Applicability of Article.

     Securities of any series which are redeemable before their Stated Maturity shall be redeemable
in accordance with their terms and (except as otherwise specified as contemplated by Section 301
for such Securities) in accordance with this Article.

Section 1102. Election to Redeem; Notice to Trustee.

     The election of the Company to redeem any Securities shall be established in or pursuant to a
Board Resolution or in another manner specified as contemplated by Section 301 for such Securities.
In case of any redemption at the election of the Company of less than all the Securities of any
series (including any such redemption affecting only a single Security), the Company shall, at
least 60 days prior to the Redemption Date fixed by the Company (unless a shorter notice shall be
satisfactory to the Trustee), notify the Trustee of such Redemption Date, of the principal amount
of Securities of such series to be redeemed and, if applicable, of the tenor of the Securities to
be redeemed. In the case of any redemption of Securities prior to the expiration of any restriction
on such redemption provided in the terms of such Securities or elsewhere in this Indenture, the
Company shall furnish the Trustee with an Officers’ Certificate evidencing compliance with such
restriction.

Section 1103. Selection by Trustee of Securities to Be Redeemed.

     If less than all the Securities of any series are to be redeemed (unless all the Securities of
such series and of a specified tenor are to be redeemed or unless such redemption affects only a
single Security), the particular Securities to be redeemed shall be selected not more than 60 days
prior to the Redemption Date by the Trustee, from the Outstanding Securities of such series not
previously called for redemption, by such method as the Trustee shall deem fair and appropriate and
which may provide for the selection for redemption of a portion of the principal amount of any
Security of such series, provided that the unredeemed portion of the principal amount of any
Security shall be in an authorized denomination (which shall not be less than the minimum
authorized denomination) for such Security. If less than all the Securities of such series and of a
specified tenor are to be redeemed (unless such redemption affects only a single Security), the
particular Securities to be redeemed shall be selected not more than 60 days prior to the
Redemption Date by the Trustee, from the Outstanding Securities of such series and specified tenor
not previously called for redemption in accordance with the preceding sentence.

     If any Security selected for partial redemption is converted in part before termination of the
conversion right with respect to the portion of the Security so selected, the converted portion of
such Security shall be deemed (so far as may be) to be the portion selected for redemption.
Securities which have been converted during a selection of Securities to be redeemed shall be
treated by the Trustee as Outstanding for the purpose of such selection.

-58-

 

     The Trustee shall promptly notify the Company and each Security Registrar in writing of the
Securities selected for redemption as aforesaid and, in case of any Securities selected for partial
redemption as aforesaid, the principal amount thereof to be redeemed.

     The provisions of the two preceding paragraphs shall not apply with respect to any redemption
affecting only a single Security, whether such Security is to be redeemed in whole or in part. In
the case of any such redemption in part, the unredeemed portion of the principal amount of the
Security shall be in an authorized denomination (which shall not be less than the minimum
authorized denomination) for such Security.

     For all purposes of this Indenture, unless the context otherwise requires, all provisions
relating to the redemption of Securities shall relate, in the case of any Securities redeemed or to
be redeemed only in part, to the portion of the principal amount of such Securities which has been
or is to be redeemed.

Section 1104. Notice of Redemption.

     Notice of redemption shall be given by first-class mail, postage prepaid, mailed not less than
30 days nor more than 60 days prior to the Redemption Date, to each Holder of Securities to be
redeemed, at his address appearing in the Security Register.

     All notices of redemption shall identify the Securities to be redeemed (including CUSIP
numbers, if any) and shall state:

     (1) the Redemption Date;

     (2) the Redemption Price or, if not then ascertainable, the manner of calculation
thereof;

     (3) if less than all the Outstanding Securities of any series consisting of more than
a single Security are to be redeemed, the identification (and, in the case of partial
redemption of any such Securities, the principal amounts) of the particular Securities to
be redeemed and, if less than all the Outstanding Securities of any series consisting of a
single Security are to be redeemed, the principal amount of the particular Security to be
redeemed;

     (4) that on the Redemption Date the Redemption Price will become due and payable upon
each such Security to be redeemed and, if applicable, that interest thereon will cease to
accrue on and after said date;

     (5) the place or places where each such Security is to be surrendered for payment of
the Redemption Price;

     (6) for any Securities that by their terms may be converted, the terms of conversion,
the date on which the right to convert the Security to be redeemed will terminate and the
place or places where such Securities may be surrendered for conversion;

     (7) that the redemption is for a sinking fund, if such is the case; and

-59-

 

     (8) such other matters as the Company shall deem desirable or appropriate.

     Notice of redemption of Securities to be redeemed at the election of the Company shall be
given by the Company or, at the Company’s request, by the Trustee in the name and at the expense of
the Company and shall be irrevocable.

Section 1105. Deposit of Redemption Price.

     By 10:00 a.m., New York City time, on any Redemption Date, the Company shall deposit with the
Trustee or with a Paying Agent (or, if the Company is acting as its own Paying Agent, segregate and
hold in trust as provided in Section 1003) an amount of money sufficient to pay the Redemption
Price of, and (except if the Redemption Date shall be an Interest Payment Date) accrued interest
on, all the Securities which are to be redeemed on that date, other than any Securities called for
redemption on that date which have been converted prior to the date of such deposit.

     If any Security called for redemption is converted, any money deposited with the Trustee or
with any Paying Agent or so segregated and held in trust for the redemption of such Security shall
(subject to any right of the Holder of such Security or any Predecessor Security to receive
interest as provided in the last paragraph of Section 307 or in the terms of such Security) be paid
to the Company upon Company Request or, if then held by the Company, shall be discharged from such
trust.

Section 1106. Securities Payable on Redemption Date.

     Notice of redemption having been given as aforesaid, the Securities so to be redeemed shall,
on the Redemption Date, become due and payable at the Redemption Price therein specified, and from
and after such date (unless the Company shall default in the payment of the Redemption Price and
accrued interest) such Securities shall cease to bear interest. Upon surrender of any such Security
for redemption in accordance with said notice, such Security shall be paid by the Company at the
Redemption Price, together with accrued interest to the Redemption Date; provided, however, that,
unless otherwise specified as contemplated by Section 301, installments of interest whose Stated
Maturity is on or prior to the Redemption Date will be payable to the Holders of such Securities,
or one or more Predecessor Securities, registered as such at the close of business on the relevant
Record Dates according to their terms and the provisions of Section 307.

     If any Security called for redemption shall not be so paid upon surrender thereof for
redemption, the principal and any premium shall, until paid, bear interest from the Redemption Date
at the rate prescribed therefor in the Security.

Section 1107. Securities Redeemed in Part.

     Any Security which is to be redeemed only in part shall be surrendered at a Place of Payment
therefor (with, if the Company or the Trustee so requires, due endorsement by, or a written
instrument of transfer in form satisfactory to the Company and the Trustee duly executed by, the
Holder thereof or his attorney duly authorized in writing), and the Company shall execute, and the
Trustee shall authenticate and deliver to the Holder of such Security without service charge, a new
Security or Securities of the same series and of like tenor, of any authorized denomination as
requested by such Holder, in

-60-

 

aggregate principal amount equal to and in exchange for the unredeemed portion of the
principal of the Security surrendered; provided, if a Global Security is so surrendered, such new
Security so issued shall be a new Global Security in a denomination equal to the unredeemed portion
of the principal of the Global Security so surrendered.

Section 1108. Optional Redemption for Tax Reasons.

     Unless otherwise specified for a particular series of Securities or as otherwise provided for
in an indenture supplemental hereto, the Company may, on giving not more than 60 nor less than 30
days’ notice to the Trustee (which notice shall be irrevocable), redeem, in whole, but not in part,
the Securities of any Series then outstanding at a redemption price equal to the principal amount
of the Securities (or if the Securities are Original Issue Discount Securities, such amount as
determined pursuant to the formula set forth in the applicable indenture supplement) plus accrued
interest or applicable premiums, in each case with respect to the Securities being redeemed, in the
event that the Company determines that, as a result of any change in or amendment to the laws (or
any regulations or rulings promulgated thereunder) of a Relevant Jurisdiction (as defined in
Section 1006 herein) affecting taxation, which becomes effective on or after the date of issuance
of that series, or, with respect to a successor entity or New Issuer, a date following the date the
successor became a successor or a New Issuer assumed the Company’s obligations under the Indenture, or any change in or amendment to any official position regarding the
application or interpretation of such laws, regulations or rulings; (a) the Company has or will
become obligated to pay Additional Amounts (as defined in Section 1006 herein) with respect to the
Securities of such Series which obligation cannot be avoided by the Company or any successor or New Issuer; or
(b) interest payable by the Company in respect of the Securities is no longer, or within 90 days of
the date of the Opinion of Counsel described below will no longer be, fully deductible by the
Company for German income tax purposes (and the Company cannot take reasonable measures that would
ensure that such interest is fully deductible by it for German income tax purposes). The Trustee
will notify the Holders at least 30 days but no more than 60 days prior to the date fixed for any
such redemption. Prior to the giving of any notice of redemption for tax reasons as described in
this paragraph, the Company shall deliver to the Trustee (i) an Officers’ Certificate stating that
the Company is entitled to effect such redemption and setting forth a statement of facts showing
that the conditions precedent to the right of the Company to so redeem have occurred and (ii) an
Opinion of Counsel to such effect based on such statement of facts; provided that no such notice of
redemption shall be given earlier than 60 days prior to the earliest date on which the Company
would be obligated to pay such Additional Amounts if a payment in respect of the Securities were
then due.

ARTICLE TWELVE

Sinking Funds

Section 1201. Applicability of Article.

     The provisions of this Article shall be applicable to any sinking fund for the retirement of
Securities of any series except as otherwise specified as contemplated by Section 301 for such
Securities.

     The minimum amount of any sinking fund payment provided for by the terms of any Securities is
herein referred to as a “mandatory sinking fund payment”, and any payment in excess of such minimum
amount provided for by the terms of such Securities

-61-

 

is herein referred to as an “optional sinking fund payment”. If provided for by the terms of
any Securities, the cash amount of any sinking fund payment may be subject to reduction as provided
in Section 1202. Each sinking fund payment shall be applied to the redemption of Securities as
provided for by the terms of such Securities.

Section 1202. Satisfaction of Sinking Fund Payments with Securities.

     The Company (1) may deliver Outstanding Securities of a series (other than any previously
called for redemption) and (2) may apply as a credit Securities of a series which have been
converted in accordance with their terms or which have been redeemed either at the election of the
Company pursuant to the terms of such Securities or through the application of permitted optional
sinking fund payments pursuant to the terms of such Securities, in each case in satisfaction of all
or any part of any sinking fund payment with respect to any Securities of such series required to
be made pursuant to the terms of such Securities as and to the extent provided for by the terms of
such Securities; provided that the Securities to be so credited have not been previously so
credited. The Securities to be so credited shall be received and credited for such purpose by the
Trustee at the Redemption Price, as specified in the Securities so to be redeemed (or at such other
prices as may be specified for such Securities as contemplated in Section 301), for redemption
through operation of the sinking fund and the amount of such sinking fund payment shall be reduced
accordingly.

Section 1203. Redemption of Securities for Sinking Fund.

     Not less than 90 days (or such shorter period as shall be satisfactory to the Trustee) prior
to each sinking fund payment date for any Securities, the Company will deliver to the Trustee an
Officers’ Certificate specifying the amount of the next ensuing sinking fund payment for such
Securities pursuant to the terms of such Securities, the portion thereof, if any, which is to be
satisfied by payment of cash and the portion thereof, if any, which is to be satisfied by
delivering and crediting Securities pursuant to Section 1202 and will also deliver to the Trustee
any Securities to be so delivered. Not less than 60 days prior to each such sinking fund payment
date, the Trustee shall select the Securities to be redeemed upon such sinking fund payment date in
the manner specified in Section 1103 and cause notice of the redemption thereof to be given in the
name of and at the expense of the Company in the manner provided in Section 1104. Such notice
having been duly given, the redemption of such Securities shall be made upon the terms and in the
manner stated in Sections 1106 and 1107.

ARTICLE THIRTEEN

Defeasance and Covenant Defeasance

Section 1301. Company’s Option to Effect Defeasance or Covenant Defeasance.

     The Company may elect, at its option at any time, to have Section 1302 or Section 1303 applied
to any Securities or any series of Securities, as the case may be, designated pursuant to Section
301 as being defeasible pursuant to such Section 1302 or 1303, in accordance with any applicable
requirements provided pursuant to Section 301 and upon compliance with the conditions set forth
below in this Article. Any such election shall be evidenced by a Board Resolution or in another
manner specified as contemplated by Section 301 for such Securities.

-62-

 

Section 1302. Defeasance and Discharge.

     Upon the Company’s exercise of its option (if any) to have this Section applied to any
Securities or any series of Securities, as the case may be, the Company shall be deemed to have
been discharged from its obligations with respect to such Securities as provided in this Section on
and after the date the conditions set forth in Section 1304 are satisfied (hereinafter called
“Defeasance”). For this purpose, such Defeasance means that the Company shall be deemed to
have paid and discharged the entire indebtedness represented by such Securities and to have
satisfied all its other obligations under such Securities and this Indenture insofar as such
Securities are concerned (and the Trustee, at the expense of the Company, shall execute proper
instruments acknowledging the same), subject to the following which shall survive until otherwise
terminated or discharged hereunder: (1) the rights of Holders of such Securities to receive, solely
from the trust fund described in Section 1304 and as more fully set forth in such Section, payments
in respect of the principal of and any premium and interest on such Securities when payments are
due, (2) the Company’s obligations with respect to such Securities under Sections 304, 305, 306,
1002 and 1003, (3) the rights, powers, trusts, duties and immunities of the Trustee hereunder and
(4) this Article. Subject to compliance with this Article, the Company may exercise its option (if
any) to have this Section applied to any Securities notwithstanding the prior exercise of its
option (if any) to have Section 1303 applied to such Securities.

Section 1303. Covenant Defeasance.

     Upon the Company’s exercise of its option (if any) to have this Section applied to any
Securities or any series of Securities, as the case may be, (1) the Company shall be released from
any covenants provided pursuant to Section 301(19), 901(2) or 901(6) for the benefit of the Holders
of such Securities and (2) the occurrence of any event specified in Sections 501(4) (with respect
to any such covenants provided pursuant to Section 301(19), 901(2) or 901(6)) and 501(7) shall be
deemed not to be or result in an Event of Default, in each case with respect to such Securities as
provided in this Section on and after the date the conditions set forth in Section 1304 are
satisfied (hereinafter called “Covenant Defeasance”). For this purpose, such Covenant
Defeasance means that, with respect to such Securities, the Company may omit to comply with and
shall have no liability in respect of any term, condition or limitation set forth in any such
specified Section (to the extent so specified in the case of Section 501(4)), whether directly or
indirectly by reason of any reference elsewhere herein to any such Section or by reason of any
reference in any such Section to any other provision herein or in any other document, but the
remainder of this Indenture and such Securities shall be unaffected thereby.

Section 1304. Conditions to Defeasance or Covenant Defeasance.

     The following shall be the conditions to the application of Section 1302 or Section 1303 to
any Securities or any series of Securities, as the case may be:

     (1) The Company shall irrevocably have deposited or caused to be deposited with the
Trustee (or another trustee which satisfies the requirements contemplated by Section 609
and agrees to comply with the provisions of this Article applicable to it) as trust funds
in trust for the purpose of making the following payments, specifically pledged as
security for, and dedicated solely to,

-63-

 

the benefits of the Holders of such Securities, (A) money in an amount, or (B) U.S.
Government Obligations which through the scheduled payment of principal and interest in
respect thereof in accordance with their terms will provide, not later than one day before
the due date of any payment, money in an amount, or (C) such other obligations or
arrangements as may be specified as contemplated by Section 301 with respect to such
Securities, or (D) a combination thereof, in each case sufficient, in the opinion of a
nationally recognized firm of independent public accountants expressed in a written
certification thereof delivered to the Trustee, to pay and discharge, and which shall be
applied by the Trustee (or any such other qualifying trustee) to pay and discharge, the
principal of and any premium and interest on such Securities on the respective Stated
Maturities, in accordance with the terms of this Indenture and such Securities. As used
herein, “U.S. Government Obligation” means (x) any security which is (i) a direct
obligation of the United States of America for the payment of which the full faith and
credit of the United States of America is pledged or (ii) an obligation of a Person
controlled or supervised by and acting as an agency or instrumentality of the United
States of America the payment of which is unconditionally guaranteed as a full faith and
credit obligation by the United States of America, which, in either case (i) or (ii), is
not callable or redeemable at the option of the issuer thereof, and (y) any depositary
receipt issued by a bank (as defined in Section 3(a)(2) of the Securities Act) as
custodian with respect to any U.S. Government Obligation which is specified in subclause
(x) above and held by such bank for the account of the holder of such depositary receipt,
or with respect to any specific payment of principal of or interest on any U.S. Government
Obligation which is so specified and held, provided that (except as required by law) such
custodian is not authorized to make any deduction from the amount payable to the holder of
such depositary receipt from any amount received by the custodian in respect of the U.S.
Government Obligation or the specific payment of principal or interest evidenced by such
depositary receipt.

     (2) In the event of an election to have Section 1302 apply to any Securities or any
series of Securities, as the case may be, the Company shall have delivered to the Trustee
an Opinion of Counsel stating that (A) the Company has received from, or there has been
published by, the Internal Revenue Service a ruling or (B) since the date of this
instrument, there has been a change in the applicable Federal income tax law, in either
case (A) or (B) to the effect that, and based thereon such opinion shall confirm that, the
Holders of such Securities will not recognize gain or loss for Federal income tax purposes
as a result of the deposit, Defeasance and discharge to be effected with respect to such
Securities and will be subject to Federal income tax on the same amount, in the same
manner and at the same times as would be the case if such deposit, Defeasance and
discharge were not to occur.

     (3) In the event of an election to have Section 1303 apply to any Securities or any
series of Securities, as the case may be, the Company shall have delivered to the Trustee
an Opinion of Counsel to the effect that the Holders of such Securities will not recognize
gain or loss for Federal income tax purposes as a result of the deposit and Covenant
Defeasance to be effected with respect to such Securities and will be subject to Federal
income tax on the same amount, in

-64-

 

the same manner and at the same times as would be the
case if such deposit and Covenant Defeasance were not to occur.

     (4) The Company shall have delivered to the Trustee an Officers’ Certificate to the
effect that neither such Securities nor any other Securities of the same series, if then
listed on any securities exchange, will be delisted as a result of such deposit.

     (5) No event which is, or after notice or lapse of time or both would become, an
Event of Default with respect to such Securities or any other Securities shall have
occurred and be continuing at the time of such deposit or, with regard to any such event
specified in Sections 501(5) and (6), at any time on or prior to the 90th day after the
date of such deposit (it being understood that this condition shall not be deemed
satisfied until after such 90th day).

     (6) Such Defeasance or Covenant Defeasance shall not cause the Trustee to have a
conflicting interest within the meaning of the Trust Indenture Act (assuming all
Securities are in default within the meaning of such Act).

     (7) Such Defeasance or Covenant Defeasance shall not result in a breach or violation
of, or constitute a default under, any other agreement or instrument to which the Company
is a party or by which it is bound.

     (8) Such Defeasance or Covenant Defeasance shall not result in the trust arising from
such deposit constituting an investment company within the meaning of the Investment
Company Act unless such trust shall be registered under the Investment Company Act or
exempt from registration thereunder.

     (9) The Company shall have delivered to the Trustee an Officers’ Certificate and an
Opinion of Counsel, each stating that all conditions precedent with respect to such
Defeasance or Covenant Defeasance have been complied with.

Section 1305. Deposited Money and U.S. Government Obligations to Be Held in Trust; Miscellaneous
Provisions.

     Subject to the provisions of the last paragraph of Section 1003, all money and U.S. Government
Obligations (including the proceeds thereof) deposited with the Trustee or other qualifying trustee
(solely for purposes of this Section and Section 1306, the Trustee and any such other trustee are
referred to collectively as the “Trustee”) pursuant to Section 1304 in respect of any Securities
shall be held in trust and applied by the Trustee, in accordance with the provisions of such
Securities and this Indenture, to the payment, either directly or through any such Paying Agent
(including the Company acting as its own Paying Agent) as the Trustee may determine, to the Holders
of such Securities, of all sums due and to become due thereon in respect of principal and any
premium and interest, but money so held in trust need not be segregated from other funds except to
the extent required by law.

     The Company shall pay and indemnify the Trustee against any tax, fee or other charge imposed
on or assessed against the U.S. Government Obligations deposited pursuant to Section 1304 or the
principal and interest received in respect thereof other

-65-

 

than any such tax, fee or other charge
which by law is for the account of the Holders of Outstanding Securities.

     Anything in this Article to the contrary notwithstanding, the Trustee shall deliver or pay to
the Company from time to time upon Company Request any money or U.S. Government Obligations held by
it as provided in Section 1304 with respect to any Securities which, in the opinion of a nationally
recognized firm of independent public accountants expressed in a written certification thereof
delivered to the Trustee, are in excess of the amount thereof which would then be required to be
deposited to effect the Defeasance or Covenant Defeasance, as the case may be, with respect to such
Securities.

Section 1306. Reinstatement.

     If the Trustee or the Paying Agent is unable to apply any money in accordance with this
Article with respect to any Securities by reason of any order or judgment of any court or
governmental authority enjoining, restraining or otherwise prohibiting such application, then the
obligations under this Indenture and such Securities from which the Company has been discharged or
released pursuant to Section 1302 or 1303 shall be revived and reinstated as though no deposit had
occurred pursuant to this Article with respect to such Securities, until such time as the Trustee
or Paying Agent is permitted to apply all money held in trust pursuant to Section 1305 with respect
to such Securities in accordance with this Article; provided, however, that if the Company makes
any payment of principal of or any premium or interest on any such Security following such
reinstatement of its obligations, the Company shall be subrogated to the rights (if any) of the
Holders of such Securities to receive such payment from the money so held in trust.

 

     This instrument may be executed in any number of counterparts, each of which so executed shall
be deemed to be an original, but all such counterparts shall together constitute but one and the
same instrument.

-66-

 

     In Witness Whereof, the Company and the Trustee have caused this Indenture to be duly
executed, as of the day and year first above written.

	 	 	 	 	 
	 	ALLIANZ SE

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	THE BANK OF NEW YORK,

As Trustee

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 

-67-

 

	 	 	 	 	 

Schedule A

[List of other indentures with The Bank Of New York]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]